Teva Pharmaceutical Industries Limited (TEVA) 20-F 9 Feb 15 2014 Q4 Annual report (foreign) Financial data

Document_and_Entity_Informatio

Document and Entity Information	12 Months Ended
	Dec. 31, 2014
Document And Entity Information [Abstract]
Document Type	20-F
Document Period End Date	31-Dec-14
Amendment Flag	TRUE
Amendment Description	N.A.
Current Fiscal Year End Date	-19
Entity Central Index Key	818686
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Registrant Name	TEVA PHARMACEUTICAL INDUSTRIES LTD
Trading Symbol	TEVA
Entity Voluntary Filers	Yes
Entity Well Known Seasoned Issuer	Yes
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q4
Entity Common Stock Shares Outstanding	956,545,474

CONSOLIDATED_STATEMENTS_OF_INC

CONSOLIDATED STATEMENTS OF INCOME (USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
CONSOLIDATED STATEMENTS OF INCOME
Net revenues	$20,272	$20,314	$20,317
Cost of sales	9,216	9,607	9,665
Gross profit	11,056	10,707	10,652
Research and development expenses	1,488	1,427	1,356
Selling and marketing expenses	3,861	4,080	3,879
General and administrative expenses	1,217	1,239	1,238
Impairments restructuring and others	650	788	1,259
Legal Settlements And Loss Contingencies	-111	1,524	715
Operating income	3,951	1,649	2,205
Financial expenses - net	313	399	386
Income before income taxes	3,638	1,250	1,819
Income taxes	591	-43	-137
Share in losses of associated companies - net	5	40	46
Net income	3,042	1,253	1,910
Net loss attributable to non-controlling interests	-13	-16	-53
Net income attributable to Teva	$3,055	$1,269	$1,963
Earnings per share attributable to Teva:
Basic	$3.58	$1.49	$2.25
Diluted	$3.56	$1.49	$2.25
Weighted average number of shares (in millions):
Basic	853	849	872
Diluted	858	850	873

COMPREHENSIVE_INCOME

COMPREHENSIVE INCOME (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Comprehensive Income [Abstract]
Net income	$3,042	$1,253	$1,910
Other Comprehensive Income (Loss) Net Of Tax [Abstract]
Currency translation adjustment	-1,440	-22	632
Unrealized gain (loss) on derivative financial instruments, net	237	-104	-63
Unrealized gain (loss) from available-for-sale securities, net	-12	12	65
Unrealized Gain (loss) on defined benefit plans, net	-43	42	-60
Total Other Comprehensive Income (Loss)	-1,258	-72	574
Total comprehensive income	1,784	1,181	2,484
Comprehensive loss attributable to the non-controlling interests	-19	-14	-51
Comprehensive income attributable to Teva	$1,803	$1,195	$2,535

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Current assets:
Cash and cash equivalents	$2,226	$1,038
Accounts receivable	5,408	5,338
Inventories	4,371	5,053
Deferred income taxes.	993	1,084
Other Current Assets	1,398	1,207
Total current assets	14,396	13,720
Other non-current assets	1,569	1,696
Property, plant and equipment, net	6,535	6,635
Identifiable intangible assets, net	5,512	6,476
Goodwill	18,408	18,981
Total assets	46,420	47,508
Current liabilities:
Short-term debt	1,761	1,804
Sales Reserves And Allowances	5,849	4,918
Accounts payable and accruals	3,171	3,317
Other current liabilities	1,508	1,926
Total current liabilities	12,289	11,965
Long-term liabilities:
Deferred income taxes	1,101	1,247
Other taxes and long term liabilities	1,109	1,273
Senior notes and loans	8,566	10,387
Total long term liabilities	10,776	12,907
Total liabilities	23,065	24,872
Teva shareholders' equity:
Ordinary shares	50	50
Additional paid-in capital	14,121	13,628
Retained earnings	14,436	12,535
Accumulated other comprehensive loss	-1,343	-91
Treasury shares	-3,951	-3,557
Stockholders' equity attributable to Teva shareholders	23,313	22,565
Non-controlling interests	42	71
Total equity	23,355	22,636
Total liabilities and equity	$46,420	$47,508

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (ILS)	Dec. 31, 2014
In Millions, except Per Share data, unless otherwise specified
CONSOLIDATED BALANCE SHEETS
Ordinary shares, authorized	2,500
Ordinary shares, issued	957
Treasury, shares	105
Common Stock, Par or Stated Value Per Share	0.1

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY	Total	Ordinary Shares: Stated value or Number of shares	Additional Paid In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Treasury Shares	Total Tevas share holders equity	Noncontrolling Interest
In Millions, except Share data	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)
Balance as of at Dec. 31, 2011	$22,343	$50	$13,374	$11,284	($589)	$1,924	$22,195	$148
Shares, balance at Period Start at Dec. 31, 2011		942,000,000
Comprehensive Income (loss)	2,484			1,963	572		2,535	-51
Exercise of options and RSUs by employees	14	0	14				14
Exercise of options and RSUs by employees, shares		2,000,000
Stock-based compensation expense	82		82				82
Dividends	-901			-901			-901
Purchase of treasury shares	1,161					1,161	1,161
Other	6		4				4	2
Balance at Period End at Dec. 31, 2012	22,867	50	13,474	12,346	-17	3,085	22,768	99
Shares, balance at Preiod End at Dec. 31, 2012		944,000,000
Comprehensive Income (loss)	1,181			1,269	-74		1,195	-14
Exercise of options and RSUs by employees	91	0	73			18	91
Exercise of options and RSUs by employees, shares		3,000,000
Stock-based compensation expense	64		64				64
Dividends	-1,080			-1,080			-1,080
Disposition of non-controlling interests	-12							-12
Purchase of treasury shares	497					497	497
Other	22		17			7	24	-2
Balance at Period End at Dec. 31, 2013	22,636	50	13,628	12,535	-91	3,557	22,565	71
Shares, balance at Preiod End at Dec. 31, 2013		947,000,000
Comprehensive Income (loss)	1,784			3,055	-1,252		1,803	-19
Exercise of options and RSUs by employees	514	0	408			106	514
Exercise of options and RSUs by employees, shares		10,000,000
Stock-based compensation expense	95		95				95
Dividends	-1,156			-1,156			-1,156
Disposition of non-controlling interests	-14							-14
Purchase of treasury shares	500					500	500
Other	-4	0	-10	2			-8	4
Balance at Period End at Dec. 31, 2014	$23,355	$50	$14,121	$14,436	($1,343)	$3,951	$23,313	$42
Shares, balance at Preiod End at Dec. 31, 2014		957,000,000

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOW (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating activities:
Net income	$3,042	$1,253	$1,910
Adjustments to reconcile net income to net cash provided by operations:
Depreciation And Amortization	1,508	1,642	1,708
Net change in operating assets and liabilities	290	968	414
Deferred Income Taxes Net And Uncertain Tax Positions	-226	-1,380	-690
Research and development in process	0	5	73
Impairment of long lived assets	387	524	1,071
Stock-based compensation	95	64	82
Other items	30	143	7
Loss (gain) from sale of long lived assets and investments	1	18	-3
Net cash provided by operating activities	5,127	3,237	4,572
Investing activities:
Acquisitions of subsidiaries, net of cash acquired	-363	-39	0
Purchase of property, plant and equipment	-929	-1,031	-1,104
Purchase of investments and other assets	-324	-160	-201
Proceeds From Sales of Long Lived Assets And Investments	196	187	264
Other investing activities	-30	-104	-93
Net cash used in investing activities	-1,450	-1,147	-1,134
Financing activities:
Proceeds From Senior Notes Net	0	0	3,783
Purchase of treasury shares	-500	-497	-1,161
Net change in short-term debt	-385	384	-2,492
Dividends paid	-1,156	-1,089	-855
Proceeds from exercise of options by employees	514	91	14
Proceeds From Long Term Loans And Other Long Term Liabilities	0	338	1,241
Repayment of long-term loans And Other Long Term Liabilities	-839	-3,133	-2,213
Other financing activities	-9	23	5
Net cash used in financing activities	-2,375	-3,883	-1,678
Translation adjustment on cash and cash equivalents	-114	-48	23
Net change in cash and cash equivalents	1,188	-1,841	1,783
Balance of cash and cash equivalents at beginning of year	1,038	2,879	1,096
Balance of cash and cash equivalents at end of year	2,226	1,038	2,879
Supplemental disclosure of cash flow information
Interest paid	294	331	297
Income taxes paid, net of refunds	675	1,298	614
Amendment Sixty Nine And Tax Audits Payments	790
Net change in operating assets and liabilities
Accounts receivable net of sales reserves and allowances	710	85	936
Inventories	230	399	-511
Other current assets	-36	106	-54
Accounts payable and accruals and other current liabilities	-614	378	-19
Inventory Step Up	0	0	62
Net change in operating assets and liabilities	$290	$968	$414

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	0 Months Ended
	Dec. 31, 2014
Significant Accounting Policies [Abstract]
Basis Of Presentation And Significant Accounting Policies	TEVA PHARMACEUTICAL INDUSTRIES LIMITED
	Notes to Consolidated Financial Statements
	NOTE 1—SIGNIFICANT ACCOUNTING POLICIES:
	a.       General:
	Operations
	Teva Pharmaceutical Industries Limited (the “Parent Company”), headquartered in Israel, together with its subsidiaries and associated companies (the “Company,” “Teva” or the “Group”), is engaged in the development, manufacturing, marketing and distribution of generic, specialty, and other pharmaceutical products. The majority of the Group's revenues are in the United States and Europe. The Group's main manufacturing facilities are located in Israel, Hungary, United States, Germany, Canada, Japan, Ireland, the United Kingdom, the Czech Republic, Croatia, Italy and India.
	Accounting principles
	The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”).
	Functional currency
	A major part of the Group's operations is carried out by the Company and its subsidiaries in the United States, Israel and certain other countries. The functional currency of these entities is the U.S. dollar (“dollar” or “$”).
	The functional currency of certain subsidiaries and associated companies is their local currency. The financial statements of those companies are included in the consolidated financial statements, translated into U.S. dollars. Assets and liabilities are translated at year-end exchange rates, while revenues and expenses are translated at monthly average exchange rates during the year. Differences resulting from translation are presented as other comprehensive income in the consolidated statements of comprehensive income.
	The financial statements of subsidiaries in a highly inflationary economy are remeasured as if the functional currency was the U.S. dollar, Teva's reporting currency, using a translation rate determined by the country's official rate. A highly inflationary economy is one that has cumulative inflation of approximately 100 percent or more over a 3-year period.
	Use of estimates in the preparation of financial statements
	The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reported years. Actual results could differ from those estimates.
	As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to uncertain tax positions, valuation allowances, assessment of impairment of intangible assets and goodwill, purchase price allocation on acquisitions, contingencies, restructuring and sales and reserves allowances.
	b.       Principles of consolidation:
	The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and Variable Interest Entities ("VIEs") for which the Company is considered the primary beneficiary. For VIEs, the Company performs an analysis to determine whether the variable interests give a controlling financial interest in a VIE; the Company periodically reassesses whether it controls its VIEs.
	Intercompany transactions and balances are eliminated in consolidation; profits from intercompany sales, not yet realized outside the Group, are also eliminated.
	The Company includes the results of operations of an acquired business from the date of acquisition.
	c.       Investee companies:
	Investments in entities in which the Company has a significant influence are accounted for using the equity method and included within other non-current assets. Under the equity method, the Company generally recognizes its proportionate share of comprehensive income or loss of the entity. Other non-marketable equity investments are carried at cost. The Company also reviews these investments for impairment whenever events indicate the carrying amount may not be recoverable.
	d.       Cash and cash equivalents:
	All highly liquid investments, which include short-term bank deposits and money market instruments, that are not restricted as to withdrawal or use, and investment in short-term debentures, the period to maturity of which did not exceed three months at the time of investment, are considered to be cash equivalents.
	e.       Inventories:
	Inventories are valued at the lower of cost or market. Cost of raw and packaging materials and purchased products is determined mainly on a “moving average” basis. Cost of finished products and products in process is calculated assuming normal manufacturing capacity of the production facilities and determined as follows: the raw and packaging materials component—mainly on a “moving average” basis; the capitalized production costs component—mainly on an average basis over the production period.
	Inventories acquired in a business combination are stepped-up to their estimated fair value and amortized to cost of sales as that inventory is sold.
	f.       Investment in securities:
	Investment in securities consists mainly of debt and equity securities classified as available-for-sale and recorded at fair value. The fair value of quoted securities is based on current market value. When debt securities do not have an active market, fair value is determined using a valuation model. This model is based on reference to other instruments with similar characteristics, or a discounted cash flow analysis, or other pricing models making use of market inputs and relying as little as possible on entity-specific inputs.
	Unrealized gains of available for sale securities, net of taxes, are reflected in other comprehensive income. Unrealized losses considered to be temporary are reflected in other comprehensive income; unrealized losses that are considered to be other-than-temporary are charged to income as an impairment charge. Realized gains and losses for both debt and equity securities are included in financial expense, net.
	The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost, and for equity securities, the Company's ability and intent to hold the investment for the length of time necessary to allow for the recovery of the market value. For debt securities, an other-than-temporary impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the other-than-temporary impairment recognized in earnings, recorded in financial expense, net, is limited to the portion attributed to credit loss. The remaining portion of the other-than-temporary impairment related to other factors is recognized in other comprehensive income.
	g.       Long-lived assets:
	Teva's long-lived, non-current assets are comprised mainly of goodwill, identifiable intangible assets and property, plant and equipment. Teva reviews its long-lived assets and performs detailed testing whenever potential impairment indicators are present. In addition, the Company performs impairment testing at the end of each year for goodwill and identifiable indefinite life intangible assets.
	Starting in 2015, the Company will change its annual goodwill impairment testing date from December 31 to October 1 of each year. This change will allow Teva to complete the annual goodwill impairment test prior to the end of the annual reporting period, and thereby better align impairment testing procedures with the Company's budget and forecasting processes and with year-end financial reporting. Accordingly, management considers this accounting change preferable. We do not expect this change to have a material effect on our valuation, nor to accelerate, delay, avoid, or trigger an impairment charge or result in adjustments to previously issued financial statements.
	Goodwill
	Goodwill reflects the excess of the consideration paid or transferred plus the fair value of contingent consideration and any non-controlling interest in the acquiree at the acquisition date over the fair values of the identifiable net assets acquired. The goodwill impairment test is performed according to the following principles:
	An initial qualitative assessment of the likelihood of impairment may be performed. If this step does not result in a more likely than not indication of impairment, no further impairment testing is required. If it does result in a more likely than not indication of impairment, the impairment test is performed.
	In step one of the impairment test, Teva compares the fair value of the reporting units to the carrying value of net assets allocated to the reporting units. If the fair value of the reporting unit exceeds the carrying value of the net assets allocated to that unit, goodwill is not impaired, and no further testing is required. Otherwise, Teva must perform the second step of the impairment test to measure the amount of the impairment.
	In the second step, the reporting unit's fair value is allocated to all the assets and liabilities of the reporting unit, including any unrecognized intangible assets, in a hypothetical analysis that simulates the business combination principles to derive an implied goodwill value. If the implied fair value of the reporting unit's goodwill is less than its carrying value, the difference is recorded as an impairment.
	Identifiable intangible assets
	Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets.
	Definite life intangible assets consist mainly of acquired product rights and other rights relating to products for which marketing approval was received from the U.S. Food and Drug Administration (“FDA”) or the equivalent agencies in other countries. These assets are amortized using mainly the straight-line method over their estimated period of useful life, or based on economic effect models, if more appropriate, which is determined by identifying the period in which substantially all of the cash flows are expected to be generated. Amortization of acquired developed products is recorded under cost of sales. Amortization of marketing and distribution rights is recorded under selling and marketing expenses.
	For definite life intangibles, whenever impairment indicators are identified, Teva reconsiders the asset's estimated life, calculates the undiscounted value of the asset's cash flows and compares such value against the asset's carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of book value over fair value based on the discounted cash flows.
	Indefinite life intangible assets are mainly comprised of research and development in-process. Teva monitors development for any triggering events. Annually or when triggering events are present, Teva determines the fair value of the asset based on discounted cash flows on and records an impairment loss if book value exceeds fair value.
	Research and development in-process acquired in a business combination is capitalized as an indefinite life intangible asset until the related research and development efforts are either completed or abandoned. In the reporting period where they are treated as indefinite life intangible assets, they are not amortized but rather are monitored and tested for impairment. Upon completion of the related research and development efforts, management determines the useful life of the intangible assets and amortizes them accordingly. In case of abandonment, the related research and development assets are impaired.
	Property, plant and equipment
	Property, plant and equipment are stated at cost, after deduction of the related investment grants, and depreciated using the straight-line method over the estimated useful life of the assets: buildings, mainly 40 years; machinery and equipment, mainly between 15 to 20 years; and other assets, between 5 to 10 years.
	For property, plant and equipment, whenever impairment indicators are identified, Teva reconsiders the asset's estimated life, calculates the undiscounted value of the asset's cash flows and compares such value against the asset's carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of book value over fair value.
	h.       Contingencies:
	The Company and its subsidiaries are involved in various patent, product liability, commercial, government investigations, environmental claims and other legal proceedings that arise from time to time in the ordinary course of business. Except for income tax contingencies or contingent consideration acquired in a business combination, Teva records accruals for these types of contingencies to the extent that Teva concludes their occurrence is probable and that the related liabilities are estimable. When accruing these costs, the Company will recognize an accrual in the amount within a range of loss that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company accrues for the minimum amount within the range. Teva records anticipated recoveries under existing insurance contracts that are virtually certain of occurring at the gross amount that is expected to be collected. Legal costs are expensed as incurred.
	i.       Uncertain tax positions:
	Teva recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. We regularly re-evaluate our tax positions based on developments in our tax audits, statute of limitations expirations, changes in tax laws and new information that can affect the technical merits and change the assessment of our ability to sustain the tax benefit. In addition, the Company classifies interest and penalties recognized in the financial statements relating to uncertain tax position under the income taxes line item.
	j.       Treasury shares:
	Treasury shares are held by Teva's subsidiaries and presented as a reduction of Teva shareholders' equity and carried at their cost to Teva, under treasury shares.
	k.       Stock-based compensation:
	Teva recognizes the estimated fair value of share-based awards, restricted share units (“RSUs”) and performance share units ("PSUs"), net of estimated forfeitures, under stock-based compensation costs. The compensation expense for PSUs is recognized only if it is probable that the performance condition will be achieved.
	Teva measures compensation expense for share-based awards based on estimated fair values on the date of grant using the Black-Scholes option-pricing model. This option pricing model requires estimates as to the option's expected term and the price volatility of the underlying stock.
	Teva measures compensation expense for the RSUs and PSUs based on the market value of the underlying stock at the date of grant, less an estimate of dividends that will not accrue to the RSU and PSU holders prior to vesting.
	l.       Revenue recognition:
	The Company recognizes revenues from product sales, including sales to distributors when persuasive evidence of an arrangement exists, delivery has occurred, the selling price is fixed or determinable and collectability is reasonably assured. This generally occurs when products are shipped and title and risk and rewards for the products are transferred to the customer.
	Revenues from product sales are recorded net of provisions for estimated chargebacks, rebates, returns, prompt pay discounts and other deductions, such as shelf stock adjustments, which can be reasonably estimated. When sales provisions are not considered reasonably estimable by Teva, the revenue is deferred to a future period when more information is available to evaluate the impact.
	Provisions for chargebacks, rebates including Medicaid and other governmental program discounts, and other promotional items, such as shelf stock adjustments, are included in SR&A under current liabilities. These provisions are recognized concurrently with the sales of products. Prompt payment discounts are netted against accounts receivable.
	Calculations for these deductions from sales are based on historical experience and the specific terms in the individual agreements. Chargebacks and rebates are the largest components of sales reserves and allowances. Provisions for chargebacks are determined using historical chargeback experience and expected chargeback levels and wholesaler sales information for new products, which are compared to externally obtained distribution channel reports for reasonableness. Rebates are recognized based on contractual obligations in place at the time of sales with consideration given to relevant factors that may affect the payment as well as historical experience for estimated market activity. Shelf-stock adjustments are granted to customers based on the existing inventory of a customer following decreases in the invoice or contract price of the related product and are estimated based on expected market performance. Teva records a reserve for estimated sales returns by applying historical experience of customer returns to the amounts invoiced and the amount of returned products to be destroyed versus products that can be placed back in inventory for resale.
	Revenue resulting from the achievement of milestone events stipulated in agreements is recognized when the milestone is achieved. Milestones are based upon the occurrence of a substantive element specified in the contract or as a measure of substantive progress towards completion under the contract.
	Revenues from licensees, sales of licensed products and technology are recorded in accordance with the contract terms, when third-party sales can be reliably measured and collection of the funds is reasonably assured.
Revenues include royalty income and income from services, which amounted to $167 million, $182 million and $438 million in the years ended December 31, 2014, 2013 and 2012, respectively.
m.       Research and development:
Research and development expenses are charged as incurred. Participations and grants in respect of research and development expenses are recognized as a reduction of research and development expenses as the related costs are incurred, or as the related milestone is met. Upfront fees received in connection with cooperation agreements are deferred and recognized over the period of the applicable agreements as a reduction of research and development expenses.
Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or the services are performed.
Research and development in-process acquired as part of an asset purchase, which has not reached technological feasibility and has no alternative future use, is expensed as incurred.
n.       Shipping and handling costs:
Shipping and handling costs, which are included in selling and marketing expenses, amounted to $151 million, $232 million and $230 million for the years ended December 31, 2014, 2013 and 2012, respectively.
o.       Advertising expenses:
Advertising expenses are charged to income as incurred. Advertising expenses for the years ended December 31, 2014, 2013 and 2012 were $302 million, $321 million and $337 million, respectively.
p.       Deferred income taxes:
Deferred income taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of temporary differences between the financial accounting and tax basis of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred income taxes are expected to be paid or realized. A valuation allowance is provided if, based upon the weight of available evidence, it is more likely than not that a portion of the deferred income tax assets will not be realized. In determining whether a valuation allowance is needed, we consider all available evidence, including historical information, long range forecast of future taxable income and evaluation of tax planning strategies. Amounts recorded for valuation allowance can result from a complex series of judgments about future events and can rely on estimates and assumptions. Deferred income tax liabilities and assets are classified as current or non-current based on the classification of the related asset or liability for financial reporting, or according to the expected reversal dates of the specific temporary differences where appropriate.
Deferred tax has not been provided on the following items:
(1) Taxes that would apply in the event of disposal of investments in subsidiaries, as it is generally the Company's intention to hold these investments, not to realize them.
(2) Amounts of tax-exempt income generated from the Company's current Approved Enterprises and unremitted earnings from foreign subsidiaries retained for reinvestment in the Group. See note 16f.
q.       Earnings per share:
Basic earnings per share are computed by dividing the net income attributable to Teva by the weighted average number of ordinary shares (including fully vested RSUs) outstanding during the year, net of treasury shares.
In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i) the exercise of options and non-vested RSUs and PSUs granted under employee stock compensation plans and one series of convertible senior debentures, using the treasury stock method; and (ii) the conversion of the remaining convertible senior debentures using the “if-converted” method, by adding to net income interest expense on the debentures and amortization of issuance costs, net of tax benefits, and by adding the weighted average number of shares issuable upon assumed conversion of the debentures.
r.       Concentration of credit risks:
Most of Teva's cash and cash equivalents (which along with investment in securities amounted to $2.6 billion at December 31, 2014) were deposited with financially sound European, U.S. and Israeli banks and financial institutions and were comprised mainly of cash deposits.
The pharmaceutical industry, particularly in the U.S., has been significantly affected by consolidation among managed care providers, large pharmacy chains, wholesaling organizations and other buyer groups. The U.S. market constitutes approximately 52.5% of Teva's consolidated revenues and a relatively small portion of total trade accounts after netting amounts in SR&A. The exposure of credit risks relating to other trade receivables is limited, due to the relatively large number of group customers and their wide geographic distribution. Teva performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for doubtful accounts and generally does not require collateral. An appropriate allowance for doubtful accounts is included in the accounts and netted against accounts receivable.
s.       Derivatives and hedging:
The Group carries out transactions involving derivative financial instruments (mainly forward exchange contracts, written and purchased currency options, cross-currency swap contracts and interest rate swap contracts). The transactions are designed to hedge the Company's currency and interest rate exposures.
The Company does not enter into derivative transactions for trading purposes.
Derivatives that do not qualify for hedge accounting are recognized on the balance sheet at their fair value, with changes in the fair value recognized as a component of financial expenses - net in the statements of income. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.
Derivatives that qualify as a fair value hedge are recognized on the balance sheet at their fair value, with changes in the fair value reported with the carrying amount of the hedged asset or liability.
For derivatives that qualify as cash-flow hedge, the effective portion of these derivatives' fair value is initially reported as a component of other comprehensive income.
For derivatives that qualify for hedge accounting, the cash flows associated with these derivatives are reported in the consolidated statements of cash flows consistently with the classification of cash flows from the underlying hedged items that these derivatives are hedging.
t.       Fair value measurement:
The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:
Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2: Observable inputs that are based on inputs not quoted on active markets, but corroborated by market data.
Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers credit risk in its assessment of fair value.
u.       Collaborative arrangements:
A Collaborative agreements are contractual arrangements in which the parties are active participants to the arrangement and are exposed to the significant risks and rewards that are dependent on the ultimate commercial success of the endeavor. See note 2.
The Company recognizes revenue generated and costs incurred on sales to third parties as they relate to a collaborative agreement as gross or net. If the Company is the principal participant in a transaction, revenues are recorded on a gross basis; otherwise, revenues are recorded on a net basis.
v.       Segment reporting:
The Company's business includes two reporting segments: generic and specialty medicines. The generics segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients ("API"). The specialty segment engages in the development, manufacture, sale and distribution of branded specialty medicines such as those for central nervous system and respiratory indications, as well as those marketed in the women's health, oncology and other specialty businesses. See note 21.
w.       Restructuring:
Restructuring charges are initially recorded at fair value, and recognized in connection with restructuring programs designed to reduce the cost structure, increase efficiency and enhance competitiveness. Judgment is used when estimating the impact of restructuring plans, including future termination benefits and other exit costs to be incurred when the actions take place. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. Actual results could vary from these estimates.
x.       Reclassifications:
Certain comparative figures have been reclassified to conform to the current year presentation.
y.       Recently issued accounting pronouncements:
In August 2014, the Financial Accounting Standards Board ("FASB") issued amended guidance related to disclosure of uncertainties about an entity's ability to continue as a going concern. The new guidance requires management to evaluate whether there is substantial doubt about the entity's ability to continue as a going concern and, as necessary, to provide related footnote disclosures. The guidance has an effective date of December 31, 2016. Teva believes that the adoption of this new standard will not have a material impact on its consolidated financial statements.
In May 2014, the FASB issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is that an entity will recognize revenue upon the transfer of goods or services to customers in an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December 15, 2016 (early adoption is not permitted). The guidance permits the use of either a retrospective or cumulative effect transition method. Teva is currently evaluating the potential effect of the amended guidance on its consolidated financial statements.
In April 2014, the FASB issued amended guidance related to discontinued operations. The new guidance limits the presentation of discontinued operations to business circumstances when the disposal of the business operation represents a strategic shift that has had or will have a major effect on operations and financial results. This guidance is effective for fiscal years beginning January 1, 2015. Teva believes that the adoption of this new standard will not materially impact its consolidated financial statements.

CERTAIN_TRANSACTIONS

CERTAIN TRANSACTIONS	0 Months Ended
	Dec. 31, 2014
Certain Transactions [Abstract]
Certain Transactions	NOTE 2 – CERTAIN TRANSACTIONS:
	a. Business transactions:
	Labrys Biologics, Inc.:
	On July 17, 2014, Teva fully acquired Labrys Biologics, Inc. ("Labrys") for an upfront cash payment of $207 million and up to $625 million in contingent payments upon achievement of certain milestones. Labrys is a development stage biotechnology company focused on treatments for chronic migraine and episodic migraine.
	At the time of the acquisition, the potential additional payments were evaluated and recorded at a fair value of $251 million. Additionally, as part of the transaction, $125 million were placed in an escrow fund and booked as a current asset, as funds will be disbursed once a milestone event is reached.
	Pro forma information giving effect to the acquisition has not been provided as the results would not be material.
	NuPathe Inc.:
	On February 21, 2014, Teva completed the acquisition of NuPathe Inc. ("NuPathe"). NuPathe's leading product is Zecuity®, a prescription migraine patch approved by the FDA for the acute treatment of migraine with or without aura in adults.
	Teva purchased all of NuPathe's shares for consideration of $163 million and up to $130 million in contingent payments upon the achievement of sales-based milestones for Zecuity®. At the time of the acquisition, these potential additional payments were evaluated and recorded at a fair value of $106 million, based on the probability of achieving these milestones.
	Pro forma information giving effect to the acquisition has not been provided as the results would not be material.
	b. Significant collaborative agreements:
	<>The Company has entered into alliances and other arrangements with third parties to acquire rights to products it does not have, to access markets it does not operate in and to otherwise share development costs or business risks. The Company's most significant agreements of this nature are summarized below. <
	<       With Takeda:
	Teva and Takeda Pharmaceutical Company Limited ("Takeda") have entered into agreements allowing Takeda to commercialize Teva's innovative treatments for Parkinson's disease and multiple scleroses (marketed globally under the product names "Copaxone®" and "Azilect®") in Japan. Under these agreements, Teva may be entitled to certain development, regulatory and sales-based milestones or royalty payments. The financial effects of these agreements were not material to our consolidated financial results.
	With The Procter & Gamble Company (“P&G”):
	In November 2011, Teva formed PGT Healthcare, a consumer healthcare joint venture with The Procter & Gamble Company (“P&G”). Headquartered in Geneva, Switzerland, the joint venture focuses on branded OTC medicines in categories such as cough/cold and allergy, digestive wellness, vitamins, minerals and supplements, analgesics and skin medications, and operates in all markets outside North America. Its leading brands are Vicks®, Metamucil®, Pepto-Bismol®, and ratiopharm. PGT Healthcare's strengths include P&G's strong brand-building, consumer-led innovation and go-to-market capabilities; Teva's broad geographic reach, experience in R&D, regulatory and manufacturing expertise and extensive portfolio of products, and each company's scale and operational efficiencies.
	Teva owns 49% of the joint venture, and P&G holds a controlling financial interest of 51%. The Company recognizes profits of the joint venture based on Teva's ownership percentage. The joint venture has certain independent operations and contracts for other services from its two partners in an effort to leverage their scale and capabilities and thereby maximize efficiencies. Such services include research and development, manufacturing, sales and distribution, administration and other services, provided under agreements with the joint venture. The partners have certain rights to terminate the joint venture after seven years and earlier under other circumstances.
	In July 2014, Teva sold its U.S. OTC plants, which were purchased as part of the agreement, back to P&G.
	c. Agreements with related parties:
	In December 2012, Teva entered into a collaborative development and exclusive worldwide license agreement with Xenon for its compound XEN402. XEN402 is currently in clinical development for a variety of painful disorders. Under the agreement, Teva paid Xenon an upfront fee of $41 million. In addition, Teva may be required to pay development, regulatory and sales-based milestones of up to $335 million. Xenon is also entitled to royalties on sales and has an option to participate in commercialization in the United States. As required by the agreement, in November 2014, Teva invested an additional $10 million in Xenon in connection with its initial public offering. Dr. Michael Hayden, Teva's President of Global R&D and Chief Scientific Officer, is the founder, a minority shareholder and a member of the board of directors of Xenon. In order to avoid potential conflicts of interest, Teva has established certain procedures to exclude Dr. Hayden from any involvement in Teva's decision-making related to Xenon.
	In September 2011, Teva entered into an agreement with CoCrystal Discovery, Inc. (now CoCrystal Pharmaceuticals, Inc.), a company focusing on the discovery and development of novel therapeutics, utilizing an innovative drug discovery technology. Under the agreement, Teva agreed to fund the company's R&D by investing up to two tranches of $7.5 million each per target (the latter one being discretionary). The first tranche was invested by Teva in 2011. We terminated this agreement effective as of November 2014. Dr. Phillip Frost, our Chairman of the Board of Directors until December 2014 and a member of our Board of Directors until February 4, 2015, and Prof. Roger Kornberg, who was a member of Teva's Board of Directors until August 2013, are both direct and indirect shareholders in and members of the board of directors of CoCrystal Pharmaceuticals. Prof. Roger Kornberg is also Chief Scientific Officer of CoCrystal Pharmaceuticals.
	CTG Weld Limited, a privately owned contract research organization, has rendered services to Teva in connection with clinical trials since 2002. In 2011, Chaim Hurvitz, a member of our Board of Directors until July 2014, invested in, and became a member of the board of directors of CTG Weld. In 2014, 2013 and 2012, Teva paid CTG Weld approximately €0.6 million, €0.8 million and €1.3 million, respectively, in connection with various clinical studies.
	Teva leases 13,500 square feet of office space located in Miami, Florida from an entity controlled by Dr. Frost, our Chairman of the Board of Directors until December 2014 and a member of our Board of Directors until February 4, 2015. The term of the lease extends until April 2015, with Teva options to renew for two additional three-year terms. Annual rent was $305,000 until April 1, 2012, $412,000 until March 31, 2013, $431,442 until March 31, 2014 and is currently $448,700 until March 31, 2015, increasing 4% per year for each renewal term. The office space includes offices Teva provided Dr. Frost in his capacity as Chairman of the Board.

FAIR_VALUE_MEASUREMENT

FAIR VALUE MEASUREMENT	0 Months Ended
	Dec. 31, 2014
Fair Value Measurement [Abstract]
Fair Value Measurement	NOTE 3 – FAIR VALUE MEASUREMENT:
	Financial items carried at fair value as of December 31, 2014 and 2013 are classified in the tables below in one of the three categories described in note 1t:
			31-Dec-14
			(U.S. $ in millions)
			Level 1		Level 2		Level 3		Total
	Cash and cash equivalents:
		Money markets	$	10	$	-	$	-	$	10
		Cash deposits and other		2,216		-		-		2,216
	Escrow fund			125		-		-		125
	Investment in securities:
		Auction rate securities		-		-		13		13
		Equity securities		66		-		-		66
		Structured investment vehicles		-		96		-		96
		Other, mainly debt securities		73		-		1		74
	Derivatives:
		Asset derivatives - options and forward contracts		-		82		-		82
		Asset derivatives - cross-currency swaps		-		20		-		20
		Liabilities derivatives - options and forward contracts		-		-54		-		-54
		Liabilities derivatives - interest rate swaps		-		-43		-		-43
	Contingent consideration *			-		-		-630		-630
	Total		$	2,490	$	101	$	-616	$	1,975
			31-Dec-13
			(U.S. $ in millions)
			Level 1		Level 2		Level 3		Total
	Cash and cash equivalents:
		Money markets	$	9	$	-	$	-	$	9
		Cash deposits and other		1,029		-		-		1,029
	Investment in securities:
		Auction rate securities		-		-		18		18
		Equity securities		70		-		-		70
		Structured investment vehicles		-		89		-		89
		Other		29		-		1		30
	Derivatives:
		Asset derivatives - options and forward contracts		-		28		-		28
		Asset derivatives- interest rate swaps		-		2		-		2
		Liability derivatives - options and forward contracts		-		-17		-		-17
		Liability derivatives- interest rate and cross-currency swaps		-		-436		-		-436
	Contingent consideration *			-		-		-366		-366
	Total		$	1,137	$	-334	$	-347	$	456
	__________________________
	* Contingent consideration represents either liabilities or assets recorded at fair value in connection with acquisitions and the sale of our animal health unit.
	Teva determined the fair value of the liability or asset of contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration is based on several factors, such as: the cash flows projected from the success of unapproved product candidates; the probability of success for product candidates including risks associated with uncertainty regarding achievement and payment of milestone events; the time and resources needed to complete the development and approval of product candidates; the life of the potential commercialized products and associated risks of obtaining regulatory approvals in the U.S. and Europe and the discount rate for fair value measurement.
	The contingent consideration is evaluated quarterly or more frequently if circumstances dictate. Changes in the fair value of contingent consideration are recorded in earnings under impairments, restructuring and others.
	Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material changes to the contingent consideration liability.
	The following table summarizes the activity for those financial assets and liabilities where fair value measurements are estimated utilizing Level 3 inputs.
			December 31,
			2014		2013
			(U.S. $ in millions)
		Fair value at the beginning of the period	$	-347	$	-98
		Amount realized		-5		-16
		Changes in contingent consideration:
		Cephalon acquisition		-35		-12
		MicroDose acquisition		140		-232
		Sale of animal health unit		-5		8
		Contingent consideration resulting from:
		NuPathe acquisition		-112		-
		Labrys acquisition		-252		-
		Other net change to fair value:
		Included in earnings - financial expense - net		-		1
		Included in accumulated other comprehensive loss		-		2
		Fair value at the end of the period	$	-616	$	-347
	Financial instruments not measured at fair value
	Teva's financial instruments consist mainly of cash and cash equivalents, investments in securities, current and non-current receivables, short-term credit, accounts payable and accruals, long-term loans and other long-term senior notes and loans, convertible senior debentures and derivatives.
	The fair value of the financial instruments included in working capital and non-current receivables approximates their carrying value. The fair value of long-term bank loans mostly approximates their carrying value, since they bear interest at rates close to the prevailing market rates.
Financial instruments measured on a basis other than fair value are mostly comprised of senior notes and convertible senior debentures, and are presented in the below table in terms of fair value:
		Estimated fair value*
		December 31,
		2014		2013
		(U.S. $ in millions)
	Senior notes included under long-term liabilities	$	-7,776	$	-8,656
	Senior notes and convertible senior debentures included under short-term liabilities		-1,731		-1,308
	Fair value at the end of the period	$	-9,507	$	-9,964
* The fair value was estimated based on quoted market prices, where available.

MARKETABLE_SECURITIES

MARKETABLE SECURITIES	0 Months Ended
	Dec. 31, 2014
Marketable Securities [Abstract]
Marketable Securities	NOTE 4—INVESTMENT IN SECURITIES:
	Available-for-sale securities:
	Available-for-sale securities are comprised mainly of debt securities and equity securities.
	At December 31, 2014 and 2013, the fair value, amortized cost and gross unrealized holding gains and losses of such securities are as follows:
		Fair value			Amortized cost		Gross unrealized holding gains		Gross unrealized holding losses
		(U.S. $ in millions)
	31-Dec-14	$	259		$	266	$	19	$	26
	31-Dec-13	$	216		$	213	$	25	$	22
	Investments in securities are classified based on the initial maturity as well as the intended time of realization.
	Investments in securities are presented in the balance sheet as follows:
		December 31,
		2014			2013
		(U.S. $ in millions)
	Other non-current assets	$	176		$	179
	Other current assets		73			28
	Cash and cash equivalents, mainly money market funds		10			9
		$	259		$	216
	b.	Contractual maturities:
	The contractual maturities of debt securities are as follows:
			December 31,
			2014
			(U.S. $ in millions)
		2015	$	83
		2016		1
		2017		0
		2018		0
		2019		0
		2020 and thereafter		109
			$	193

INVENTORIES

INVENTORIES	0 Months Ended
	Dec. 31, 2014
Inventories [Abstract]
Inventories	NOTE 5—INVENTORIES:
		Inventories, net of reserves, consisted of the following:
				December 31,
				2014		2013
				(U.S. $ in millions)
			Finished products	$	2,268	$	2,567
			Raw and packaging materials		1,279		1,576
			Products in process		638		715
			Materials in transit and payments on account		186		195
				$	4,371	$	5,053

PROPERTY_PLANT_AND_EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	0 Months Ended
	Dec. 31, 2014
Property Plant And Equipment [Abstract]
Property, Plant and Equipment	NOTE 6—PROPERTY, PLANT AND EQUIPMENT:
		Property, plant and equipment, net, consisted of the following:
				December 31,
				2014		2013
				(U.S. $ in millions)
			Machinery and equipment	$	4,893	$	4,633
			Buildings		2,653		2,635
			Computer equipment and other assets		1,391		1,310
			Payments on account		571		716
			Land*		372		446
					9,880		9,740
			Less—accumulated depreciation		3,345		3,105
				$	6,535	$	6,635
		*	Land includes long-term leasehold rights in various locations, with useful lives of between 30 and 99 years.
		Depreciation expenses were $464 million, $458 million and $428 million in the years ended December 31, 2014, 2013 and 2012, respectively. During the years ended December 31, 2014, 2013 and 2012, Teva had impairments of property, plant and equipment in the amount of $163 million, $61 million and $190 million, respectively. See note 19.

GOODWILL_DISCLOSURE

GOODWILL DISCLOSURE	0 Months Ended
	Dec. 31, 2014
Goodwill [Abstract]
Goodwill Disclosure	NOTE 7—GOODWILL:
	The changes in the carrying amount of goodwill for the year ended December 31, 2014 was as follows:
			Generics		Specialty		Other		Total
				(U.S. $ in millions)
		Balance as of January 1, 2014	$	9,088	$	8,668	$	1,225	$	18,981
		Changes during year:
		Goodwill acquired		-		183		-		183
		Translation differences and other		-358		-349		-49		-756
		Balance as of December 31, 2014	$	8,730	$	8,502	$	1,176	$	18,408
	<><As of December 31, 2014, 2013 and 2012, the Company determined that there was no impairment with respect to goodwill.

IDENTIFIABLE_INTANGIBLE_ASSET

IDENTIFIABLE INTANGIBLE ASSET	0 Months Ended
	Dec. 31, 2014
Identifiable Intangible Asset [Abstract]
Identifiable Intangible Asset [Text Block]	NOTE 8 - IDENTIFIABLE INTANGIBLE ASSETS:
		Identifiable intangible assets consisted of the following:
			Original amount net of impairment				Accumulated amortization				Amortized balance
			December 31,
			2014		2013		2014		2013		2014		2013
			(U.S. $ in millions)
		Product rights	$	9,606	$	10,037	$	5,343	$	4,601	$	4,263	$	5,436
		Trade names		243		270		54		55		189		215
		Research and development in process		1,060		825		0		0		1,060		825
		Total	$	10,909	$	11,132	$	5,397	$	4,656	$	5,512	$	6,476
	Product rights and trade names are assets presented at amortized cost. These assets represent a portfolio of pharmaceutical products from various categories with a weighted average life of approximately 10 years. Amortization of intangible assets amounted to $1,036 million, $1,180 million and $1,272 million in the years ended December 31, 2014, 2013 and 2012, respectively.
	Teva's in process research and development are assets that have not yet been approved in major markets. Teva's in process research and development is comprised mainly of the following assets: LBR-101 (Labrys) - $439 million; Revascor ® (Cephalon) - $258 million; Reslizumab (formerly known as Cinquil®, Cephalon) - $215 million; and LAMA/LABA (MicroDose) - $62 million. In-process research and development carry intrinsic risks that the asset might not succeed in advanced phases and will be impaired in future periods.
	<><><>Impairment of identifiable intangible assets amounted to $224 million, $393 million and $858 million in the years ended December 31, 2014, 2013 and 2012, respectively, and are recorded in earnings under impairments, restructuring and others. See note 19.
	<><><>As of December 31, 2014, the estimated aggregate amortization of intangible assets for the years 2015 to 2019 is as follows: 2015—$796 million; 2016—$677 million; 2017—$650 million; 2018—$609 million and 2019—$489 million.

SHORT_TERM_DEBT

SHORT TERM DEBT	0 Months Ended
	Dec. 31, 2014
Short Term Debt [Abstract]
Short Term Debt	NOTE 9—SHORT-TERM DEBT:
	a.	Short-term debt:	December 31,
			2014		2013
			(U.S. $ in millions)
		Banks and financial institutions	$	46	$	458
		Convertible debentures (see note 13)		530		530
		Current maturities of long-term liabilities		1,185		816
		Total	$	1,761	$	1,804
	<>Short-term debt has an earliest date of repayment within 12 months.
	Bank loans had a weighted average interest rate of 1.1% and 0.9% at December 31, 2014 and 2013, respectively.
	b.       Line of credit:
	In December 2012, the Company entered into a five-year $3.0 billion unsecured syndicated credit facility, which replaced the previous $2.5 billion facility. As of December 31, 2014, the credit facility remained unutilized.

SALES_RESEARVES_AND_ALLOWANCES

SALES RESEARVES AND ALLOWANCES	0 Months Ended
	Dec. 31, 2014
Sales Researves And Allowancess [Abstract]
Sales Researves And Allowancess [Text Block]	NOTE 10—SALES RESERVES AND ALLOWANCES:
	Sales reserves and allowances consisted of the following:
			December 31,
			2014		2013
			(U.S. $ in millions)
		Rebates	$	2,842	$	2,242
		Chargebacks		1,129		1,114
		Medicaid		1,099		848
		Returns		593		573
		Other		186		141
			$	5,849	$	4,918

LONG_TERM_EMPLOYEE_RELATED_OBL

LONG TERM EMPLOYEE RELATED OBLIGATIONS	0 Months Ended
	Dec. 31, 2014
Long Term Employee Related Obligations [Abstract]
Long Term Employee Related Obligations	NOTE 11—LONG-TERM EMPLOYEE-RELATED OBLIGATIONS:
	a.	Long-term employee-related obligations consisted of the following:
			December 31,
			2014		2013
			(U.S. $ in millions)
		Accrued severance obligations	$	146	$	132
		Defined benefit plans		188		149
		Total	$	334	$	281
	<>As of December 31, 2014 and 2013, the Group had $146 million and $156 million, respectively, deposited in funds managed by financial institutions that are earmarked by management to cover severance pay liability mainly in respect of Israeli employees. Such deposits are not considered to be “plan assets” and are therefore included in long-term investments and receivables.
	Most of the change resulted from actuarial updates, as well as from exiting from several defined benefit plans in several countries.
	<>The Company expects to contribute approximately $126 million in 2015 to the pension funds and insurance companies in respect of its severance and pension pay obligations.
	<>The main terms of the different arrangements with employees are described in b. below.
	<>b.       Terms of arrangements:
	<><><Israel
	Israeli law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Parent Company and its Israeli subsidiaries make ongoing deposits into employee pension plans to fund their severance liabilities. According to the general collective pension agreement in Israel, Company deposits with respect to employees who were employed by the Company after the agreement took effect are made in lieu of the Company's severance liability, therefore no obligation is provided for in the financial statements. Severance pay liabilities with respect to employees who were employed by the Parent Company and its Israeli subsidiaries prior to the collective pension agreement effective date, as well as employees who have special contractual arrangements, are provided for in the financial statements based upon the number of years of service and the latest monthly salary.
	<><>Europe
	Many of the employees in the Company's European subsidiaries are entitled to a retirement grant when they leave. In the consolidated financial statements, the liability of the subsidiaries is accrued, based on the length of service and remuneration of each employee at the balance sheet date. Other employees in Europe are entitled to a pension according to a defined benefit scheme providing benefits based on final or average pensionable pay or according to a hybrid pension scheme that provides retirement benefits on a defined benefit and a defined contribution basis. Independent certified actuaries value these schemes and determine the rates of contribution payable. Pension costs for the defined benefit section of the scheme are accounted for on the basis of charging the expected cost of providing pensions over the period during which the subsidiaries benefit from the employees' services. The Company uses December 31 as the measurement date for defined benefit plans.
	<><>North America<>
	The Company's North American subsidiaries mainly provide various defined contribution plans for the benefit of their employees. Under these plans, contributions are based on specified percentages of pay. Additionally, a multi-employer plan is maintained in accordance with various union agreements.
	<><>Latin America<>
	The majority of the employees in Latin America are entitled to severance under local law. The severance payments are calculated based on service term and employee remuneration, and accruals are maintained to reflect these amounts. In some Latin American countries it is Teva practice to offer retirement health benefits to employees who met the service term requirements. Based on the specific plan requirements and benefits accruals are maintained to reflect the estimated amounts or if future plans are modified.
	<>The Company expects to pay the following future minimum benefits to its employees: $8 million in 2015; $10 million in 2016; $10 million in 2017; $12 million in 2018; $10 million in 2019 and $57 million between 2020 to 2024. These amounts do not include amounts that might be paid to employees who cease working with the Company before their normal retirement age.

SENIOR_NOTES_AND_LOANS

SENIOR NOTES AND LOANS	0 Months Ended
	Dec. 31, 2014
Senior Notes and Loans [Abstract]
Senior Notes and Loans	NOTE 12—SENIOR NOTES AND LOANS:
	a.	Senior notes and loans consisted of the following:
			Weighted average interest rate as of December 31, 2014		December 31,
					2014		2013
			%		(U.S. $ in millions)
	Senior notes (1)(2)(3)		2.9		$	8,335	$	9,517
	Loans, mainly from banks (4)(5)		1.2			1,401		1,671
	Debentures (5)		7.2			15		15
						9,751		11,203
	Less - current portion (included under “short-term debt”)					-1,185		-816
					$	8,566	$	10,387
	1. Senior notes as of December 31, 2014 are effectively denominated (taking into consideration cross currency swap agreements) in the following currencies: U.S. dollar 58%, euro 37% and Swiss franc 5%. The senior notes bear floating and fixed interest ranging from 1.5% to 6.15%.
	2. In March 2014, the Company repaid at maturity $750 million principal amount comprised of $500 million of LIBOR + 0.5% floating rate senior notes and $250 million of 1.7% senior notes, both issued in March 2011.
	3. The above includes derivative instruments defined as hedge accounting- see note 17.
	4. The balance as of December 31, 2014 and 2013 is mainly comprised of:
	* A ¥100.5 billion senior unsecured fixed rate term loan agreement for five and seven years, bearing interest of 0.99% and 1.42%, respectively (approximately $0.8 billion).
	* A ¥35 billion senior unsecured floating rate term loan agreement for five years, borrowed in December 2013, bearing interest of JPY LIBOR + 0.3% (approximately $0.3 billion).
	* Loan from the European Investment Bank (EIB) in the amount of $148 million and $168 million, respectively (denominated in Euro). The loan bears interest determined on the basis of Euro LIBOR + 1%. The loan was fully repaid in January 2015.
	* Debt raised in Japan in the amount of $118 million and $207 million, respectively, mainly related to the Taiyo ayo acquisition comprised of bank loans, capital leases and other loans.
	5. Certain loan agreements and debentures contain restrictive covenants, mainly the requirement to maintain certain financial ratios. As of December 31, 2014, the Company met all financial covenants.
	6. In January 2014, Teva entered into a term loan facility agreement under which Teva can draw up to $1.0 billion with a term of five years. Teva did not utilize the facility and the agreement was terminated in December 2014.
	b.       The Company and certain subsidiaries entered into negative pledge agreements with certain banks and institutional investors. Under the agreements, the Company and such subsidiaries have undertaken not to register floating charges on assets in favor of any third parties without the prior consent of the banks, to maintain certain financial ratios and to fulfill other restrictions, as stipulated by the agreements.
	c. The required annual principal payments of long-term debt as of December 31, 2014, starting with the year 2016, are as follows:
			December 31,
			2014
			(U.S. $ in millions)
		2016	$	978
		2017		568
		2018		779
		2019		1,517
		2020 and thereafter		4,724
			$	8,566

CONVERTIBLE_SENIOR_DEBENTURES

CONVERTIBLE SENIOR DEBENTURES	0 Months Ended
	Dec. 31, 2014
Convertible Senior Debentures [Abstract]
Convertible Senior Debentures	NOTE 13—CONVERTIBLE SENIOR DEBENTURES:
	Convertible senior debentures amounted to $530 million principal amount at both December 31, 2014 and 2013.
	The convertible debentures at December 31, 2014 consist of the 0.25% convertible senior debentures due 2026. These convertible senior debentures include a “net share settlement” feature according to which the principal amount will be paid in cash and in case of conversion, only the residual conversion value above the principal amount will be paid in Teva shares. Due to the “net share settlement” feature, exercisable at any time, these convertible senior debentures are classified in the balance sheet under short-term debt. The earliest redemption by its holders is February 1, 2016.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	0 Months Ended
	Dec. 31, 2014
Commitments And Contingencies [Abstract]
Commitments And Contingencies	NOTE 14—COMMITMENTS AND CONTINGENCIES:
	a.              Commitments:
	Operating leases:
	As of December 31, 2014, minimum future rentals under operating leases of buildings, machinery and equipment for periods in excess of one year were as follows: 2015—$139 million; 2016—$114 million; 2017—$96 million; 2018—$79 million; 2019—$69 million; 2020 and thereafter—$145 million.
	The lease fees expensed in each of the years ended December 31, 2014, 2013 and 2012 were $153 million, $117 million and $132 million, respectively, of which less than $0.5 million was to related parties in each of the years ended December 31, 2014, 2013 and 2012.
	Royalty commitments:
	The Company is committed to paying royalties to owners of know-how, partners in alliances and other certain arrangements and to parties that financed research and development, at a wide range of rates as a percentage of sales or of the gross margin of certain products, as defined in the underlying agreements.
	Milestone commitments:
	The Company is committed to paying milestone payments, usually as part of business transactions. Such payments are contingent upon the achievement of certain regulatory milestones and sales targets. As of December 31, 2014, were all milestones and targets, for compounds in Phase II and more advanced stages of development, to be achieved, the total contingent payments could reach an aggregate of up to approximately $2.4 billion.
	b.        Contingencies:
	General
	From time to time, Teva and/or its subsidiaries are subject to claims for damages and/or equitable relief arising in the ordinary course of business. In addition, as described below, in large part as a result of the nature of its business, Teva is frequently subject to litigation. Teva believes that it has meritorious defenses to all actions brought against it and vigorously pursues the defense or settlement of each such action. Except as described below, Teva does not currently have a reasonable basis to estimate the loss, or range of loss, that is reasonably possible with respect to matters disclosed in this note.
	Teva records a provision in its financial statements to the extent that it concludes that a contingent liability is probable and the amount thereof is estimable. Based upon the status of these cases, management's assessments of the likelihood of damages, and the advice of counsel, no provisions have been made regarding the matters disclosed in this note, except as noted below. Litigation outcomes and contingencies are unpredictable, and excessive verdicts can occur. Accordingly, management's assessments involve complex judgments about future events and often rely heavily on estimates and assumptions.
	Based on currently available information, Teva believes that none of the proceedings brought against it described below is likely to have a material adverse effect on its financial condition. However, if one or more of such proceedings were to result in final judgments against Teva, such judgments could be material to its results of operations and cash flow in a given period. In addition, Teva incurs significant legal fees and related expenses in the course of defending its positions even if the facts and circumstances of a particular litigation do not give rise to a provision in the financial statements.
	In connection with third-party agreements, Teva may under certain circumstances be required to indemnify, and may be indemnified by, in unspecified amounts, the parties to such agreements against third-party claims. Teva's agreements with third parties may require Teva to indemnify them, or require them to indemnify Teva, for the costs and damages incurred in connection with product liability claims, in specified or unspecified amounts.
	Except as otherwise noted, all of the litigation matters disclosed below involve claims arising in the United States. All third-party sales figures given below are based on IMS data.
	Intellectual Property Litigation
	From time to time, Teva seeks to develop generic versions of patent-protected pharmaceuticals for sale prior to patent expiration in various markets. In the United States, to obtain approval for most generics prior to the expiration of the originator's patents, Teva must challenge the patents under the procedures set forth in the Hatch-Waxman Act of 1984, as amended. To the extent that Teva seeks to utilize such patent challenge procedures, Teva is and expects to be involved in patent litigation regarding the validity, enforceability or infringement of the originator's patents. Teva may also be involved in patent litigation involving the extent to which its product or manufacturing process techniques may infringe other originator or third-party patents.
	Additionally, depending upon a complex analysis of a variety of legal and commercial factors, Teva may, in certain circumstances, elect to market a generic version even though litigation is still pending. This could be before any court decision is rendered or while an appeal of a lower court decision is pending. To the extent Teva elects to proceed in this manner, it could face substantial liability for patent infringement if the final court decision is adverse to Teva.
	The general rule for damages in patent infringement cases in the United States is that the patentee should be compensated by no less than a reasonable royalty, and it may also be able in certain circumstances to be compensated for its lost profits. The amount of a reasonable royalty award would be calculated based on the sales of Teva's generic product. The amount of lost profits would be based on the lost sales of the branded product. The launch of an authorized generic and other generic competition may be relevant to the damages calculation. In addition, the patentee may seek consequential damages as well as enhanced damages of up to three times the profits lost by the patent holder for willful infringement, although courts have typically awarded much lower multiples.
	Teva is also involved in litigation regarding patents in other countries where it does business, particularly in Europe, where Teva has in recent years increased the number of launches of its generic versions of branded pharmaceuticals prior to the expiration of the innovator's patents. The laws concerning generic pharmaceuticals and patents differ from country to country. Damages for patent infringement in Europe may include lost profits or a reasonable royalty, but enhanced damages for willful infringement are generally not available.
	In June 2013, Teva settled its pantoprazole patent litigation with Wyeth and agreed to pay $1.6 billion, which was completed on October 1, 2014. Teva has sought insurance coverage to defray such amount, and in 2014, Teva recovered approximately $200 million from certain of its insurance carriers. Management believes it may have up to approximately $250 million in additional coverage, subject to recovery from the other insurance carriers, which are currently disputing both their obligation to cover and the claimed limits of coverage.
	In September 2012, Teva launched its 10, 20, 30, 40, 50, and 60 mg methylphenidate ER products, which are the AB-rated generic versions of UCB's Metadate CD® capsules, which had annual sales of approximately $154 million for the twelve months ended September 2012. In December 2012, UCB sued Teva in the United States District Court for the Northern District of Georgia for infringement of UCB's formulation patent, which expires in October 2020. No trial date has been scheduled. Teva's motion for summary judgment of non-infringement is pending before the Court. Were UCB ultimately to be successful in its allegation of patent infringement, Teva could be required to pay damages relating to past sales of its methylphenidate ER products and enjoined from selling its methylphenidate ER products until patent expiry.
	Product Liability Litigation
	Teva's business inherently exposes it to potential product liability claims, and in recent years the number of product liability claims asserted against Teva has increased. Teva maintains a program of insurance, which may include commercial insurance, self-insurance (including direct risk retention), or a combination of both approaches, in amounts and on terms that it believes are reasonable and prudent in light of its business and related risks. However, Teva sells, and will continue to sell, pharmaceuticals that are not covered by insurance; in addition, it may be subject to claims for which insurance coverage is denied as well as claims that exceed its policy limits. Product liability coverage for pharmaceutical companies is becoming more expensive and increasingly difficult to obtain. As a result, Teva may not be able to obtain the type and amount of commercial insurance it desires, or any commercial insurance on reasonable terms, in all of its markets.
	Teva and/or its subsidiaries have been named as defendants in approximately 4,000 product liability lawsuits brought against them and other manufacturers by approximately 4,400 plaintiffs claiming injuries (including allegations of neurological disorders, such as tardive dyskinesia) from the use of metoclopramide (the generic form of Reglan®). Certain of these claims are covered by insurance. For over 20 years, the FDA-approved label for metoclopramide has contained warning language about the risk of tardive dyskinesia, and that the risk of developing the disorder increases with duration of treatment and total cumulative dose. In February 2009, the FDA announced that manufacturers of metoclopramide would be required to revise the label, including the addition of a “black box” warning about the risk of tardive dyskinesia resulting from long-term usage. The cases of approximately 500 of the plaintiffs have been dismissed or otherwise resolved to date. Teva expects to be dismissed from at least some of the remaining cases on the basis that some plaintiffs cannot demonstrate that they used a Teva product.
	Approximately 40% of the plaintiffs are parties to cases against Teva that are part of a mass tort proceeding in the Philadelphia Court of Common Pleas. These cases have been stayed pending resolution of Teva's petition for certiorari, which was filed with the United States Supreme Court on December 16, 2014.
	In addition, there are mass tort proceedings under way in state courts in California and New Jersey. In the California litigation, which now includes about half of the total plaintiffs, the defendants' motion to dismiss has been denied. In the New Jersey proceeding, the trial court granted the defendants' motion to dismiss, on federal preemption grounds, all claims other than those based on an alleged failure to timely update the label. The appellate court affirmed that decision, and Teva has sought leave to appeal to the New Jersey Supreme Court. All of the cases in the New Jersey proceeding with respect to the generic defendants have been stayed pending resolution of the appeal. Four or five cases outside the mass tort jurisdictions in which Pliva, Inc. is a defendant are or may be scheduled for trial in 2015.
	Competition Matters
	As part of its generic pharmaceuticals business, Teva has challenged a number of patents covering branded pharmaceuticals, some of which are among the most widely-prescribed and well-known drugs on the market. Many of Teva's patent challenges have resulted in litigation relating to Teva's attempts to market generic versions of such pharmaceuticals under the federal Hatch-Waxman Act. Some of this litigation has been resolved through settlement agreements in which Teva obtained a license to market a generic version of the drug, often years before the patents expire. Occasionally, Teva and its subsidiaries have been named as defendants in cases that allege antitrust violations arising from such settlement agreements. Teva believes that its settlement agreements are lawful and serve to increase competition, and intends to defend them vigorously. However, the plaintiffs in these cases typically allege (1) that Teva received something of value from the innovator in exchange for an agreement to delay generic entry, and (2) that they would have realized significant savings if there had been no settlement and competition had commenced earlier. These cases seek various forms of injunctive and monetary relief, including damages based on the difference between the brand price and what the generic price allegedly would have been, and disgorgement of profits, trebled under the relevant statutes, plus attorneys' fees and costs. The damages allegedly caused by the alleged delays in generic entry generally depend on the size of the branded market and the length of the alleged delay, and can be substantial, particularly where the alleged delays are lengthy or branded drugs with sales in the billions of dollars are involved. Nonetheless, as in the modafinil opt-out case described below, many such cases may be resolved through settlement for amounts considerably less than the damages initially alleged.
	On June 17, 2013, the United States Supreme Court held, in Federal Trade Commission v. Actavis, Inc. (the “AndroGel case”), that a rule of reason test should be applied in analyzing whether such settlements potentially violate the federal antitrust laws. The Supreme Court held that a trial court must analyze each agreement in its entirety in order to determine whether it violates the antitrust laws. This new test may lead to increased scrutiny of Teva's patent settlements, additional administrative action by the Federal Trade Commission (“FTC”), and an increased risk of liability in Teva's currently pending antitrust litigations.
	In April 2006, certain subsidiaries of Teva were named in a class action lawsuit filed in the United States District Court for the Eastern District of Pennsylvania. The case alleges that the settlement agreements involving finished modafinil products (the generic version of Provigil®) that Cephalon, Inc., a Teva subsidiary (“Cephalon”), entered into with various generic pharmaceutical companies in late 2005 and early 2006 were unlawful because they had the effect of excluding generic competition. The first lawsuit was brought by King Drug Company of Florence, Inc. on behalf of itself and as a proposed class action on behalf of any other person or entity that purchased Provigil® directly from Cephalon from January 2006 until the alleged unlawful conduct ceases. The first generic modafinil product was launched in March 2012. Similar allegations have been made in a number of additional complaints, including those filed on behalf of proposed classes of direct and indirect purchasers, by an individual indirect purchaser, by certain retail chain pharmacies and by Apotex, Inc. Annual sales of Provigil® were approximately $500 million at the time of the settlement agreements, and approximately $1 billion when the first generic modafinil product was launched in March 2012.
	In February 2008, following an investigation, the FTC sued Cephalon, alleging that Cephalon violated Section 5 of the Federal Trade Commission Act, which prohibits unfair or deceptive acts or practices in the marketplace, by unlawfully maintaining a monopoly in the sale of Provigil® and improperly excluding generic competition. In March 2010, the District Court denied defendants' motions to dismiss the federal antitrust claims and some of the related state law claims. No fines or penalties have been asserted against Cephalon to date and no provision has been recorded for this matter. The FTC has indicated that it intends to seek disgorgement of profits as an equitable remedy.
	Teva has settled with certain of the retail chain pharmacies (representing approximately half of the direct purchases of Provigil® from Cephalon) and, given the significant similarities in the claims asserted and damages claimed by certain other purchaser plaintiffs, has concluded that a provision for certain other parts of the litigation is warranted. Accordingly, in 2013 management recorded a charge of $495 million in the financial statements covering both the settlement and the litigation with other parties. Management expects that the settlement demands of the remaining parties could be significantly higher, and there can be no assurance that Teva will be able to reach settlements on terms comparable to the initial settlement.
	In October 2011, the District Court hearing the antitrust cases described above, as well as patent claims brought by plaintiff Apotex, issued its decision regarding Apotex's invalidity claims, finding a Cephalon patent to be invalid based on obviousness, among other things, and unenforceable based on inequitable conduct. In March 2012, the District Court ruled that Apotex's product does not infringe Cephalon's patent. On April 8, 2013, the United States Court of Appeals for the Federal Circuit affirmed the District Court's rulings of invalidity and inequitable conduct. The plaintiffs in the antitrust case filed motions for summary judgment asking the District Court (1) to apply the inequitable conduct and invalidity findings to the antitrust cases in an effort to establish antitrust liability, and (2) to find a conspiracy between and among Cephalon and the generic companies. Teva opposed those motions and moved for summary judgment, asserting that the FTC's case against Cephalon is moot and that the conspiracy claims should be dismissed. In addition, all defendants moved for summary judgment on the grounds that there were no impermissible payments from Cephalon to the generic defendants. On March 13, 2014, the District Court denied, in part, plaintiffs' motion for summary judgment to apply the inequitable conduct and invalidity findings to the antitrust case to establish antitrust liability. On July 29, 2014, the District Court denied Cephalon's motion to dismiss the FTC's case as moot, and granted the FTC's motion that Cephalon is precluded from raising arguments about the merits of the patent case or the strength of the patent in the FTC case. This ruling applies only in the FTC's case. On June 23, 2014, the District Court granted defendants' summary judgment motion that there was no conspiracy between and among Cephalon and the generic defendants. On August 19, 2014, the District Court denied Apotex's motion for partial summary judgment seeking a ruling that Cephalon possessed monopoly power, holding that the motion raised fact issues that must be resolved at trial. Defendants' summary judgment motion that none of the settlement agreements contained an impermissible reverse payment was denied on January 28, 2015.. Management has recorded a provision in the financial statements for the Apotex litigation.
	In April 2011, the European Commission opened a formal investigation against both Cephalon and Teva to assess whether the 2005 settlement agreement between the parties might have had the object or effect of hindering the entry of generic modafinil. The opening of proceedings indicates that the Commission will investigate the case as a matter of priority, but does not mean that there has been a definitive finding of violation of law.
	Barr Laboratories, Inc., a subsidiary of Teva (“Barr”), is a defendant in actions in California, Florida and Kansas alleging that a January 1997 patent litigation settlement agreement between Barr and Bayer Corporation was anticompetitive and violated state antitrust and consumer protection laws. In the California case, the trial court granted defendants' summary judgment motions, and the California Court of Appeal affirmed in October 2011. The trial court approved a $74 million class settlement with Bayer, and the California Supreme Court has received supplemental briefs addressing the effect of the AndroGel case on plaintiffs' appeal of the grant of summary judgment for the remaining defendants in this case. Based on the plaintiffs' expert testimony in a prior federal multidistrict litigation, estimated sales of ciprofloxacin in California were approximately $500 million during the alleged damages period. In the Kansas action, class certification briefing concluded on August 22, 2014 and the court heard oral argument on plaintiffs' class certification motion on December 15, 2014 before taking it under advisement; no schedule has been set in the Florida action.
	In December 2011, three groups of plaintiffs sued Wyeth and Teva for alleged violations of the antitrust laws in connection with their settlement of patent litigation involving extended release venlafaxine (generic Effexor® XR) entered into in November 2005. The cases were filed by a purported class of direct purchasers, by a purported class of indirect purchasers and by certain chain pharmacies. The plaintiffs claim that the settlement agreement between Wyeth and Teva unlawfully delayed generic entry. On October 7, 2014, the court granted Teva's motion to dismiss in the direct purchaser cases and requested briefing on the impact of its ruling for the indirect purchaser cases. The parties have submitted proposed orders that would dismiss all claims against Teva so that all plaintiffs can proceed to appeal. Certain plaintiffs have filed notices of appeal. Annual sales of Effexor® XR were approximately $2.6 billion at the time of settlement and at the time generic versions were launched in July 2010.
	In February 2012, two purported classes of direct-purchaser plaintiffs sued GlaxoSmithKline (“GSK”) and Teva for alleged violations of the antitrust laws in connection with their settlement of patent litigation involving lamotrigine (generic Lamictal®) entered into in February 2005. In August 2012, a purported class of indirect purchaser plaintiffs filed a nearly identical complaint against GSK and Teva. The plaintiffs claim that the settlement agreement unlawfully delayed generic entry and seek unspecified damages. In December 2012, the District Court dismissed the cases. On January 24, 2014, the District Court denied the direct purchaser plaintiffs' motion for reconsideration and affirmed its original dismissal of the cases. The direct purchaser plaintiffs have appealed this ruling. Oral argument for the appeal was held on November 20, 2014. Annual sales of Lamictal® were approximately $950 million at the time of the settlement, and approximately $2.3 billion at the time generic competition commenced in July 2008.
	Starting in September 2012, plaintiffs in numerous cases, including overlapping purported class actions, sued AstraZeneca and Teva, as well as Ranbaxy and Dr. Reddy's, for violating the antitrust laws by entering into settlement agreements to resolve the esomeprazole (generic Nexium®) patent litigation. Teva entered into its settlement agreement in January 2010. These cases were consolidated and transferred to the United States District Court for the District of Massachusetts. On November 24, 2014, Teva agreed to settle with all plaintiffs on all claims. On December 5, 2014, the jury returned a verdict in favor of AstraZeneca and Ranbaxy, finding that their settlement agreement was not the cause of delay for the entry of generic Nexium®.
	On June 18, 2014, two groups of end payors who opted out of the action in the District of Massachusetts filed complaints in the Philadelphia Court of Common Pleas (the “Philadelphia Actions”) with allegations nearly identical to those in the District of Massachusetts action. Proceedings in the Philadelphia Actions are stayed pending resolution of the action in the District of Massachusetts. Annual sales of Nexium® were approximately $6.3 billion at the time the Teva settlement agreement was entered into, and annual sales are currently approximately $6 billion.
	In April 2013, purported classes of direct purchasers of and end payors for Niaspan® (extended release niacin) sued Teva and Abbott for violating the antitrust laws by entering into a settlement agreement in April 2005 to resolve patent litigation over the product. A multidistrict litigation has been established in the United States District Court for the Eastern District of Pennsylvania. Teva and Abbott's motion to dismiss was denied on September 8, 2014. Annual sales of Niaspan® were approximately $416 million at the time of the settlement and approximately $1.1 billion at the time generic competition commenced in September 2013.
	Since July 2013, numerous lawsuits have been filed in several federal courts by purported classes of end payors for, and direct purchasers of, Solodyn® ER (minocycline hydrochloride) against Medicis, the innovator, and several generic manufacturers, including Teva. The lawsuits allege, among other things, that the settlement agreements between Medicis and the generic manufacturers violated the antitrust laws. Teva entered into its agreement with Medicis in March 2009. A multidistrict litigation has been established in the United States District Court for the District of Massachusetts. On September 12, 2014, plaintiffs filed an amended complaint that did not name Teva as a defendant. Annual sales of Solodyn® ER were approximately $380 million at the time Teva settled, and approximately $765 million at the time generic competition entered the market on a permanent basis in November 2011.
	Since November 2013, numerous lawsuits have been filed in several federal courts by purported classes of end payors for, and direct purchasers of, Aggrenox® (dipyridamole/aspirin tablets) against Boehringer Ingelheim (“BI”), the innovator, and several Teva entities. The lawsuits allege, among other things, that the settlement agreement between BI and Barr entered into in August 2008 violated the antitrust laws. A multidistrict litigation has been established in the United States District Court for the District of Connecticut. Oral argument on Teva and BI's motion to dismiss was held on October 27, 2014. Annual sales of Aggrenox® were approximately $340 million at the time of the settlement, and are approximately $470 million at the current time.
	Since January 2014, numerous lawsuits have been filed in the United States District Court for the Southern District of New York by purported classes of end payors for ACTOS® and ACTOplus Met® (pioglitazone and pioglitazone plus metformin) against Takeda, the innovator, and several generic manufacturers, including Teva. The lawsuits allege, among other things, that the settlement agreements between Takeda and the generic manufacturers violated the antitrust laws. Teva entered into its agreement with Takeda in December 2010. Defendants' motions to dismiss are pending, and argument has been set for early February. At the time of the settlement, annual sales of ACTOS® were approximately $3.7 billion and annual sales of ACTOplus Met® were approximately $500 million. At the time generic competition commenced in August 2012, annual sales of ACTOS® were approximately $2.8 billion and annual sales of ACTOplus Met® were approximately $430 million.
	On September 8, 2014, the FTC sued AbbVie Inc. and certain of its affiliates (“AbbVie”) and Teva in the United States District Court for the Eastern District of Pennsylvania alleging that they violated the antitrust laws when they entered into a settlement agreement to resolve the AndroGel® patent litigation and a supply agreement under which AbbVie would supply authorized generic product for TriCor® to Teva. The FTC alleges that Teva agreed to delay the entry of its generic testosterone gel product in exchange for entering into the TriCor supply agreement. Defendants' motions to dismiss, which were filed on November 12, 2014, are pending.
	Government Investigations and Litigation Relating to Pricing and Marketing
	Teva is involved in government investigations and litigation arising from the marketing and promotion of its specialty pharmaceutical products in the United States. Many of these investigations originate through what are known as qui tam complaints, in which the government reviews a complaint filed under seal by a whistleblower (a “relator”) that alleges violations of the federal False Claims Act. The government considers whether to investigate the allegations and will, in many cases, issue subpoenas requesting documents and other information, including conducting witness interviews. The government must decide whether to intervene and pursue the claims as the plaintiff. Once a decision is made by the government, the complaint is unsealed. If the government decides not to intervene, then the relator may decide to pursue the lawsuit on his own without the active participation of the government.
	Under the federal False Claims Act, the government (or relators who pursue the claims without the participation of the government in the case) may seek to recover up to three times the amount of damages in addition to a civil penalty of $5,500 to $11,000 for each allegedly false claim submitted to the government for payment. Generally speaking, these cases take several years for the investigation to be completed and, ultimately, to be resolved (either through litigation or settlement) after the complaint is unsealed. In addition, some states have pursued investigations under state false claims statutes or consumer protection laws, either in conjunction with a government investigation or separately. There is often collateral litigation that arises from public disclosures of government investigations, including the filing of class action lawsuits by third party payors alleging fraud-based claims or by shareholders alleging violations of the securities laws.
	A number of state attorneys general and others have filed various actions against Teva and/or certain of its subsidiaries in the United States relating to reimbursements or drug price reporting under Medicaid or other programs. Such price reporting is alleged to have caused governments and others to pay inflated reimbursements for covered drugs. Teva and its subsidiaries have reached settlements in most of these cases, and remain parties to litigation in Illinois. A provision for the cases has been included in the financial statements. Trial in the Illinois case concluded in the fourth quarter of 2013, and post-trial briefing has been submitted and is under consideration. The State of Illinois is seeking approximately $100 million in compensatory damages. Any such damages ultimately awarded by the court are subject to automatic trebling. In addition, the state is seeking unspecified statutory penalties that could range, depending on the method used for calculation, from a de minimis amount to well over $100 million. Teva denies any liability, and will argue that even if the court finds liability, compensatory damages and penalties should be significantly less than the amount sought by the state.
	Several qui tam complaints have been unsealed in recent years as a result of government decisions not to participate in the cases. The following is a summary of certain government investigations, qui tam actions and related matters.
	In December 2009, the United States District Court for the District of Massachusetts unsealed a complaint alleging that numerous drug manufacturers, including certain Teva subsidiaries, violated the federal False Claims Act in connection with Medicaid reimbursement for certain vitamins, dietary supplements and DESI products that were allegedly ineligible for reimbursement. The Department of Justice declined to join in the matter. The defendants, including Teva, filed a motion to dismiss, which was granted on February 25, 2013. The plaintiffs' deadline to appeal the dismissal has not yet expired.
	In September 2013, the State of Louisiana filed a complaint seeking unspecified damages against 54 pharmaceutical companies, including several Teva subsidiaries. The complaint asserts that each of the defendants allegedly defrauded the state by falsely representing that its products were FDA-approved drugs, which allegedly caused the state Medicaid program to pay millions of dollars in reimbursement claims for products that it would not otherwise have covered.
	Cephalon has received and responded to subpoenas related to Treanda®, Nuvigil® and Fentora®. In March 2013, a federal False Claims Act complaint filed against Cephalon in the United States District Court for the Southern District of New York was unsealed. The case was transferred to the Eastern District of Pennsylvania. The complaint alleges off-label promotion of Treanda® and Fentora®. On October 9, 2014, the District Court granted Cephalon's motion to dismiss the Fentora claims; Cephalon's motion to dismiss the Treanda claims remains pending. In January 2014, a separate federal False Claims Act complaint that had been filed in the United States District Court for the Eastern District of Pennsylvania was served on Cephalon. The complaint alleges off-label promotion of Fentora®, Nuvigil® and Provigil®. Cephalon filed motions to dismiss, and on October 9, 2014, the District Court dismissed the Fentora claims, stayed its decision on the Provigil claims, and denied Cephalon's motion to dismiss as to two of the Nuvigil claims. Cephalon's motion to dismiss the Nuvigil and Provigil claims remain pending.
	Cephalon is a defendant in a putative class action filed in the United States District Court for the Eastern District of Pennsylvania in which plaintiffs, third party payors, allege approximately $700 million in losses resulting from the promotion and prescription of Actiq® for uses not approved by the FDA despite the availability of allegedly less expensive pain management drugs that were more appropriate for patients' conditions. A hearing on the plaintiffs' motion for class certification was held in July 2013. If the court grants certification, a jury trial will be scheduled. Cephalon is defending a separate putative class action law suit with similar off-label claims involving Provigil® and Gabitril® brought by the American Federation of State, County and Municipal Employees, District Council 47 Health and Welfare Fund.
	In July 2014, the court granted Cephalon and Teva's motion to dismiss an action brought by certain Travelers entities that was filed in the Eastern District of Pennsylvania alleging off-label marketing of Actiq® and Fentora®. The plaintiffs' motion to amend the judgment and file a second amended complaint was denied on September 24, 2014, and the plaintiffs are currently appealing. Cephalon is also a defendant in a lawsuit filed by the State of South Carolina alleging violations of the state's unfair trade practices law and common law in connection with the alleged off-label promotion of Actiq®, Provigil® and Gabitril®.
	On May 21, 2014, counsel for Santa Clara County and Orange County, purportedly on behalf of the People of California, filed a complaint in the Superior Court for Orange County, California against Teva and Cephalon, along with several other pharmaceutical companies, contending that defendants allegedly engaged in off-label promotion in the sale of opioids, including Actiq® and Fentora®. On June 2, 2014, the City of Chicago filed a similar complaint against Teva and Cephalon in the Circuit Court of Cook County, Illinois, which has been removed to the Northern District of Illinois. Both complaints assert claims under state law based upon alleged off-label promotion in the sale of opioids, and both seek a variety of damages, including restitution, civil penalties, disgorgement of profits, treble damages, attorneys' fees and injunctive relief. Neither complaint specifies the exact amount of damages at issue. Teva and Cephalon have not yet responded to the complaint in the California action and have filed a motion to dismiss in the Chicago action.
	On January 8, 2014, Teva received a civil investigative demand from the United States Attorney for the Southern District of New York seeking documents and information from January 1, 2006 related to sales, marketing and promotion of Copaxone® and Azilect®. The demand states that the government is investigating possible civil violations of the federal False Claims Act. Teva is complying with the subpoena.
	For several years, Teva has been conducting a voluntary worldwide investigation into business practices that may have implications under the U.S. Foreign Corrupt Practices Act (“FCPA”). Teva has engaged outside counsel to assist in its investigation, which was prompted by the receipt, beginning in 2012, of subpoenas and informal document requests from the SEC and the Department of Justice (“DOJ”) to produce documents with respect to compliance with the FCPA in certain countries. Teva has provided and will continue to provide documents and other information to the SEC and the DOJ, and is cooperating with these agencies in their investigations of these matters. In the course of its investigation, which is continuing, Teva has identified certain business practices and transactions in Russia, certain European countries, certain Latin American countries and other countries in which it conducts business, which likely constitute violations of the FCPA and/or local law. In connection with its investigation, Teva has also become aware that Teva affiliates in certain countries under investigation provided to local authorities inaccurate or altered information relating to marketing or promotional practices. Teva has brought and continues to bring these issues to the attention of the SEC and the DOJ. Teva cannot predict at this time the impact on the Company as a result of these matters, which may include material fines in amounts that are not currently estimable, limitations on the Company's conduct, the imposition of a compliance monitor and/or other civil and criminal penalties.
	Shareholder Litigation
	On December 18, 2013, a putative class action securities lawsuit was filed in the United States District Court for the Southern District of New York on behalf of purchasers of Teva's securities between January 1, 2012 and October 29, 2013. The complaint alleges that Teva and certain directors and officers violated Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and that the individual defendants violated Section 20 of the Exchange Act, by making false and misleading statements that failed to disclose the existence of significant internal discord between Teva's board of directors and senior management concerning execution of Teva's strategies, including implementation of a cost reduction program. On July 8, 2014, an amended complaint was filed, changing the starting date of the alleged class period to August 1, 2013. On October 17, 2014, Teva filed a motion to dismiss the complaint. The plaintiff is seeking unspecified compensatory damages and reimbursement for litigation expenses.
	Other Litigation
	In January 2013, GSK filed a lawsuit against Teva for violations of the Lanham Act in the marketing of its Budeprion XL 300 mg product. The lawsuit alleges that Teva made false representations in claiming that Budeprion XL 300 mg was bioequivalent to GSK's Wellbutrin® XL 300 mg and “implicitly communicated” that the product was as safe and efficacious as GSK's product. At the time Teva began selling Budeprion XL 300 mg, annual sales of Wellbutrin® XL 300 mg were approximately $1 billion. In April 2013, Teva filed a motion to dismiss the complaint on the grounds that GSK cannot retroactively challenge through the Lanham Act a determination of bioequivalence made by the FDA, and that Teva's alleged statements were not false or misleading as a matter of law. On March 10, 2014, the motion was denied, and Teva's motion for reconsideration was denied on July 18, 2014.
	Environmental Matters
Teva is party to a number of environmental proceedings, or has received claims, including some brought pursuant to the Comprehensive Environmental Response, Compensation and Liability Act (commonly known as the Superfund law) or other national, federal, provincial or state and local laws imposing liability for alleged noncompliance with various environmental laws and regulations or for the investigation and remediation of releases of hazardous substances and for natural resource damages. Many of these proceedings and claims seek to require the generators of hazardous wastes disposed of at a third-party-owned site, or the party responsible for a release of hazardous substances into the environment that impacted a site, to investigate and clean up the site or to pay for such activities, including for oversight by governmental authorities, the response costs associated with such oversight and any related damages to natural resources. Teva has received claims, or has been made a party to these proceedings, along with other potentially responsible parties, as an alleged generator of wastes that were disposed of or treated at third-party waste disposal sites, or as a result of an alleged release from one of Teva's facilities or former facilities that may have adversely impacted the environment.
In many of these cases, the government or private litigants allege that the responsible parties are jointly and severally liable for the investigation and cleanup costs. Although the liability among the responsible parties, under certain circumstances, may be joint and several, these proceedings are frequently resolved so that the allocation of cleanup and other costs among the parties reflects the relative contributions of the parties to the site conditions and takes into account other pertinent factors. Teva's potential liability varies greatly at each of the sites in the proceedings or for which claims have been asserted; for some sites the costs of the investigation, cleanup and natural resource damages have not yet been determined, and for others Teva's allocable share of liability has not been determined. At other sites, Teva has been paying a share of the costs, the amounts of which have not been, and are not expected to be, material. Teva has taken an active role in identifying those costs, to the extent they are identifiable and estimable, which do not include reductions for potential recoveries of cleanup costs from insurers, indemnitors, former site owners or operators or other potentially responsible parties. In addition, enforcement proceedings relating to alleged federal and state regulatory violations at some of Teva's facilities have resulted, or may result, in the imposition of significant penalties (in amounts not expected to materially adversely affect Teva's results of operations) and the recovery of certain state costs and natural resource damages, and have required, or may require, that corrective measures and enhanced compliance measures be implemented.

EQUITY

EQUITY	0 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Equity	<>NOTE 15—EQUITY:
	<>a.       Share capital:
	<>As of December 31, 2014, there were 957 million ordinary shares issued (December 31, 2013—947 million). Teva shares are traded on the Tel-Aviv Stock Exchange (“TASE”) and, in the form of American Depositary Shares, each of which represents one ordinary share, on the New York Stock Exchange ("NYSE") in the United States.
	Share repurchase program
	In October 2014, Teva's board of directors authorized the Company to increase its share repurchase program up to $3 billion of its ordinary shares and American Depositary Shares. As of December 31, 2014, $2.5 billion remain available for repurchases. This repurchase authorization has no time limit. Repurchases may be commenced or suspended at any time or from time to time.
	The following table summarizes the shares repurchased and the amount Teva spent on these repurchases:
					Year ended December 31,
					2014			2013			2012
					(in millions)
		Amount spent on shares repurchased			$	500		$	497		$	1,161
		Number of shares repurchased				8.7			12.8			28.1
	b. Stock-based compensation plans:
	<>Stock-based compensation plans are comprised of employee stock option plans, RSUs, PSUs, and other equity-based awards to employees, officers and directors. The purpose of the plans is to enable the Company to attract and retain qualified personnel and to motivate such persons by providing them with equity participation in the Company.
	On June 29, 2010, the Teva Long-Term Equity-Based Incentive Plan was approved by the shareholders, under which 70 million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant. As of December 31, 2014, 23 million equivalent share units remained available for future awards.
	In the past, Teva had various employee stock and incentive plans under which stock options and other share-based awards were granted. Stock options and other share-based awards granted under such prior plans continue in accordance with the terms of the respective plans.
	<>The vesting period of the outstanding options, RSUs and PSUs is generally from 1 to 4 years from the date of grant. The rights of the ordinary shares obtained from the exercise of options, RSUs or PSUs are identical to those of the other ordinary shares of the Company. The contractual term of these options is primarily for seven years in prior plans and ten years for options granted under the 2010 plan described above.
	<>Status of options
	<>A summary of the status of the options as of December 31, 2014, 2013 and 2012, and changes during the years ended on those dates, is presented below (the number of options represents ordinary shares exercisable in respect thereof).
					Year ended December 31,
					2014				2013				2012
					Number (in thousands)		Weighted average exercise price		Number (in thousands)		Weighted average exercise price		Number (in thousands)	Weighted average exercise price
	Balance outstanding at beginning of year				32,481		$45.05		36,580		$44.40		33,298	$44.92
	Changes during the year:
		Granted			6,935		48.6		1,701		38.37		7,231	40.5
		Exercised			-11,423		45.05		-2,797		32.17		-704	33.36
		Forfeited			-1,260		46.11		-3,003		45.51		-3,245	44.76
	Balance outstanding at end of year				26,733		45.91		32,481		45.05		36,580	44.4
	Balance exercisable at end of year				12,632		47.16		17,082		47.3		14,230	44.3
	The weighted average fair value of options granted during the years was estimated by using the Black-Scholes option-pricing model:
					Year ended December 31,
					2014		2013		2012
		Weighted average fair value			$9.30		$6.60		$7.40
	The fair value of these options was estimated on the date of grant, based on the following weighted average assumptions:
					Year ended December 31,
					2014		2013		2012
		Dividend yield			2.90%		3.30%		2.60%
		Expected volatility			25%		23%		24%
		Risk-free interest rate			1.90%		2.10%		1.30%
		Expected term			6 years		9 years		8 years
	The expected term was estimated based on the weighted average period the options granted are expected to be outstanding taking into consideration the current vesting of options and the historical exercise patterns of existing options. The expected volatility assumption used is based on a blend of the historical and implied volatility of the Company's stock. The risk-free interest rate used is based on the yield of U.S. Treasuries with a maturity closest to the expected term of the options granted. The dividend yield assumption reflects the expected dividend yield based on historical dividends and expected dividend growth.
	The following tables summarize information at December 31, 2014 regarding the number of ordinary shares issuable upon (1) outstanding options and (2) vested options:
	(1) Number of ordinary shares issuable upon exercise of outstanding options
	Range of exercise prices				Balance at end of period (in thousands)		Weighted average exercise price		Weighted average remaining life		Aggregate intrinsic value (in thousands)
					Number of shares		$		Years		$
	$35.11	-	$40.10		4,686		38.65		8.07		88,370
	$40.11	-	$45.10		7,365		41.96		6.11		114,519
	$45.11	-	$50.10		9,909		48.6		7.98		88,293
	$50.11	-	$55.10		4,134		52.42		2.73		21,042
	$55.11	-	$60.10		475		59.48		2.99		-
	$60.11	-	$65.00		164		64.31		2.15		-
	Total				26,733		45.91		6.54		312,224
	(2) Number of ordinary shares issuable upon exercise of vested options
	Range of exercise prices				Balance at end of period (in thousands)		Weighted average exercise price		Weighted average remaining life		Aggregate intrinsic value (in thousands)
					Number of shares		$		Years		$
	$35.11	-	$40.10		1,896		38.81		7.98		35,460
	$40.11	-	$45.10		3,267		41.87		4.78		51,093
	$45.11	-	$50.10		3,170		48.72		5.76		27,869
	$50.11	-	$55.10		3,711		52.57		2.18		18,331
	$55.11	-	$60.10		425		59.74		2.15		-
	$60.11	-	$65.00		163		64.31		2.15		-
	Total				12,632		47.16		4.62		132,753
	<>The aggregate intrinsic value in the above tables represents the total pre-tax intrinsic value, based on the Company's closing stock price of $57.51 on December 31, 2014, less the weighted average exercise price in each range. This represents the potential amount receivable by the option holders had all option holders exercised their options as of such date. The total number of in-the-money options exercisable as of December 31, 2014 was 12 million.
	<>The total intrinsic value of options exercised during the years ended December 31, 2014, 2013 and 2012 was $74 million, $19 million and $6 million, respectively, based on the Company's average stock price of $51.57, $38.99 and $41.63 during the years then ended, respectively.
	<>Status of non-vested RSUs
<>The fair value of RSUs and PSUs is estimated based on the market value of the Company's stock on the date of award, less an estimate of dividends that will not accrue to RSU and PSU holders prior to vesting.
<>The following table summarizes information about the number of RSUs and PSUs issued and outstanding:
		Year ended December 31,
		2014				2013				2012
		Number (in thousands)		Weighted average grant date fair value		Number (in thousands)		Weighted average grant date fair value		Number (in thousands)		Weighted average grant date fair value
Balance outstanding at beginning of year		2,512		$40.48		3,744		$41.04		3,093		$43.23
Granted		1,342		46.09		289		35.8		1,320		38
Vested		-1,146		41.55		-1,222		41.04		-519		45.65
Forfeited		-242		40.05		-299		40.98		-150		43.97
Balance outstanding at end of year		2,466		43.05		2,512		40.48		3,744		41.04
<>The Company has expensed compensation costs, net of estimated forfeitures, based on the grant-date fair value. For the years ended December 31, 2014, 2013 and 2012, the Company recorded stock-based compensation costs as follows:
	Year ended December 31,
		2014			2013			2012
		(U.S. $ in millions)
Employee stock options		$	47		$	40		$	58
RSUs and PSUs			38			24			24
Total stock-based compensation expense			85			64			82
Tax effect on stock-based compensation expense			14			14			13
Net effect		$	71		$	50		$	69
<>The total unrecognized compensation cost before tax on employee stock options and RSUs (along with PSUs) amounted to $87 million and $77 million, respectively, at December 31, 2014, and is expected to be recognized over a weighted average period of approximately 1 year.
<>c.        Dividends and accumulated other comprehensive income (loss): <><><<><><>Divid
Dividends are declared in New Israeli Shekels (“NIS”), and paid in NIS and USD. Dividends paid per share in the years ended December 31, 2014, 2013 and 2012 were $1.34, $1.28 and $1.03, respectively. Subsequent to December 31, 2014, the Company declared an additional dividend of 1.33 NIS per share in respect of the fourth quarter of 2014.
Commencing in April 2015, our dividends will be declared and paid in U.S. dollars.
The components of accumulated other comprehensive loss attributable to Teva are presented in the table below:
<><><>
		December 31,
		2014			2013			2012
		(U.S. $ in millions)
	Currency translation adjustment	$	-1,283		$	151		$	175
	Unrealized loss on defined benefit plans, net		-93			-50			-92
	Unrealized gain (loss) on derivative financial instruments, net		40			-197			-93
	Unrealized gain (loss) from available-for-sale securities, net		-7			5			-7
	Accumulated other comprehensive loss attributable to Teva	$	-1,343		$	-91		$	-17
	The following tables present the changes in the components of accumulated other comprehensive loss for the year ended December 31, 2014 and 2013:
					Year ended December 31, 2014
Components of accumulated other comprehensive loss			Description of the reclassification to the statement of income		Other comprehensive income (loss) before reclassifications			Amounts reclassified to the statement of income			Net other comprehensive income (loss) before tax		Corresponding income tax		Net other comprehensive income (loss) after tax
Currency translation adjustment			Currency translation adjustment, reclassified to general and administrative expenses		$	-1,429		$	-5		$	-1,434	$	-	$	-1,434
Unrealized gain (loss) from available-for-sale securities			Loss on marketable securities, reclassified to financial expenses - net			-12			2			-10		-2		-12
Unrealized gain (loss) from derivative financial instruments			Gain on derivative financial instruments, reclassified to net revenues			240			-3			237		-		237
Unrealized gain (loss) on defined benefit plans			Gain on defined benefit plans, reclassified to various statement of income items**			-55			-2			-57		14		-43
Total accumulated other comprehensive income (loss)					$	-1,256		$	-8		$	-1,264	$	12	$	-1,252
					Year ended December 31, 2013
Components of accumulated other comprehensive loss			Description of the reclassification to the statement of income		Other comprehensive income (loss) before reclassifications			Amounts reclassified to the statement of income			Net other comprehensive income (loss) before tax		Corresponding income tax		Net other comprehensive income (loss) after tax
Currency translation adjustment			Currency translation adjustment, reclassified to financial expenses - net		$	-46		$	17		$	-29	$	5	$	-24
Unrealized gain (loss) from available-for-sale securities			Gain on marketable securities, reclassified to financial expenses - net			18			-6			12		*		12
Unrealized gain (loss) from derivative financial instruments			Loss on derivative financial instruments, reclassified to net revenues			-111			7			-104		*		-104
Unrealized gain (loss) on defined benefit plans			Loss on defined benefit plans, reclassified to various statement of income items**			20			24			44		-2		42
Total accumulated other comprehensive income (loss)					$	-119		$	42		$	-77	$	3	$	-74
* Represents an amount of less than $0.5 million.
** Affected cost of sales, research and development expenses, selling and marketing expenses and general and administrative expenses.

INCOME_TAXES

INCOME TAXES	0 Months Ended
	Dec. 31, 2014
Income Taxes [Absract]
Income Taxes	NOTE 16—INCOME TAXES:
	a.	Income before income taxes is comprised of the following:
				Year ended December 31,
				2014		2013		2012
				(U.S. $ in millions)
	The Parent Company and its Israeli subsidiaries			$	2,139	$	1,303	$	1,660
	Non-Israeli subsidiaries				1,499		-53		159
				$	3,638	$	1,250	$	1,819
	b.	Income taxes:
				Year ended December 31,
				2014		2013		2012
				(U.S. $ in millions)
	In Israel			$	147	$	197	$	5
	Outside Israel				444		-240		-142
				$	591	$	-43	$	-137
	Current			$	879	$	1,096	$	564
	Deferred				-288		-1,139		-701
				$	591	$	-43	$	-137
					Year ended December 31,
				2014		2013		2012
					(U.S. $ in millions)
	Income before income taxes			$	3,638	$	1,250	$	1,819
	Statutory tax rate in Israel				26.50%		25%		25%
	Theoretical provision for income taxes			$	964	$	313	$	455
	Increase (decrease) in effective tax rate due to:
		The Parent Company and its Israeli subsidiaries -
			Mainly tax benefits arising from reduced tax rates under benefit programs		-524		-535		-520
			Amendment 69 payments and finalization of prior years' tax audits, net of decrease of related uncertain tax positions		-		248		-
		Non-Israeli subsidiaries			88		-275		-83
		Increase in other uncertain tax positions—net			63		206		11
	Effective consolidated income taxes			$	591	$	-43	$	-137
	The effective tax rate is the result of a variety of factors, including the geographic mix and type of products sold during the year, different effective tax rates applicable to non-Israeli subsidiaries that have tax rates above Teva's average tax rates, the impact of impairment, restructuring and legal settlement charges and adjustments to valuation allowances on deferred tax assets on such subsidiaries.
	c.	Deferred income taxes:
				Year ended December 31,
				2014		2013
				(U.S. $ in millions)
	Short-term deferred tax assets—net:
		Inventory related		$	383	$	405
		Sales reserves and allowances			357		321
		Provision for legal settlements			229		235
		Provisions for employee-related obligations			66		81
		Carryforward losses and deductions (*)			59		179
		Other			78		75
					1,172		1,296
	Valuation allowance—in respect of carryforward losses and deductions that may not be utilized				-213		-249
				$	959	$	1,047
	*	The amount in 2014 is shown after reduction for unrecognized tax benefits of $143 million, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to offset any additional income taxes that would result from the settlement of a tax position. For additional information, see below.
				Year ended December 31,
				2014		2013
	Long-term deferred tax assets (liabilities)—net:			(U.S. $ in millions)
		Intangible assets		$	-1,098	$	-1,412
		Carryforward losses and deductions(*)(**)			1,043		1,415
		Property, plant and equipment			-218		-181
		Provisions for employee related obligations			39		19
		Other			-21		60
					-255		-99
	Valuation allowance—in respect of carryforward losses and deductions that may not be utilized				-458		-542
				$	-713	$	-641
				$	246	$	406
	*	The amount in 2014 is shown after reduction for unrecognized tax benefits of $150 million, see above
	**	This amount represents the tax effect of gross carryforward losses and deductions with the following expirations: 2016-2017 — $192 million; 2018-2024 — $302 million; 2025 and thereafter — $194 million. The remaining balance—$505 million—can be utilized with no expiration date.
		The deferred income taxes are reflected in the balance sheets among:
				December 31,
				2014		2013
			(U.S. $ in millions)
	Current assets—deferred income taxes		$	993	$	1,084
	Current liabilities—other current liabilities			-34		-37
	Other non-current assets			388		606
	Long-term liabilities—deferred income taxes			-1,101		-1,247
			$	246	$	406
Deferred taxes have not been provided for tax-exempt profits earned by the Company from Approved Enterprises through December 31, 2014 (except to the extent released due to payments made in 2013 under Amendment 69 of the Investment Law, as described below), as the Company intends to permanently reinvest these profits and does not currently foresee a need to distribute dividends out of these earnings. For the same reason, deferred taxes have not been provided for distributions of income from the Company's foreign subsidiaries. See Note 16g.
d.       Adoption of new accounting standard
The Company adopted ASU 2013-11 on January 1, 2014. As a result, we changed the presentation of certain unrecognized tax benefits, where Teva has net operating loss carryforwards, similar tax losses, and/or a tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to offset any additional income taxes that would result from the settlement of the tax position. Those unrecognized tax benefits are now presented as a reduction of the deferred tax assets for such net operating loss/tax credit carryforwards. Accordingly, the Company reduced its reserve for uncertain tax positions and deferred tax assets by $293 million as of December 31, 2014 in accordance with ASU 2013-11.
e.       Uncertain tax positions:
<>The following table summarizes the activity of Teva's gross unrecognized tax benefits:
			Year ended December 31,
			2014		2013		2012
			(U.S. $ in millions)
	Balance at the beginning of the year		$	665	$	903	$	907
	Increase (decrease) related to prior year tax positions, net			38		29		-10
	Increase related to current year tax positions			51		176		151
	Decrease related to settlements with tax authorities and lapse of applicable statutes of limitations			-38		-461		-146
	Other			-3		18		1
	Balance at the end of the year		$	713	$	665	$	903
Uncertain tax positions, mainly of a long-term nature, included accrued potential penalties and interest of $87 million, $75 million and $144 million, at December 31, 2014, 2013 and 2012, respectively. The total amount of interest and penalties in the consolidated statements of income was a net increase of $12 million for the year ended December 31, 2014, a net release of $69 million for the year ended December 31, 2013 and a net increase of $29 million for the year ended December 31, 2012. Substantially all the above uncertain tax benefits, if recognized, would reduce Teva's annual effective tax rate. Teva does not expect uncertain tax positions to change significantly over the next 12 months, except in the case of settlements with tax authorities, the likelihood and timing of which is difficult to estimate.
<>f.       Tax assessments:
<>We file income tax returns in various jurisdictions with varying statutes of limitations. The Parent Company and its subsidiaries in Israel have received final tax assessments through tax year 2007.
In 2013, Teva settled the 2005-2007 income tax assessments with the Israeli tax authorities, paying $213 million. No further taxes are due in relation to these years. Certain guidelines which were set pursuant to the agreement reached in relation to the 2005-2007 assessment will also be implemented in the audit of tax years 2008-2011, and are reflected in the provisions.
Following the audit of Teva's 2008 Israeli corporate tax returns, the Israeli tax authorities issued a tax assessment decree for 2008 and tax assessment for 2009-2010, challenging the Company's positions on several issues. Teva has protested the assessment. The Company believes it has adequately provided for these items and that any adverse results would have an immaterial impact on Teva's financial statements.
The Company's subsidiaries in North America and Europe have received final tax assessments mainly through tax year 2005.
<>g.       Basis of taxation:
<>The Company and its subsidiaries are subject to tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. The Company believes that its accruals for tax liabilities are adequate for all open years. The Company considers various factors in making these assessments, including past history, recent interpretations of tax law, and the specifics of each matter. Because tax regulations are subject to interpretation and tax litigation is inherently uncertain, these assessments can involve a series of complex judgments regarding future events.
<>Most of the Parent Company's industrial projects and those of several of its Israeli subsidiaries have been granted “Approved Enterprise” status under the Israeli Law for the Encouragement of Capital Investments ("Investment Law"). For the vast majority of such Approved Enterprises, the companies elected to apply for alternative tax benefits – i.e., the waiver of government grants in return for tax exemptions on undistributed income. Upon distribution of such exempt income, the distributing company will be subject to corporate tax at the rate ordinarily applicable to the Approved Enterprise's income. Such tax exemption on undistributed income applies for a limited period of between two to ten years, depending upon the location of the enterprise. During the remainder of the benefits period (generally until the expiration of ten years), a corporate tax rate not exceeding 25% is applied. One Approved Enterprise of an Israeli subsidiary enjoyed special benefits under the "Strategic Investment Track"; income accrued under this track during the benefits period was exempt from tax, and dividends distributed from such income are also exempt from Israeli tax.
Teva is a foreign investors company, or FIC, as defined by the Israeli Investment Law. Under the incentives regime that applied to Teva until 2013, FICs were entitled to further reductions in the tax rate normally applicable to Approved Enterprises. Depending on the foreign ownership in each tax year, the tax rate ranged between 10% (when foreign ownership exceeded 90%) to 25% (when the foreign ownership was below 49%).
Pursuant to Amendment 69 to the Israeli Investment Law ("Amendment 69"), a company that elected by November 11, 2013 to pay a reduced corporate tax rate as set forth in that amendment (rather than the tax rate applicable to Approved Enterprise income) with respect to undistributed exempt income accumulated by the company until December 31, 2011 is entitled to distribute a dividend from such income without being required to pay additional corporate tax with respect to such dividend. A company that has so elected must make certain qualified investments in Israel over the five-year period commencing in 2013. A company that has elected to apply the amendment cannot withdraw from its election.
During 2013, Teva applied the provisions of Amendment 69 to certain exempt profits accrued prior to 2012 by Teva and one of its Israeli subsidiaries. Consequently, the Company paid $577 million corporate tax on exempt income of $9.4 billion. Part of this income was distributed as dividends during 2013, while the remainder is available to be distributed as dividends in future years with no additional corporate tax liability. As a result, Teva was required to invest $286 million in its industrial enterprises in Israel over a five year period. Such investment may be in the form of the acquisition of industrial assets (excluding real estate assets), investment in R&D in Israel, or payroll payments to new employees to be hired by the enterprise. Teva already fully invested the required amount in 2013.
The amount of tax-exempt profits earned by the Company from Approved Enterprises through December 31, 2013 that were not released under Amendment 69 is approximately $9.7 billion, and the tax that would have been payable had the Company distributed dividends out of that income is approximately $1.5 billion. However, deferred taxes have not been provided for such tax-exempt income, as the Company intends to permanently reinvest these profits and does not currently foresee a need to distribute dividends out of these earnings (see note 1p).
Likewise, the Company intends to reinvest, rather than distribute, the income of its foreign subsidiaries. An assessment of the tax that would have been payable had the Company's foreign subsidiaries distributed their income to the Company is not practicable because of the multiple levels of corporate ownership and multiple tax jurisdictions involved in each hypothetical dividend distribution.
Income not eligible for Approved Enterprise benefits is taxed at a regular rate, which was 26.5% in 2014.
Under Amendment 68 to the Israeli Investment Law ("Amendment 68"), which Teva started applying in 2014, upon an irrevocable election made by a company, a uniform corporate tax rate will apply to all qualifying industrial income of such company ("Industrial Company"), as opposed to the previous law's incentives, which were limited to income from Approved Enterprises during their benefits period. Under the law, when the election is made, the uniform tax rate (for 2014 and on) will be 9% in areas in Israel designated as Development Zone A and 16% elsewhere in Israel. The profits of these Industrial Companies will be freely distributable as dividends, subject to a withholding tax of 20% or lower, under an applicable tax treaty. “Special Industrial Companies” that meet more stringent criteria (significant investment, R&D or employment thresholds) will enjoy further reduced tax rates of 5% in Zone A and 8% elsewhere. In order to be classified as a "Special Industrial Company," the approval of three governmental authorities in Israel is required.
Teva is currently examining its eligibility to be regarded as a "Special Industrial Company" under the new law.
The Parent Company and its Israeli subsidiaries elected to compute their taxable income in accordance with Income Tax Regulations (Rules for Accounting for Foreign Investors Companies and Certain Partnerships and Setting their Taxable Income), 1986. Accordingly, the taxable income or loss is calculated in U.S. dollars. Applying these regulations reduces the effect of U.S. dollar – NIS exchange rate on the Company's Israeli taxable income.
<>Non-Israeli subsidiaries are taxed according to the tax laws in their respective country of residence. Certain manufacturing subsidiaries operate in several jurisdictions outside Israel, some of which benefit from tax incentives such as reduced tax rates, investment tax credits and accelerated deductions.

FINANCIAL_INSTRUMENTS_AND_RISK

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT	0 Months Ended
	Dec. 31, 2014
Financial Instruments And Risk Management Abstract]
Financial Instruments and Risk Management	<>NOTE 17 – DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES:
	<><       Foreign exchange risk management:
	The Company enters into forward exchange contracts in non-functional currencies and purchases and writes non-functional currency options in order to hedge the currency exposure on identifiable balance sheet items. In addition, the Company takes steps to reduce exposure by using “natural” hedging. The Company also acts to offset risks in opposite directions among the companies in the Group. The currency hedged items are usually denominated in the following main currencies: the euro (EUR), Hungarian forint (HUF), British pound (GBP), new Israeli shekel (NIS), Canadian dollar (CAD), Croatian kuna (HRK), Russian ruble (RUB), Czech koruna (CZK), Swiss franc (CHF) and Japanese yen (JPY). The writing of options is part of a comprehensive currency hedging strategy.
	<>The counterparties to the derivatives are comprised mainly of major banks and, in light of the current financial environment, the Company is monitoring the associated inherent credit risks. The Company does not enter into derivative transactions for trading purposes.
	Teva operates in certain territories where the official exchange rates deviate significantly from unofficial market rates and remittance of cash outside the country is limited. As a result, Teva is exposed to a potential income statement devaluation loss on its total monetary balances in these territories, which, as of December 31, 2014, amounted to approximately $274 million.
	<><>
	b. Derivative instrument disclosure:
	The following table summarizes the notional amounts for hedged items, when transactions are designated as hedge accounting:
			December 31,
			2014			2013
			(U.S. $ in millions)
	Interest rate swap - fair value hedge *		$	1,750		$	2,500
	Cross currency swap - cash flow hedge			1,875			1,875
	Forecasted transactions - cash flow hedge			280			300
	*In October 2014, Teva terminated an interest rate swap agreement, designated as a fair value hedge, with respect to $500 million notional amount.
	The following table summarizes the classification and fair values of derivative instruments:
					Fair value
				Designated as hedging instruments					Not designated as hedging instruments
					31-Dec-14			31-Dec-13		31-Dec-14		31-Dec-13
	Reported under				U.S. $ in millions
	Asset derivatives:
	Other current assets:
		Cross currency swaps - cash flow hedge		$	14		$	-	$		$
		Interest rate swaps - fair value hedge			-			2
		Option and forward contracts -cash flow hedge			14			3
		Option and forward contracts								68		25
	Other non-current assets:
		Cross currency swaps - cash flow hedge			6			-
	Liability derivatives:
	Other current liabilities:
		Option and forward contracts -cash flow hedge			-1			-8
		Option and forward contracts								-53		-9
	Senior notes and loans:
		Cross currency swaps - cash flow hedge			-			-203
		Interest rate swaps - fair value hedge			-43			-233
	Derivatives on foreign exchange contracts hedge Teva's balance sheet items from currency exposure but are not designated as hedging instruments for accounting purposes. With respect to such derivatives, gains of $85 million, gains of $76 million and losses of $45 million were recognized under financial expenses - net for the years ended December 31, 2014, 2013 and 2012 respectively. Such gains and losses offset the revaluation of the balance sheet items also booked under financial expenses—net.
	With respect to the interest rate and cross-currency swap agreements, gains of $41 million, $35 million and $18 million were recognized under financial expenses - net for the years ended December 31, 2014, 2013 and 2012, respectively. Such gains mainly reflect the differences between the fixed interest rate and the floating interest rate.
	c.       Securitization:
	In April 2011, Teva established an accounts receivable securitization program with BNP Paribas Bank ("BNP Paribas"). Under the program, Teva sells, on an ongoing basis, certain accounts receivable and the right to the collections on those accounts receivable to BNP Paribas.
	Once sold to BNP Paribas, the accounts receivable and rights to collection are separate and distinct from Teva's own assets. These assets are unavailable to Teva's creditors should Teva become insolvent. BNP Paribas has all the rights ensuing from the sale of the securitized accounts receivable, including the right to pledge or exchange the assets it received. Consequently, the accounts receivable in Teva's consolidated balance sheets is presented net of the securitized receivables.
	As of December 31, 2014 and 2013, the balance of Teva's securitized assets sold amounted to $585 million and $590 million, respectively. Gains and losses related to these transactions were immaterial for the three years ended December 31, 2014.
	The following table summarizes the net balance outstanding due to outstanding securitization programs:
			As of and for the year ended December 31,
			2014			2013
			(U.S. $ in millions)
	Sold receivables at the beginning of the year		$	590		$	535
	Proceeds from sale of receivables			4,287			3,662
	Cash collections (remitted to the owner of the receivables)			-4,202			-3,635
	Effect of currency exchange rate changes			-90			28
	Sold receivables at the end of the year		$	585		$	590

FINANCIAL_EXPENSES_NET

FINANCIAL EXPENSES NET	0 Months Ended
	Dec. 31, 2014
Financial Expenses Net [Abstract]
Financial Expenses - Net	NOTE 18—FINANCIAL EXPENSES- NET:
		Year ended December, 31
		2014		2013		2012
		(U.S. $ in millions)
	Interest expenses and other bank charges	$	300	$	314	$	355
	Foreign exchange losses - net		30		8		25
	Income from investments		-24		-32		-26
	Other		7		109		32
	Total finance expense — net	$	313	$	399	$	386

RESTRUCTURING_AND_IMPAIRMENTS

RESTRUCTURING AND IMPAIRMENTS	0 Months Ended
	Dec. 31, 2014
Restructuring And Impairment [Abstract]
Restructuring And Impairment	NOTE 19—IMPAIRMENTS, RESTRUCTURING AND OTHERS:
		Impairments, restructuring and others consisted of the following:
			Year ended December 31 ,
			2014		2013		2012
			(U.S. $ in millions)
		Impairment of long-lived assets (see also notes 6 and 8)	$	387	$	524	$	1,071
		Restructuring		246		201		221
		Other		17		63		-33
		Total	$	650	$	788	$	1,259
	Impairments
	In determining the estimated fair value of the long-lived assets, Teva utilized a discounted cash flow model. The key assumptions within the model related to forecasting future revenue and operating income, an appropriate weighted average cost of capital, and an appropriate terminal value based on the nature of the long-lived asset. The Company's updated forecasts of net cash flows for the impaired assets reflect, among other things, the following: (i) for research and development in-process assets, the impact of changes to the development programs, the projected development and regulatory timeframes and the risks associated with these assets; and (ii) for product rights, pricing and volume projections as well as patent life and any significant changes to the competitive environment.
	Impairment of long-lived assets in 2014 amounted to $387 million, comprised of:
	Property, plant and equipment - $163 million, based on management decisions regarding their expected use as a result of our planned plant rationalization, which triggered a reassessment of fair value. In 2013 and 2012, property, plant and equipment impairment was $61 million and $190 million, respectively.
	Identifiable intangible assets - $224 million:
	a.       Product rights impairments of $116 million were recorded due to current market conditions and supply chain challenges in various Teva markets. Impairments of product rights for the year ended December 31, 2013 were $227 million and $233 million for 2012.
	b.       In-process R&D impairments of $108 million are comprised mainly of a $102 million impairment of MDT-637 development project following the negative results of Phase II trial. Impairment of in-process R&D for the year ended December 31, 2013 amounted to $166 million and $625 million for 2012.
	Restructuring
	For the year ended December 31, 2014, Teva recorded $246 million of restructuring expenses, compared to $201 million for the year ended December 31, 2013 and $221 million for 2012. These expenses are primarily incurred in various initiatives as part of cost saving efforts.

LEGAL_SETTLEMENTS

LEGAL SETTLEMENTS	0 Months Ended
	Dec. 31, 2014
Legal [Abstract]
Legal [TextBlock]	NOTE 20—LEGAL SETTLEMENTS AND LOSS CONTINGENCIES:
	Legal settlements and loss contingencies for 2014 amounted to a gain of $111 million, compared to an expense of $1.5 billion in 2013. The 2014 balance is comprised mainly of insurance proceeds relating to the settlement of the pantoprazole patent litigation. The 2013 expenses are composed mainly of additional charges of $930 million relating to the settlement of the pantoprazole patent litigation and $495 million relating to the modafinil antitrust litigation.

SEGMENTS

SEGMENTS	0 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment Reporting Disclosure	<>NOTE 21 – SEGMENTS: <><><
	Teva has two reportable segments: generic and specialty medicines. The generics segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients (“API”). The specialty segment engages in the development, manufacture, sale and distribution of branded specialty medicines such as those for central nervous system and respiratory indications, as well as those marketed in the women's health, oncology and other specialty businesses.
	Teva's other activities include the over-the-counter (“OTC”) medicines business, distribution activity mainly in Israel and Hungary and medical devices. The OTC activity is primarily conducted through a joint venture with P&G, which combines Teva's production capabilities and market reach with P&G's marketing expertise and expansive global platform.
	Teva's chief executive officer, who is the chief operating decision maker (“CODM”), reviews financial information prepared on a consolidated basis, accompanied by disaggregated information about revenues and contributed profit by the two identified reportable segments, namely generic and specialty medicines, and revenues by geographical markets.
	The accounting policies of the individual segments are the same as those described in the summary of significant accounting policies in note 1 to the consolidated financial statements.
	Segment profit is comprised of gross profit for the segment, less S&M and R&D expenses related to the segment. Segment profit does not include G&A expenses, amortization and certain other items.
	Teva manages its assets on a total company basis, not by segments, as many of its assets are shared or commingled. Teva's CODM does not regularly review asset information by reportable segment, and therefore Teva does not report asset information by reportable segment.
	During 2014, the classification of certain of our products was changed, in line with the Company's strategy. The comparable figures have been conformed to reflect the revised classification for all periods.
	Teva's chief executive officer is reviewing the Company's strategy and organizational structure on a continuing basis. Any changes in strategy may lead to a reevaluation of Teva's current segments and goodwill assignment. In connection with such organizational changes, effective July 1, 2014, Teva appointed a new President of Global Generic Medicines to lead all of its generic and OTC businesses. Going forward, Teva will continue to evaluate the impact of management changes on its segment reporting.
	a. Segment information:
		Generics									Specialty
		Year ended December 31,									Year ended December 31,
		2014			2013			2012			2014			2013		2012
		(U.S.$ in millions)									(U.S.$ in millions)
	Revenues	$	9,814		$	9,902		$	10,385		$	8,560		$	8,388	$	8,150
	Gross profit		4,247			4,079			4,518			7,457			7,274		7,173
	R&D expenses		517			492			485			881			883		793
	S&M expenses		1,582			1,919			1,971			2,001			1,864		1,686
	Segment profit	$	2,148		$	1,668		$	2,062		$	4,575		$	4,527	$	4,694
			2014			2013			2012
			U.S.$ in millions
	Generic medicines profit	$	2,148		$	1,668		$	2,062
	Specialty medicines profit		4,575			4,527			4,694
	Total segment profit		6,723			6,195			6,756
	Profit of other activities		226			242			197
	Total profit		6,949			6,437			6,953
	Amounts not allocated to segments:
	Amortization		1,036			1,180			1,272
	General and administrative expenses		1,217			1,239			1,238
	Impairments, restructuring and others		650			788			1,259
	Legal settlements and loss contingencies		-111			1,524			715
	Other unallocated amounts		206			57			264
	Consolidated operating income		3,951			1,649			2,205
	Financial expenses - net		313			399			386
	Consolidated income before income taxes	$	3,638		$	1,250		$	1,819
	b.	Segment revenues by geographic area:
			Year ended December 31,
			2014			2013			2012
			(U.S.$ in millions)
	Generic Medicine
		United States	$	4,418		$	4,172		$	4,381
		Europe*		3,148			3,362			3,482
		Rest of the World		2,248			2,368			2,522
	Total Generic Medicine			9,814			9,902			10,385
	Specialty Medicine
		United States		6,110			6,025			5,857
		Europe*		1,898			1,854			1,575
		Rest of the World		552			509			718
	Total Specialty Medicine			8,560			8,388			8,150
	Other Revenues
		United States		106			264			200
		Europe*		777			772			741
		Rest of the World		1,015			988			841
	Total Other Revenues			1,898			2,024			1,782
	Total Revenues		$	20,272		$	20,314		$	20,317
	*	All members of the European Union, Switzerland, Norway, Albania and the countries of former Yugoslavia.
	c. Net revenues from specialty medicines were as follows:
						Year ended December 31,
						2014			2013			2012
						(U.S. $ in millions)
		CNS				$	5,575		$	5,545		$	5,464
			Copaxone®				4,237			4,328			3,996
			Azilect®				428			371			330
			Nuvigil®				388			320			347
	Respiratory					957			964			856
		ProAir®				478			429			406
		Qvar®				286			328			297
	Oncology					1,180			1,005			860
		Treanda®				767			709			608
	Women's health					504			510			448
	Other Specialty					344			364			522
	Total Specialty Medicines				$	8,560		$	8,388		$	8,150
The data presented have been conformed to reflect the revised classification of certain of our products for all periods.
A significant portion of our revenues, and a higher proportion of our profits, come from the manufacture and sale of patent-protected pharmaceuticals. Many of our specialty medicines are covered by several patents that expire at different times. Nevertheless, once patent protection has expired, or has been lost prior to the expiration date as a result of a legal challenge, we no longer have patent exclusivity on these products, and subject to regulatory approval, generic pharmaceutical manufacturers are able to produce similar (or purportedly similar) products and sell them for a lower price. The commencement of generic competition, even in the form of non-equivalent products, can result in a substantial decrease in revenues for a particular specialty medicine in a very short time. Any such expiration or loss of intellectual property rights could therefore significantly adversely affect our results of operations and financial condition.
In particular, we rely heavily on sales of Copaxone®, our leading specialty medicine. A key element of our business strategy for Copaxone® is the continued migration of current daily Copaxone® 20 mg/mL patients to the three-times-a-week 40 mg/mL version introduced in 2014, and the maintenance of patients on that new version.  Any substantial reduction in the number of patients taking Copaxone®, whether due to the introduction of generic competition or to the increased use of oral medicines or other competing products, would likely have a material adverse effect on our financial results and cash flow.
In 2014, Copaxone® revenues in the United States, which include revenues from both Copaxone® 20 mg/mL and the new Copaxone® 40 mg/mL product, amounted to $3.1 billion in the U.S. (approximately 29% of our total 2014 U.S. revenues) and approximately $1.1 billion in markets outside the U.S. (approximately 12% of our total 2014 non-U.S. revenues).
Our multiple sclerosis franchise includes our Copaxone® products and laquinimod (a developmental compound for the treatment of multiple sclerosis). The profitability of our multiple sclerosis franchise is comprised of Copaxone® revenues and cost of goods sold as well as S&M and R&D expenses related to our MS franchise. It does not include G&A expenses, amortization and non-recurring items. Our MS franchise profitability was 75.1%, 75.6% and 74.5% in 2014, 2013 and 2012, respectively.
<>d. Supplemental data - major customers:
The percentages of total consolidated revenues for the years ended December 31, 2014, 2013 and 2012 to one customer were 18%, 17% and 16%, respectively. The percentage of total consolidated revenues for another customer accounted for 17% and 13% for the years ended December 31, 2014 and 2013, respectively. Most of Teva's revenues from these customers were made in the United States. The balance due from the Company's largest customer accounted for 31% of the gross trade accounts receivable at December 31, 2014. Sales reserves and allowances on these balances are recorded in current liabilities (refer to note 1l).
e.	Property, plant and equipment—by geographical location were as follows:
			December 31,
			2014			2013			2012
			(U.S. $ in millions)
Israel			$	1,949		$	1,834		$	1,649
United States				691			852			896
Hungary				520			526			498
Croatia				515			479			415
Japan				446			492			644
Germany				367			403			367
Other				2,047			2,049			1,846
Total property, plant and equipment			$	6,535		$	6,635		$	6,315

EARNINGS_PER_SHARE

EARNINGS PER SHARE	0 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Earnings Per Share	NOTE 22—EARNINGS PER SHARE:
	The net income attributable to Teva and the weighted average number of shares used in computation of basic and diluted earnings per share for the years ended December 31, 2014, 2013 and 2012 are as follows:
		2014			2013			2012
		(U.S. $ in millions, except share data)
	Net income attributable to Teva	$	3,055		$	1,269		$	1,963+
	Interest expense on convertible senior debentures, and issuance costs, net of tax benefits		*			*			*+
	Net income used for the computation of diluted earnings per share	$	3,055		$	1,269		$	1,963
	Weighted average number of shares used in the computation of basic earnings per share			853			849			872
	Add:
		Additional shares from the assumed exercise of employee stock options and unvested RSUs and PSUs		3			1			1
		Weighted average number of additional shares issued upon the assumed conversion of convertible senior debentures		2			*			*
	Weighted average number of shares used in the computation of diluted earnings per share			858			850			873
		* Represents an amount of less than 0.5 million.
	In computing dilutive earnings per share for the years ended December 31, 2014, 2013 and 2012, no account was taken of the potential dilution of the assumed exercise of employee stock options, amounting to 1 million, 7 million and 6 million weighted average shares, respectively, since they had an anti-dilutive effect on earnings per share.

SCHEDULE_II_VALUATION_AND_QUAL

SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS	0 Months Ended
	Dec. 31, 2014
Schedule Of Valuation And Qualifying Accounts [Abstract]
Schedule of Valuation and Qualifying Accounts	TEVA PHARMACEUTICAL INDUSTRIES LIMITED
	SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS
	Three Years Ended December 31, 2014
	(U.S. $ in millions)
	Column A		Column B		Column C				Column D		Column E
			Balance at beginning of period		Charged to costs and expenses		Charged to other accounts		Deductions		Balance at end of period
	Allowance for doubtful accounts:
		Year ended December 31, 2014	$	187	$	22	$	-18	$	-42	$	149
		Year ended December 31, 2013	$	145	$	44	$	3	$	-5	$	187
		Year ended December 31, 2012	$	116	$	32	$	5	$	-8	$	145
	Allowance in respect of carryforward tax losses:
		Year ended December 31, 2014	$	791	$	128	$	0	$	-248	$	671
		Year ended December 31, 2013	$	726	$	182	$	0	$	-117	$	791
		Year ended December 31, 2012	$	452	$	384	$	2	$	-112	$	726

SIGNIFICANT_ACCOUNTING_POLICIE1

SIGNIFICANT ACCOUNTING POLICIES (Policies)	0 Months Ended
	Dec. 31, 2014
Significant Accounting Policies [Abstract]
General	a.       General:
	Operations
	Teva Pharmaceutical Industries Limited (the “Parent Company”), headquartered in Israel, together with its subsidiaries and associated companies (the “Company,” “Teva” or the “Group”), is engaged in the development, manufacturing, marketing and distribution of generic, specialty, and other pharmaceutical products. The majority of the Group's revenues are in the United States and Europe. The Group's main manufacturing facilities are located in Israel, Hungary, United States, Germany, Canada, Japan, Ireland, the United Kingdom, the Czech Republic, Croatia, Italy and India.
	Accounting principles
	The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”).
	Functional currency
	A major part of the Group's operations is carried out by the Company and its subsidiaries in the United States, Israel and certain other countries. The functional currency of these entities is the U.S. dollar (“dollar” or “$”).
	The functional currency of certain subsidiaries and associated companies is their local currency. The financial statements of those companies are included in the consolidated financial statements, translated into U.S. dollars. Assets and liabilities are translated at year-end exchange rates, while revenues and expenses are translated at monthly average exchange rates during the year. Differences resulting from translation are presented as other comprehensive income in the consolidated statements of comprehensive income.
	The financial statements of subsidiaries in a highly inflationary economy are remeasured as if the functional currency was the U.S. dollar, Teva's reporting currency, using a translation rate determined by the country's official rate. A highly inflationary economy is one that has cumulative inflation of approximately 100 percent or more over a 3-year period.
	Use of estimates in the preparation of financial statements
	The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reported years. Actual results could differ from those estimates.
	As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to uncertain tax positions, valuation allowances, assessment of impairment of intangible assets and goodwill, purchase price allocation on acquisitions, contingencies, restructuring and sales and reserves allowances.
Principles of consolidation	b.       Principles of consolidation:
	The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and Variable Interest Entities ("VIEs") for which the Company is considered the primary beneficiary. For VIEs, the Company performs an analysis to determine whether the variable interests give a controlling financial interest in a VIE; the Company periodically reassesses whether it controls its VIEs.
	Intercompany transactions and balances are eliminated in consolidation; profits from intercompany sales, not yet realized outside the Group, are also eliminated.
	The Company includes the results of operations of an acquired business from the date of acquisition.
Investee companies	c.       Investee companies:
	Investments in entities in which the Company has a significant influence are accounted for using the equity method and included within other non-current assets. Under the equity method, the Company generally recognizes its proportionate share of comprehensive income or loss of the entity. Other non-marketable equity investments are carried at cost. The Company also reviews these investments for impairment whenever events indicate the carrying amount may not be recoverable.
Cash and cash equivalents	d.       Cash and cash equivalents:
	All highly liquid investments, which include short-term bank deposits and money market instruments, that are not restricted as to withdrawal or use, and investment in short-term debentures, the period to maturity of which did not exceed three months at the time of investment, are considered to be cash equivalents.
Inventories Policy	e.       Inventories:
	Inventories are valued at the lower of cost or market. Cost of raw and packaging materials and purchased products is determined mainly on a “moving average” basis. Cost of finished products and products in process is calculated assuming normal manufacturing capacity of the production facilities and determined as follows: the raw and packaging materials component—mainly on a “moving average” basis; the capitalized production costs component—mainly on an average basis over the production period.
	Inventories acquired in a business combination are stepped-up to their estimated fair value and amortized to cost of sales as that inventory is sold.
Marketable securities	f.       Investment in securities:
	Investment in securities consists mainly of debt and equity securities classified as available-for-sale and recorded at fair value. The fair value of quoted securities is based on current market value. When debt securities do not have an active market, fair value is determined using a valuation model. This model is based on reference to other instruments with similar characteristics, or a discounted cash flow analysis, or other pricing models making use of market inputs and relying as little as possible on entity-specific inputs.
	Unrealized gains of available for sale securities, net of taxes, are reflected in other comprehensive income. Unrealized losses considered to be temporary are reflected in other comprehensive income; unrealized losses that are considered to be other-than-temporary are charged to income as an impairment charge. Realized gains and losses for both debt and equity securities are included in financial expense, net.
	The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost, and for equity securities, the Company's ability and intent to hold the investment for the length of time necessary to allow for the recovery of the market value. For debt securities, an other-than-temporary impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the other-than-temporary impairment recognized in earnings, recorded in financial expense, net, is limited to the portion attributed to credit loss. The remaining portion of the other-than-temporary impairment related to other factors is recognized in other comprehensive income.
Impairment in value of long-lived assets	g.       Long-lived assets:
	Teva's long-lived, non-current assets are comprised mainly of goodwill, identifiable intangible assets and property, plant and equipment. Teva reviews its long-lived assets and performs detailed testing whenever potential impairment indicators are present. In addition, the Company performs impairment testing at the end of each year for goodwill and identifiable indefinite life intangible assets.
	Starting in 2015, the Company will change its annual goodwill impairment testing date from December 31 to October 1 of each year. This change will allow Teva to complete the annual goodwill impairment test prior to the end of the annual reporting period, and thereby better align impairment testing procedures with the Company's budget and forecasting processes and with year-end financial reporting. Accordingly, management considers this accounting change preferable. We do not expect this change to have a material effect on our valuation, nor to accelerate, delay, avoid, or trigger an impairment charge or result in adjustments to previously issued financial statements.
Goodwill and indefinite life intangible assets	Goodwill
	Goodwill reflects the excess of the consideration paid or transferred plus the fair value of contingent consideration and any non-controlling interest in the acquiree at the acquisition date over the fair values of the identifiable net assets acquired. The goodwill impairment test is performed according to the following principles:
	An initial qualitative assessment of the likelihood of impairment may be performed. If this step does not result in a more likely than not indication of impairment, no further impairment testing is required. If it does result in a more likely than not indication of impairment, the impairment test is performed.
	In step one of the impairment test, Teva compares the fair value of the reporting units to the carrying value of net assets allocated to the reporting units. If the fair value of the reporting unit exceeds the carrying value of the net assets allocated to that unit, goodwill is not impaired, and no further testing is required. Otherwise, Teva must perform the second step of the impairment test to measure the amount of the impairment.
	In the second step, the reporting unit's fair value is allocated to all the assets and liabilities of the reporting unit, including any unrecognized intangible assets, in a hypothetical analysis that simulates the business combination principles to derive an implied goodwill value. If the implied fair value of the reporting unit's goodwill is less than its carrying value, the difference is recorded as an impairment.
Definite life intangible assets	Identifiable intangible assets
	Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets.
	Definite life intangible assets consist mainly of acquired product rights and other rights relating to products for which marketing approval was received from the U.S. Food and Drug Administration (“FDA”) or the equivalent agencies in other countries. These assets are amortized using mainly the straight-line method over their estimated period of useful life, or based on economic effect models, if more appropriate, which is determined by identifying the period in which substantially all of the cash flows are expected to be generated. Amortization of acquired developed products is recorded under cost of sales. Amortization of marketing and distribution rights is recorded under selling and marketing expenses.
	For definite life intangibles, whenever impairment indicators are identified, Teva reconsiders the asset's estimated life, calculates the undiscounted value of the asset's cash flows and compares such value against the asset's carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of book value over fair value based on the discounted cash flows.
	Indefinite life intangible assets are mainly comprised of research and development in-process. Teva monitors development for any triggering events. Annually or when triggering events are present, Teva determines the fair value of the asset based on discounted cash flows on and records an impairment loss if book value exceeds fair value.
	Research and development in-process acquired in a business combination is capitalized as an indefinite life intangible asset until the related research and development efforts are either completed or abandoned. In the reporting period where they are treated as indefinite life intangible assets, they are not amortized but rather are monitored and tested for impairment. Upon completion of the related research and development efforts, management determines the useful life of the intangible assets and amortizes them accordingly. In case of abandonment, the related research and development assets are impaired.
Property, plant and equipment	Property, plant and equipment
	Property, plant and equipment are stated at cost, after deduction of the related investment grants, and depreciated using the straight-line method over the estimated useful life of the assets: buildings, mainly 40 years; machinery and equipment, mainly between 15 to 20 years; and other assets, between 5 to 10 years.
	For property, plant and equipment, whenever impairment indicators are identified, Teva reconsiders the asset's estimated life, calculates the undiscounted value of the asset's cash flows and compares such value against the asset's carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of book value over fair value.
Contingencies	h.       Contingencies:
	The Company and its subsidiaries are involved in various patent, product liability, commercial, government investigations, environmental claims and other legal proceedings that arise from time to time in the ordinary course of business. Except for income tax contingencies or contingent consideration acquired in a business combination, Teva records accruals for these types of contingencies to the extent that Teva concludes their occurrence is probable and that the related liabilities are estimable. When accruing these costs, the Company will recognize an accrual in the amount within a range of loss that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company accrues for the minimum amount within the range. Teva records anticipated recoveries under existing insurance contracts that are virtually certain of occurring at the gross amount that is expected to be collected. Legal costs are expensed as incurred.
Tax contingencies	i.       Uncertain tax positions:
	Teva recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. We regularly re-evaluate our tax positions based on developments in our tax audits, statute of limitations expirations, changes in tax laws and new information that can affect the technical merits and change the assessment of our ability to sustain the tax benefit. In addition, the Company classifies interest and penalties recognized in the financial statements relating to uncertain tax position under the income taxes line item.
Treasury shares	j.       Treasury shares:
	Treasury shares are held by Teva's subsidiaries and presented as a reduction of Teva shareholders' equity and carried at their cost to Teva, under treasury shares.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	k.       Stock-based compensation:
	Teva recognizes the estimated fair value of share-based awards, restricted share units (“RSUs”) and performance share units ("PSUs"), net of estimated forfeitures, under stock-based compensation costs. The compensation expense for PSUs is recognized only if it is probable that the performance condition will be achieved.
	Teva measures compensation expense for share-based awards based on estimated fair values on the date of grant using the Black-Scholes option-pricing model. This option pricing model requires estimates as to the option's expected term and the price volatility of the underlying stock.
	Teva measures compensation expense for the RSUs and PSUs based on the market value of the underlying stock at the date of grant, less an estimate of dividends that will not accrue to the RSU and PSU holders prior to vesting.
Revenue recognition	l.       Revenue recognition:
	The Company recognizes revenues from product sales, including sales to distributors when persuasive evidence of an arrangement exists, delivery has occurred, the selling price is fixed or determinable and collectability is reasonably assured. This generally occurs when products are shipped and title and risk and rewards for the products are transferred to the customer.
	Revenues from product sales are recorded net of provisions for estimated chargebacks, rebates, returns, prompt pay discounts and other deductions, such as shelf stock adjustments, which can be reasonably estimated. When sales provisions are not considered reasonably estimable by Teva, the revenue is deferred to a future period when more information is available to evaluate the impact.
	Provisions for chargebacks, rebates including Medicaid and other governmental program discounts, and other promotional items, such as shelf stock adjustments, are included in SR&A under current liabilities. These provisions are recognized concurrently with the sales of products. Prompt payment discounts are netted against accounts receivable.
	Calculations for these deductions from sales are based on historical experience and the specific terms in the individual agreements. Chargebacks and rebates are the largest components of sales reserves and allowances. Provisions for chargebacks are determined using historical chargeback experience and expected chargeback levels and wholesaler sales information for new products, which are compared to externally obtained distribution channel reports for reasonableness. Rebates are recognized based on contractual obligations in place at the time of sales with consideration given to relevant factors that may affect the payment as well as historical experience for estimated market activity. Shelf-stock adjustments are granted to customers based on the existing inventory of a customer following decreases in the invoice or contract price of the related product and are estimated based on expected market performance. Teva records a reserve for estimated sales returns by applying historical experience of customer returns to the amounts invoiced and the amount of returned products to be destroyed versus products that can be placed back in inventory for resale.
	Revenue resulting from the achievement of milestone events stipulated in agreements is recognized when the milestone is achieved. Milestones are based upon the occurrence of a substantive element specified in the contract or as a measure of substantive progress towards completion under the contract.
	Revenues from licensees, sales of licensed products and technology are recorded in accordance with the contract terms, when third-party sales can be reliably measured and collection of the funds is reasonably assured.
	Revenues include royalty income and income from services, which amounted to $167 million, $182 million and $438 million in the years ended December 31, 2014, 2013 and 2012, respectively.
Research and development expenses	m.       Research and development:
	Research and development expenses are charged as incurred. Participations and grants in respect of research and development expenses are recognized as a reduction of research and development expenses as the related costs are incurred, or as the related milestone is met. Upfront fees received in connection with cooperation agreements are deferred and recognized over the period of the applicable agreements as a reduction of research and development expenses.
	Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or the services are performed.
	Research and development in-process acquired as part of an asset purchase, which has not reached technological feasibility and has no alternative future use, is expensed as incurred.
Shipping and handling costs	n.       Shipping and handling costs:
	Shipping and handling costs, which are included in selling and marketing expenses, amounted to $151 million, $232 million and $230 million for the years ended December 31, 2014, 2013 and 2012, respectively.
Advertising expenses	o.       Advertising expenses:
	Advertising expenses are charged to income as incurred. Advertising expenses for the years ended December 31, 2014, 2013 and 2012 were $302 million, $321 million and $337 million, respectively.
Income taxes	p.       Deferred income taxes:
	Deferred income taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of temporary differences between the financial accounting and tax basis of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred income taxes are expected to be paid or realized. A valuation allowance is provided if, based upon the weight of available evidence, it is more likely than not that a portion of the deferred income tax assets will not be realized. In determining whether a valuation allowance is needed, we consider all available evidence, including historical information, long range forecast of future taxable income and evaluation of tax planning strategies. Amounts recorded for valuation allowance can result from a complex series of judgments about future events and can rely on estimates and assumptions. Deferred income tax liabilities and assets are classified as current or non-current based on the classification of the related asset or liability for financial reporting, or according to the expected reversal dates of the specific temporary differences where appropriate.
	Deferred tax has not been provided on the following items:
	(1) Taxes that would apply in the event of disposal of investments in subsidiaries, as it is generally the Company's intention to hold these investments, not to realize them.
	(2) Amounts of tax-exempt income generated from the Company's current Approved Enterprises and unremitted earnings from foreign subsidiaries retained for reinvestment in the Group. See note 16f.
Earnings per share	q.       Earnings per share:
	Basic earnings per share are computed by dividing the net income attributable to Teva by the weighted average number of ordinary shares (including fully vested RSUs) outstanding during the year, net of treasury shares.
	In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i) the exercise of options and non-vested RSUs and PSUs granted under employee stock compensation plans and one series of convertible senior debentures, using the treasury stock method; and (ii) the conversion of the remaining convertible senior debentures using the “if-converted” method, by adding to net income interest expense on the debentures and amortization of issuance costs, net of tax benefits, and by adding the weighted average number of shares issuable upon assumed conversion of the debentures.
Concentration of credit risks	r.       Concentration of credit risks:
	Most of Teva's cash and cash equivalents (which along with investment in securities amounted to $2.6 billion at December 31, 2014) were deposited with financially sound European, U.S. and Israeli banks and financial institutions and were comprised mainly of cash deposits.
	The pharmaceutical industry, particularly in the U.S., has been significantly affected by consolidation among managed care providers, large pharmacy chains, wholesaling organizations and other buyer groups. The U.S. market constitutes approximately 52.5% of Teva's consolidated revenues and a relatively small portion of total trade accounts after netting amounts in SR&A. The exposure of credit risks relating to other trade receivables is limited, due to the relatively large number of group customers and their wide geographic distribution. Teva performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for doubtful accounts and generally does not require collateral. An appropriate allowance for doubtful accounts is included in the accounts and netted against accounts receivable.
Derivative	s.       Derivatives and hedging:
	The Group carries out transactions involving derivative financial instruments (mainly forward exchange contracts, written and purchased currency options, cross-currency swap contracts and interest rate swap contracts). The transactions are designed to hedge the Company's currency and interest rate exposures.
	The Company does not enter into derivative transactions for trading purposes.
	Derivatives that do not qualify for hedge accounting are recognized on the balance sheet at their fair value, with changes in the fair value recognized as a component of financial expenses - net in the statements of income. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.
	Derivatives that qualify as a fair value hedge are recognized on the balance sheet at their fair value, with changes in the fair value reported with the carrying amount of the hedged asset or liability.
	For derivatives that qualify as cash-flow hedge, the effective portion of these derivatives' fair value is initially reported as a component of other comprehensive income.
	For derivatives that qualify for hedge accounting, the cash flows associated with these derivatives are reported in the consolidated statements of cash flows consistently with the classification of cash flows from the underlying hedged items that these derivatives are hedging.
Fair value measurement	t.       Fair value measurement:
	The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
	The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:
	Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
	Level 2: Observable inputs that are based on inputs not quoted on active markets, but corroborated by market data.
	Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
	In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers credit risk in its assessment of fair value.
Collaborative arrangements	u.       Collaborative arrangements:
	A Collaborative agreements are contractual arrangements in which the parties are active participants to the arrangement and are exposed to the significant risks and rewards that are dependent on the ultimate commercial success of the endeavor. See note 2.
	The Company recognizes revenue generated and costs incurred on sales to third parties as they relate to a collaborative agreement as gross or net. If the Company is the principal participant in a transaction, revenues are recorded on a gross basis; otherwise, revenues are recorded on a net basis.
Segment reporting	v.       Segment reporting:
	The Company's business includes two reporting segments: generic and specialty medicines. The generics segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients ("API"). The specialty segment engages in the development, manufacture, sale and distribution of branded specialty medicines such as those for central nervous system and respiratory indications, as well as those marketed in the women's health, oncology and other specialty businesses. See note 21.
Costs associated with exit or disposal activities or restructurings	w.       Restructuring:
	Restructuring charges are initially recorded at fair value, and recognized in connection with restructuring programs designed to reduce the cost structure, increase efficiency and enhance competitiveness. Judgment is used when estimating the impact of restructuring plans, including future termination benefits and other exit costs to be incurred when the actions take place. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. Actual results could vary from these estimates.
Reclassifications	x.       Reclassifications:
	Certain comparative figures have been reclassified to conform to the current year presentation.
Recently issued accounting pronouncements	y.       Recently issued accounting pronouncements:
	In August 2014, the Financial Accounting Standards Board ("FASB") issued amended guidance related to disclosure of uncertainties about an entity's ability to continue as a going concern. The new guidance requires management to evaluate whether there is substantial doubt about the entity's ability to continue as a going concern and, as necessary, to provide related footnote disclosures. The guidance has an effective date of December 31, 2016. Teva believes that the adoption of this new standard will not have a material impact on its consolidated financial statements.
	In May 2014, the FASB issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is that an entity will recognize revenue upon the transfer of goods or services to customers in an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December 15, 2016 (early adoption is not permitted). The guidance permits the use of either a retrospective or cumulative effect transition method. Teva is currently evaluating the potential effect of the amended guidance on its consolidated financial statements.
	In April 2014, the FASB issued amended guidance related to discontinued operations. The new guidance limits the presentation of discontinued operations to business circumstances when the disposal of the business operation represents a strategic shift that has had or will have a major effect on operations and financial results. This guidance is effective for fiscal years beginning January 1, 2015. Teva believes that the adoption of this new standard will not materially impact its consolidated financial statements.

FAIR_VALUE_MEASUREMENT_Tables

FAIR VALUE MEASUREMENT (Tables)	0 Months Ended
	Dec. 31, 2014
Fair Value Measurement Tables [Abstract]
Financial items carried at fair value			31-Dec-14
			(U.S. $ in millions)
			Level 1		Level 2		Level 3		Total
	Cash and cash equivalents:
		Money markets	$	10	$	-	$	-	$	10
		Cash deposits and other		2,216		-		-		2,216
	Escrow fund			125		-		-		125
	Investment in securities:
		Auction rate securities		-		-		13		13
		Equity securities		66		-		-		66
		Structured investment vehicles		-		96		-		96
		Other, mainly debt securities		73		-		1		74
	Derivatives:
		Asset derivatives - options and forward contracts		-		82		-		82
		Asset derivatives - cross-currency swaps		-		20		-		20
		Liabilities derivatives - options and forward contracts		-		-54		-		-54
		Liabilities derivatives - interest rate swaps		-		-43		-		-43
	Contingent consideration *			-		-		-630		-630
	Total		$	2,490	$	101	$	-616	$	1,975
			31-Dec-13
			(U.S. $ in millions)
			Level 1		Level 2		Level 3		Total
	Cash and cash equivalents:
		Money markets	$	9	$	-	$	-	$	9
		Cash deposits and other		1,029		-		-		1,029
	Investment in securities:
		Auction rate securities		-		-		18		18
		Equity securities		70		-		-		70
		Structured investment vehicles		-		89		-		89
		Other		29		-		1		30
	Derivatives:
		Asset derivatives - options and forward contracts		-		28		-		28
		Asset derivatives- interest rate swaps		-		2		-		2
		Liability derivatives - options and forward contracts		-		-17		-		-17
		Liability derivatives- interest rate and cross-currency swaps		-		-436		-		-436
	Contingent consideration *			-		-		-366		-366
	Total		$	1,137	$	-334	$	-347	$	456
	Financial instruments measured on a basis other than fair value are mostly comprised of senior notes and convertible senior debentures, and are presented in the below table in terms of fair value:
			Estimated fair value*
			December 31,
			2014		2013
			(U.S. $ in millions)
		Senior notes included under long-term liabilities	$	-7,776	$	-8,656
		Senior notes and convertible senior debentures included under short-term liabilities		-1,731		-1,308
		Fair value at the end of the period	$	-9,507	$	-9,964
	* The fair value was estimated based on quoted market prices, where available.
Activity for financial assets estimated utilizing Level 3 inputs	The following table summarizes the activity for those financial assets and liabilities where fair value measurements are estimated utilizing Level 3 inputs.
			December 31,
			2014		2013
			(U.S. $ in millions)
		Fair value at the beginning of the period	$	-347	$	-98
		Amount realized		-5		-16
		Changes in contingent consideration:
		Cephalon acquisition		-35		-12
		MicroDose acquisition		140		-232
		Sale of animal health unit		-5		8
		Contingent consideration resulting from:
		NuPathe acquisition		-112		-
		Labrys acquisition		-252		-
		Other net change to fair value:
		Included in earnings - financial expense - net		-		1
		Included in accumulated other comprehensive loss		-		2
		Fair value at the end of the period	$	-616	$	-347

MARKETABLE_SECURITIES_Tables

MARKETABLE SECURITIES (Tables)	0 Months Ended
	Dec. 31, 2014
Marketable Securities Tables [Abstract]
Available-for-sale securities		Fair value			Amortized cost		Gross unrealized holding gains		Gross unrealized holding losses
		(U.S. $ in millions)
	31-Dec-14	$	259		$	266	$	19	$	26
	31-Dec-13	$	216		$	213	$	25	$	22
Marketable securities		December 31,
		2014			2013
		(U.S. $ in millions)
	Other non-current assets	$	176		$	179
	Other current assets		73			28
	Cash and cash equivalents, mainly money market funds		10			9
		$	259		$	216
Contractual maturities of debt securities	b.	Contractual maturities:
	The contractual maturities of debt securities are as follows:
			December 31,
			2014
			(U.S. $ in millions)
		2015	$	83
		2016		1
		2017		0
		2018		0
		2019		0
		2020 and thereafter		109
			$	193

INVENTORIES_Tables

INVENTORIES (Tables)	0 Months Ended
	Dec. 31, 2014
Inventories Tables [Abstract]
Inventory current	NOTE 5—INVENTORIES:
		Inventories, net of reserves, consisted of the following:
				December 31,
				2014		2013
				(U.S. $ in millions)
			Finished products	$	2,268	$	2,567
			Raw and packaging materials		1,279		1,576
			Products in process		638		715
			Materials in transit and payments on account		186		195
				$	4,371	$	5,053

PROPERTY_PLANT_AND_EQUIPMENT_T

PROPERTY, PLANT AND EQUIPMENT (Tables)	0 Months Ended
	Dec. 31, 2014
Property Plant And Equipment Tables [Abstract]
Property, plant and equipment, net	NOTE 6—PROPERTY, PLANT AND EQUIPMENT:
		Property, plant and equipment, net, consisted of the following:
				December 31,
				2014		2013
				(U.S. $ in millions)
			Machinery and equipment	$	4,893	$	4,633
			Buildings		2,653		2,635
			Computer equipment and other assets		1,391		1,310
			Payments on account		571		716
			Land*		372		446
					9,880		9,740
			Less—accumulated depreciation		3,345		3,105
				$	6,535	$	6,635
		*	Land includes long-term leasehold rights in various locations, with useful lives of between 30 and 99 years.
		Depreciation expenses were $464 million, $458 million and $428 million in the years ended December 31, 2014, 2013 and 2012, respectively. During the years ended December 31, 2014, 2013 and 2012, Teva had impairments of property, plant and equipment in the amount of $163 million, $61 million and $190 million, respectively. See note 19.

GOODWILL_DISCLOSURE_Tables

GOODWILL DISCLOSURE (Tables)	0 Months Ended
	Dec. 31, 2014
Goodwill [Abstract]
Schedule of goodwill	NOTE 7—GOODWILL:
	The changes in the carrying amount of goodwill for the year ended December 31, 2014 was as follows:
			Generics		Specialty		Other		Total
				(U.S. $ in millions)
		Balance as of January 1, 2014	$	9,088	$	8,668	$	1,225	$	18,981
		Changes during year:
		Goodwill acquired		-		183		-		183
		Translation differences and other		-358		-349		-49		-756
		Balance as of December 31, 2014	$	8,730	$	8,502	$	1,176	$	18,408

IDENTIFIABLE_INTANGIBLE_ASSET_

IDENTIFIABLE INTANGIBLE ASSET (Tables)	0 Months Ended
	Dec. 31, 2014
Identifiable Intangible Asset [Abstract]
Identifiable Intangible Asset [Table Text Block]	NOTE 8 - IDENTIFIABLE INTANGIBLE ASSETS:
		Identifiable intangible assets consisted of the following:
			Original amount net of impairment				Accumulated amortization				Amortized balance
			December 31,
			2014		2013		2014		2013		2014		2013
			(U.S. $ in millions)
		Product rights	$	9,606	$	10,037	$	5,343	$	4,601	$	4,263	$	5,436
		Trade names		243		270		54		55		189		215
		Research and development in process		1,060		825		0		0		1,060		825
		Total	$	10,909	$	11,132	$	5,397	$	4,656	$	5,512	$	6,476

SHORT_TERM_DEBT_Tables

SHORT TERM DEBT (Tables)	0 Months Ended
	Dec. 31, 2014
Short Term Debt Tables [Abstract]
Schedule of short term debt	NOTE 9—SHORT-TERM DEBT:
	a.	Short-term debt:	December 31,
			2014		2013
			(U.S. $ in millions)
		Banks and financial institutions	$	46	$	458
		Convertible debentures (see note 13)		530		530
		Current maturities of long-term liabilities		1,185		816
		Total	$	1,761	$	1,804

SALE_RESERVES_AND_ALLOWENCES_T

SALE RESERVES AND ALLOWENCES (Tables)	0 Months Ended
	Dec. 31, 2014
Sales Researves And Allowancess [Abstract]
Sales Researves And Allowancess [Table Text Block]	NOTE 10—SALES RESERVES AND ALLOWANCES:
	Sales reserves and allowances consisted of the following:
			December 31,
			2014		2013
			(U.S. $ in millions)
		Rebates	$	2,842	$	2,242
		Chargebacks		1,129		1,114
		Medicaid		1,099		848
		Returns		593		573
		Other		186		141
			$	5,849	$	4,918

LONG_TERM_EMPLOYEE_RELATED_OBL1

LONG TERM EMPLOYEE RELATED OBLIGATIONS (Tables)	0 Months Ended
	Dec. 31, 2014
Long Term Employee Related Obligations Tables [Abstract]
Long-term employee-related obligations	NOTE 11—LONG-TERM EMPLOYEE-RELATED OBLIGATIONS:
	a.	Long-term employee-related obligations consisted of the following:
			December 31,
			2014		2013
			(U.S. $ in millions)
		Accrued severance obligations	$	146	$	132
		Defined benefit plans		188		149
		Total	$	334	$	281

SENIOR_NOTES_AND_LOANS_Tables

SENIOR NOTES AND LOANS (Tables)	0 Months Ended
	Dec. 31, 2014
Senior Notes And Loans Tables [Abstract]
Schedule of senior notes and loans	NOTE 12—SENIOR NOTES AND LOANS:
	a.	Senior notes and loans consisted of the following:
			Weighted average interest rate as of December 31, 2014		December 31,
					2014		2013
			%		(U.S. $ in millions)
	Senior notes (1)(2)(3)		2.9		$	8,335	$	9,517
	Loans, mainly from banks (4)(5)		1.2			1,401		1,671
	Debentures (5)		7.2			15		15
						9,751		11,203
	Less - current portion (included under “short-term debt”)					-1,185		-816
					$	8,566	$	10,387
	c. The required annual principal payments of long-term debt as of December 31, 2014, starting with the year 2016, are as follows:
			December 31,
			2014
			(U.S. $ in millions)
		2016	$	978
		2017		568
		2018		779
		2019		1,517
		2020 and thereafter		4,724
			$	8,566

EQUITY_Tables

EQUITY (Tables)	0 Months Ended
	Dec. 31, 2014
Equity Tables [Abstract]
Status of option plans					Year ended December 31,
					2014				2013				2012
					Number (in thousands)		Weighted average exercise price		Number (in thousands)		Weighted average exercise price		Number (in thousands)	Weighted average exercise price
	Balance outstanding at beginning of year				32,481		$45.05		36,580		$44.40		33,298	$44.92
	Changes during the year:
		Granted			6,935		48.6		1,701		38.37		7,231	40.5
		Exercised			-11,423		45.05		-2,797		32.17		-704	33.36
		Forfeited			-1,260		46.11		-3,003		45.51		-3,245	44.76
	Balance outstanding at end of year				26,733		45.91		32,481		45.05		36,580	44.4
	Balance exercisable at end of year				12,632		47.16		17,082		47.3		14,230	44.3
Schedule of ordinary shares issued upon outstanding options	The following tables summarize information at December 31, 2014 regarding the number of ordinary shares issuable upon (1) outstanding options and (2) vested options:
	(1) Number of ordinary shares issuable upon exercise of outstanding options
	Range of exercise prices				Balance at end of period (in thousands)		Weighted average exercise price		Weighted average remaining life		Aggregate intrinsic value (in thousands)
					Number of shares		$		Years		$
	$35.11	-	$40.10		4,686		38.65		8.07		88,370
	$40.11	-	$45.10		7,365		41.96		6.11		114,519
	$45.11	-	$50.10		9,909		48.6		7.98		88,293
	$50.11	-	$55.10		4,134		52.42		2.73		21,042
	$55.11	-	$60.10		475		59.48		2.99		-
	$60.11	-	$65.00		164		64.31		2.15		-
	Total				26,733		45.91		6.54		312,224
Schedule of ordinary shares issued upon vested options	(2) Number of ordinary shares issuable upon exercise of vested options
	Range of exercise prices				Balance at end of period (in thousands)		Weighted average exercise price		Weighted average remaining life		Aggregate intrinsic value (in thousands)
					Number of shares		$		Years		$
	$35.11	-	$40.10		1,896		38.81		7.98		35,460
	$40.11	-	$45.10		3,267		41.87		4.78		51,093
	$45.11	-	$50.10		3,170		48.72		5.76		27,869
	$50.11	-	$55.10		3,711		52.57		2.18		18,331
	$55.11	-	$60.10		425		59.74		2.15		-
	$60.11	-	$65.00		163		64.31		2.15		-
	Total				12,632		47.16		4.62		132,753
Schedule of the number of RSUs issued and outstanding			Year ended December 31,
			2014				2013				2012
			Number (in thousands)		Weighted average grant date fair value		Number (in thousands)		Weighted average grant date fair value		Number (in thousands)		Weighted average grant date fair value
	Balance outstanding at beginning of year		2,512		$40.48		3,744		$41.04		3,093		$43.23
	Granted		1,342		46.09		289		35.8		1,320		38
	Vested		-1,146		41.55		-1,222		41.04		-519		45.65
	Forfeited		-242		40.05		-299		40.98		-150		43.97
	Balance outstanding at end of year		2,466		43.05		2,512		40.48		3,744		41.04
Components of accumulated other comprehensive income (loss)			December 31,
			2014			2013			2012
			(U.S. $ in millions)
		Currency translation adjustment	$	-1,283		$	151		$	175
		Unrealized loss on defined benefit plans, net		-93			-50			-92
		Unrealized gain (loss) on derivative financial instruments, net		40			-197			-93
		Unrealized gain (loss) from available-for-sale securities, net		-7			5			-7
		Accumulated other comprehensive loss attributable to Teva	$	-1,343		$	-91		$	-17
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	The weighted average fair value of options granted during the years was estimated by using the Black-Scholes option-pricing model:
					Year ended December 31,
					2014		2013		2012
		Weighted average fair value			$9.30		$6.60		$7.40
	The fair value of these options was estimated on the date of grant, based on the following weighted average assumptions:
					Year ended December 31,
					2014		2013		2012
		Dividend yield			2.90%		3.30%		2.60%
		Expected volatility			25%		23%		24%
		Risk-free interest rate			1.90%		2.10%		1.30%
		Expected term			6 years		9 years		8 years
Treasury Stock Shares Acquired [Table Text Block]					Year ended December 31,
					2014			2013			2012
					(in millions)
		Amount spent on shares repurchased			$	500		$	497		$	1,161
		Number of shares repurchased				8.7			12.8			28.1
Accumulated Other Comprehensive Income/(Loss) (net of tax)		The following tables present the changes in the components of accumulated other comprehensive loss for the year ended December 31, 2014 and 2013:
						Year ended December 31, 2014
	Components of accumulated other comprehensive loss			Description of the reclassification to the statement of income		Other comprehensive income (loss) before reclassifications			Amounts reclassified to the statement of income			Net other comprehensive income (loss) before tax		Corresponding income tax		Net other comprehensive income (loss) after tax
	Currency translation adjustment			Currency translation adjustment, reclassified to general and administrative expenses		$	-1,429		$	-5		$	-1,434	$	-	$	-1,434
	Unrealized gain (loss) from available-for-sale securities			Loss on marketable securities, reclassified to financial expenses - net			-12			2			-10		-2		-12
	Unrealized gain (loss) from derivative financial instruments			Gain on derivative financial instruments, reclassified to net revenues			240			-3			237		-		237
	Unrealized gain (loss) on defined benefit plans			Gain on defined benefit plans, reclassified to various statement of income items**			-55			-2			-57		14		-43
	Total accumulated other comprehensive income (loss)					$	-1,256		$	-8		$	-1,264	$	12	$	-1,252
						Year ended December 31, 2013
	Components of accumulated other comprehensive loss			Description of the reclassification to the statement of income		Other comprehensive income (loss) before reclassifications			Amounts reclassified to the statement of income			Net other comprehensive income (loss) before tax		Corresponding income tax		Net other comprehensive income (loss) after tax
	Currency translation adjustment			Currency translation adjustment, reclassified to financial expenses - net		$	-46		$	17		$	-29	$	5	$	-24
	Unrealized gain (loss) from available-for-sale securities			Gain on marketable securities, reclassified to financial expenses - net			18			-6			12		*		12
	Unrealized gain (loss) from derivative financial instruments			Loss on derivative financial instruments, reclassified to net revenues			-111			7			-104		*		-104
	Unrealized gain (loss) on defined benefit plans			Loss on defined benefit plans, reclassified to various statement of income items**			20			24			44		-2		42
	Total accumulated other comprehensive income (loss)					$	-119		$	42		$	-77	$	3	$	-74
	* Represents an amount of less than $0.5 million.
	** Affected cost of sales, research and development expenses, selling and marketing expenses and general and administrative expenses.

INCOME_TAXES_Tables

INCOME TAXES (Tables)	0 Months Ended
	Dec. 31, 2014
Income Taxes [Absract]
Schedule of income before income taxes	NOTE 16—INCOME TAXES:
	a.	Income before income taxes is comprised of the following:
				Year ended December 31,
				2014		2013		2012
				(U.S. $ in millions)
	The Parent Company and its Israeli subsidiaries			$	2,139	$	1,303	$	1,660
	Non-Israeli subsidiaries				1,499		-53		159
				$	3,638	$	1,250	$	1,819
Schedule of the provision for income taxes	b.	Income taxes:
				Year ended December 31,
				2014		2013		2012
				(U.S. $ in millions)
	In Israel			$	147	$	197	$	5
	Outside Israel				444		-240		-142
				$	591	$	-43	$	-137
	Current			$	879	$	1,096	$	564
	Deferred				-288		-1,139		-701
				$	591	$	-43	$	-137
Accumulated Other Comprehensive Income/(Loss) (net of tax)					Year ended December 31,
				2014		2013		2012
					(U.S. $ in millions)
	Income before income taxes			$	3,638	$	1,250	$	1,819
	Statutory tax rate in Israel				26.50%		25%		25%
	Theoretical provision for income taxes			$	964	$	313	$	455
	Increase (decrease) in effective tax rate due to:
		The Parent Company and its Israeli subsidiaries -
			Mainly tax benefits arising from reduced tax rates under benefit programs		-524		-535		-520
			Amendment 69 payments and finalization of prior years' tax audits, net of decrease of related uncertain tax positions		-		248		-
		Non-Israeli subsidiaries			88		-275		-83
		Increase in other uncertain tax positions—net			63		206		11
	Effective consolidated income taxes			$	591	$	-43	$	-137
Schedule of deferred income taxes	c.	Deferred income taxes:
				Year ended December 31,
				2014		2013
				(U.S. $ in millions)
	Short-term deferred tax assets—net:
		Inventory related		$	383	$	405
		Sales reserves and allowances			357		321
		Provision for legal settlements			229		235
		Provisions for employee-related obligations			66		81
		Carryforward losses and deductions (*)			59		179
		Other			78		75
					1,172		1,296
	Valuation allowance—in respect of carryforward losses and deductions that may not be utilized				-213		-249
				$	959	$	1,047
	*	The amount in 2014 is shown after reduction for unrecognized tax benefits of $143 million, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to offset any additional income taxes that would result from the settlement of a tax position. For additional information, see below.
				Year ended December 31,
				2014		2013
	Long-term deferred tax assets (liabilities)—net:			(U.S. $ in millions)
		Intangible assets		$	-1,098	$	-1,412
		Carryforward losses and deductions(*)(**)			1,043		1,415
		Property, plant and equipment			-218		-181
		Provisions for employee related obligations			39		19
		Other			-21		60
					-255		-99
	Valuation allowance—in respect of carryforward losses and deductions that may not be utilized				-458		-542
				$	-713	$	-641
				$	246	$	406
	*	The amount in 2014 is shown after reduction for unrecognized tax benefits of $150 million, see above
	**	This amount represents the tax effect of gross carryforward losses and deductions with the following expirations: 2016-2017 — $192 million; 2018-2024 — $302 million; 2025 and thereafter — $194 million. The remaining balance—$505 million—can be utilized with no expiration date.
Schedule of deferred income taxes by report caption		The deferred income taxes are reflected in the balance sheets among:
				December 31,
				2014		2013
				(U.S. $ in millions)
		Current assets—deferred income taxes		$	993	$	1,084
		Current liabilities—other current liabilities			-34		-37
		Other non-current assets			388		606
		Long-term liabilities—deferred income taxes			-1,101		-1,247
				$	246	$	406
Schedule of unrecognized tax benefits				Year ended December 31,
				2014		2013		2012
				(U.S. $ in millions)
		Balance at the beginning of the year		$	665	$	903	$	907
		Increase (decrease) related to prior year tax positions, net			38		29		-10
		Increase related to current year tax positions			51		176		151
		Decrease related to settlements with tax authorities and lapse of applicable statutes of limitations			-38		-461		-146
		Other			-3		18		1
		Balance at the end of the year		$	713	$	665	$	903

FINANCIAL_INSTRUMENTS_AND_RISK1

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)	0 Months Ended
	Dec. 31, 2014
Derivative Instruments and Hedging Activities [Absract]
Schedule of Accounts Receivable Securitization	The following table summarizes the net balance outstanding due to outstanding securitization programs:
			As of and for the year ended December 31,
			2014			2013
			(U.S. $ in millions)
	Sold receivables at the beginning of the year		$	590		$	535
	Proceeds from sale of receivables			4,287			3,662
	Cash collections (remitted to the owner of the receivables)			-4,202			-3,635
	Effect of currency exchange rate changes			-90			28
	Sold receivables at the end of the year		$	585		$	590
Financial Instruments And Risk Management Tables [Abstract[
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	b. Derivative instrument disclosure:
	The following table summarizes the notional amounts for hedged items, when transactions are designated as hedge accounting:
			December 31,
			2014			2013
			(U.S. $ in millions)
	Interest rate swap - fair value hedge *		$	1,750		$	2,500
	Cross currency swap - cash flow hedge			1,875			1,875
	Forecasted transactions - cash flow hedge			280			300
	*In October 2014, Teva terminated an interest rate swap agreement, designated as a fair value hedge, with respect to $500 million notional amount.
	The following table summarizes the classification and fair values of derivative instruments:
					Fair value
				Designated as hedging instruments					Not designated as hedging instruments
					31-Dec-14			31-Dec-13		31-Dec-14		31-Dec-13
	Reported under				U.S. $ in millions
	Asset derivatives:
	Other current assets:
		Cross currency swaps - cash flow hedge		$	14		$	-	$		$
		Interest rate swaps - fair value hedge			-			2
		Option and forward contracts -cash flow hedge			14			3
		Option and forward contracts								68		25
	Other non-current assets:
		Cross currency swaps - cash flow hedge			6			-
	Liability derivatives:
	Other current liabilities:
		Option and forward contracts -cash flow hedge			-1			-8
		Option and forward contracts								-53		-9
	Senior notes and loans:
		Cross currency swaps - cash flow hedge			-			-203
		Interest rate swaps - fair value hedge			-43			-233

FINANCIAL_EXPENSES_NET_Tables

FINANCIAL EXPENSES NET (Tables)	0 Months Ended
	Dec. 31, 2014
Financial Expenses Net Tables [Abstract]
Schedule of financial expenses	NOTE 18—FINANCIAL EXPENSES- NET:
		Year ended December, 31
		2014		2013		2012
		(U.S. $ in millions)
	Interest expenses and other bank charges	$	300	$	314	$	355
	Foreign exchange losses - net		30		8		25
	Income from investments		-24		-32		-26
	Other		7		109		32
	Total finance expense — net	$	313	$	399	$	386

RESTRUCTURING_AND_IMPAIRMENTS_

RESTRUCTURING AND IMPAIRMENTS (Tables)	0 Months Ended
	Dec. 31, 2014
Restructuring And Impairment [Abstract]
Schedule Of Restructuring Reserve By Type Of Cost [TextBlock]	NOTE 19—IMPAIRMENTS, RESTRUCTURING AND OTHERS:
		Impairments, restructuring and others consisted of the following:
			Year ended December 31 ,
			2014		2013		2012
			(U.S. $ in millions)
		Impairment of long-lived assets (see also notes 6 and 8)	$	387	$	524	$	1,071
		Restructuring		246		201		221
		Other		17		63		-33
		Total	$	650	$	788	$	1,259

SEGMENTS_Tables

SEGMENTS (Tables)	0 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	a. Segment information:
		Generics									Specialty
		Year ended December 31,									Year ended December 31,
		2014			2013			2012			2014			2013		2012
		(U.S.$ in millions)									(U.S.$ in millions)
	Revenues	$	9,814		$	9,902		$	10,385		$	8,560		$	8,388	$	8,150
	Gross profit		4,247			4,079			4,518			7,457			7,274		7,173
	R&D expenses		517			492			485			881			883		793
	S&M expenses		1,582			1,919			1,971			2,001			1,864		1,686
	Segment profit	$	2,148		$	1,668		$	2,062		$	4,575		$	4,527	$	4,694
			2014			2013			2012
			U.S.$ in millions
	Generic medicines profit	$	2,148		$	1,668		$	2,062
	Specialty medicines profit		4,575			4,527			4,694
	Total segment profit		6,723			6,195			6,756
	Profit of other activities		226			242			197
	Total profit		6,949			6,437			6,953
	Amounts not allocated to segments:
	Amortization		1,036			1,180			1,272
	General and administrative expenses		1,217			1,239			1,238
	Impairments, restructuring and others		650			788			1,259
	Legal settlements and loss contingencies		-111			1,524			715
	Other unallocated amounts		206			57			264
	Consolidated operating income		3,951			1,649			2,205
	Financial expenses - net		313			399			386
	Consolidated income before income taxes	$	3,638		$	1,250		$	1,819
	b.	Segment revenues by geographic area:
			Year ended December 31,
			2014			2013			2012
			(U.S.$ in millions)
	Generic Medicine
		United States	$	4,418		$	4,172		$	4,381
		Europe*		3,148			3,362			3,482
		Rest of the World		2,248			2,368			2,522
	Total Generic Medicine			9,814			9,902			10,385
	Specialty Medicine
		United States		6,110			6,025			5,857
		Europe*		1,898			1,854			1,575
		Rest of the World		552			509			718
	Total Specialty Medicine			8,560			8,388			8,150
	Other Revenues
		United States		106			264			200
		Europe*		777			772			741
		Rest of the World		1,015			988			841
	Total Other Revenues			1,898			2,024			1,782
	Total Revenues		$	20,272		$	20,314		$	20,317
	*	All members of the European Union, Switzerland, Norway, Albania and the countries of former Yugoslavia.
Schedule of net sales by product line	c. Net revenues from specialty medicines were as follows:
						Year ended December 31,
						2014			2013			2012
						(U.S. $ in millions)
		CNS				$	5,575		$	5,545		$	5,464
			Copaxone®				4,237			4,328			3,996
			Azilect®				428			371			330
			Nuvigil®				388			320			347
		Respiratory					957			964			856
			ProAir®				478			429			406
			Qvar®				286			328			297
		Oncology					1,180			1,005			860
			Treanda®				767			709			608
		Women's health					504			510			448
		Other Specialty					344			364			522
		Total Specialty Medicines				$	8,560		$	8,388		$	8,150
Schedule of PPE by geographical area	e.	Property, plant and equipment—by geographical location were as follows:
				December 31,
				2014			2013			2012
				(U.S. $ in millions)
	Israel			$	1,949		$	1,834		$	1,649
	United States				691			852			896
	Hungary				520			526			498
	Croatia				515			479			415
	Japan				446			492			644
	Germany				367			403			367
	Other				2,047			2,049			1,846
	Total property, plant and equipment			$	6,535		$	6,635		$	6,315

EARNINGS_PER_SHARE_Tables

EARNINGS PER SHARE (Tables)	0 Months Ended
	Dec. 31, 2014
Earnings Per Share Tables [Abstract]
Schedule of earnings per share	NOTE 22—EARNINGS PER SHARE:
	The net income attributable to Teva and the weighted average number of shares used in computation of basic and diluted earnings per share for the years ended December 31, 2014, 2013 and 2012 are as follows:
		2014			2013			2012
		(U.S. $ in millions, except share data)
	Net income attributable to Teva	$	3,055		$	1,269		$	1,963+
	Interest expense on convertible senior debentures, and issuance costs, net of tax benefits		*			*			*+
	Net income used for the computation of diluted earnings per share	$	3,055		$	1,269		$	1,963
Schedule of weighted average number of shares	Weighted average number of shares used in the computation of basic earnings per share			853			849			872
	Add:
		Additional shares from the assumed exercise of employee stock options and unvested RSUs and PSUs		3			1			1
		Weighted average number of additional shares issued upon the assumed conversion of convertible senior debentures		2			*			*
	Weighted average number of shares used in the computation of diluted earnings per share			858			850			873
		* Represents an amount of less than 0.5 million.

SCHEDULE_II_VALUATION_AND_QUAL1

SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS (Tables)	0 Months Ended
	Dec. 31, 2014
Schedule Of Valuation And Qualifying Accounts Tables [Abstract]
Schedule Of Valuation And Qualifying Accounts Disclosure Table [Text Block]	TEVA PHARMACEUTICAL INDUSTRIES LIMITED
	SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS
	Three Years Ended December 31, 2014
	(U.S. $ in millions)
	Column A		Column B		Column C				Column D		Column E
			Balance at beginning of period		Charged to costs and expenses		Charged to other accounts		Deductions		Balance at end of period
	Allowance for doubtful accounts:
		Year ended December 31, 2014	$	187	$	22	$	-18	$	-42	$	149
		Year ended December 31, 2013	$	145	$	44	$	3	$	-5	$	187
		Year ended December 31, 2012	$	116	$	32	$	5	$	-8	$	145
	Allowance in respect of carryforward tax losses:
		Year ended December 31, 2014	$	791	$	128	$	0	$	-248	$	671
		Year ended December 31, 2013	$	726	$	182	$	0	$	-117	$	791
		Year ended December 31, 2012	$	452	$	384	$	2	$	-112	$	726

SIGNIFICANT_ACCOUNTING_POLICIE2

SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	0 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Significant Accounting Policies [Abstract]
Percentage of consolidated sales in North America	52.50%
Shipping and handling costs, which are included in selling and marketing expenses		$151,000,000	$232,000,000	$230,000,000
Advertising expense		302,000,000	321,000,000	337,000,000
Property Plant And Equipment [Line Items]
Other Revenue		167,000,000	182,000,000	438,000,000
Cash And Cash Equivalents And Marketable Securities Deposited In Banks And Financial Institutions	$2,600,000,000	$2,600,000,000
Building [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Useful Life Mainly	40
Other Machinery And Equipment [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Useful Life		15 years 12 months 31 days
Other Machinery And Equipment [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Useful Life		20 years 12 months 31 days
Other Capitalized Property Plant And Equipment [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Useful Life		5 years 12 months 31 days
Other Capitalized Property Plant And Equipment [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Useful Life		10 years 12 months 31 days

CERTAIN_TRANSACTIONS_Details

CERTAIN TRANSACTIONS (Details) (Labrys Biologics [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Labrys Biologics [Member]
Noncash Or Part Noncash Acquisitions [Line Items]
Total consideration	$207
Purchase price in US dollars	$207

CERTAIN_TRANSACTIONS_Details_1

CERTAIN TRANSACTIONS (Details 1) (USD $)	0 Months Ended	9 Months Ended	0 Months Ended
In Millions, unless otherwise specified	Jan. 05, 2011	Oct. 26, 2011	Oct. 14, 2011	Jul. 14, 2011	Sep. 28, 2011	Sep. 26, 2011	Jul. 09, 2013	Dec. 31, 2014
Laboratoire Theramex [Member]
Business Acquisition [Line Items]
Business Acquisition Effective Date Of Acquisition1	1-Jan-11
Infarmasa [Member]
Business Acquisition [Line Items]
Business Acquisition Effective Date Of Acquisition1		1-Jan-11
Cephalon [Member]
Business Acquisition [Line Items]
Business Acquisition Effective Date Of Acquisition1			1-Oct-11
Taiyo [Member]
Business Acquisition [Line Items]
Business Acquisition Effective Date Of Acquisition1				1-Jul-11
Curetech [Member]
Business Acquisition [Line Items]
Business Acquisition Effective Date Of Acquisition1					9-Jan-11
Japanese Venture [Member]
Business Acquisition [Line Items]
Business Acquisition Effective Date Of Acquisition1						1-Sep-11
Microdose Therpeutix [Member]
Business Acquisition [Line Items]
Business Acquisition Effective Date Of Acquisition1							8-Jul-13
NuPathe [Member]
Business Acquisition [Line Items]
Business Acquisition Cost O fAcquired Entity Purchase Price								$163
potential additional payments of purchase price								106
LabrysBiologics1 [Member]
Business Acquisition [Line Items]
Business Combination Contingent Consideration Liability Fair Value								251
potential additional payments of purchase price								$625

CERTAIN_TRANSACTIONS_Details_4

CERTAIN TRANSACTIONS (Details 4) (USD $)	0 Months Ended
	Dec. 31, 2014	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012
Schedule Of Equity Method Investments [Line Items]
Related Party Transaction Expenses From Transactions With Related Party	$448,700	$431,442	$412,000	$305,000
Xenon [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Arrangement, Rights and Obligations					Under the agreement, Teva paid Xenon an upfront fee of $41 million. Dr. Michael Hayden, Teva’s President of Global R&D and Chief Scientific Officer, is the founder, a minority shareholder and a member of the board of directors of Xenon. In order to avoid potential conflicts of interest, Teva has established certain procedures to exclude Dr. Hayden from any involvement in Teva's decision-making related to Xenon.

CERTAIN_TRANSACTIONS_Details_6

CERTAIN TRANSACTIONS (Details 6)	0 Months Ended
	Dec. 31, 2014	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 02, 2011
	USD ($)	USD ($)	USD ($)	USD ($)	Ctg Weld [Member]	Ctg Weld [Member]	Ctg Weld [Member]	CoCrystal [ Member]
					EUR (€)	EUR (€)	EUR (€)
Business Acquisition [Line Items]
Related Party Transaction Expenses From Transactions With Related Party	$448,700	$431,442	$412,000	$305,000	€ 600,000	€ 800,000	€ 1,300,000
Date Of Investment Agreement								In September 2011, Teva entered into an agreement with CoCrystal Discovery, Inc. (now CoCrystal Pharmaceuticals, Inc.), a company focusing on the discovery and development of novel therapeutics, utilizing an innovative drug discovery technology. Under the agreement, Teva will fund the company’s R&D under the Research Agreement by investing into the company up to two tranches of $7.5 million each per target (the latter one being discretionary). The first tranche was invested by Teva in 2011. We terminated this agreement effective as of November 2014. Dr. Phillip Frost, our Chairman of the Board of Directors until December 2014 and currently a member of our Board of Directors, and Prof. Roger Kornberg, who was a member of Teva's Board of Directors until August 2013, are both direct and indirect shareholders in and members of the board of directors of CoCrystal Pharmaceuticals. Prof. Roger Kornberg is also Chief Scientific Officer of CoCrystal Pharmaceuticals..

FAIR_VALUE_MEASUREMENT_Details

FAIR VALUE MEASUREMENT (Details) (USD $)	0 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Total	$1,975	$456
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value [Abstract]
Carrying value			-347	-98
Amount realized	-5	-16
Net Change In Fair Value Of Level 3 Assets [Abstract]
Fair Value Assets Measured On Recurring Basis Gain Loss Included in earnings financial income	0	1
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain LossI ncluded In Other Comprehensive Income Loss	0	2
Carrying value	-616	-347	-616	-347
Fair value of the senior notes, convertible senior debentures and interest rate swap agreements			-7,776	-8,656
Fair value of the interest rate swap agreements			0	0
Fair value convertible senior debentures and derivatives liabilities			-1,731	-1,308
Fair value, option, credit risk, gains (losses) on assets			0	2
Carrying Value Of Senior Notes Included Under Long And Short Term Liabilities And Convertibale Senior Debentures			-9,507	-9,964
Contingent Consideration In Connection With Cephalon Acquisition	-35	-12	-35	-12
Contingent Consideration In Connection With Microdose Acquisition	140	-232	140	-232
Contingent Consideration In Connection With Animal Health Acquisition	-5	8	-5	8
Contingent Consideration In Connection With Nupathe Acquisition	-112	0	-112	0
Contingent Consideration In Connection With Labrys Acquisition	-252	0	-252	0
Level 1 [Member]
Total	2,490	1,137
Level 2 [Member]
Total	101	-334
Level 3 [Member]
Total	-616	-347
Money Market Funds [Member]
Cash And Cash Equivalents Fair Value Disclosure	10	9	10	9
Money Market Funds [Member] | Level 1 [Member]
Cash And Cash Equivalents Fair Value Disclosure	10	9	10	9
Money Market Funds [Member] | Level 2 [Member]
Cash And Cash Equivalents Fair Value Disclosure	0		0
Money Market Funds [Member] | Level 3 [Member]
Cash And Cash Equivalents Fair Value Disclosure	0	0	0	0
Demand Deposits [Member]
Cash And Cash Equivalents Fair Value Disclosure	2,216	1,029	2,216	1,029
Demand Deposits [Member] | Level 1 [Member]
Cash And Cash Equivalents Fair Value Disclosure	2,216	1,029	2,216	1,029
Demand Deposits [Member] | Level 2 [Member]
Cash And Cash Equivalents Fair Value Disclosure	0	0	0	0
Demand Deposits [Member] | Level 3 [Member]
Cash And Cash Equivalents Fair Value Disclosure	0	0	0	0
Auction Rate Securities [Member]
Investments Fair Value Disclosure	13	18	13	18
Auction Rate Securities [Member] | Level 1 [Member]
Investments Fair Value Disclosure	0	0	0	0
Auction Rate Securities [Member] | Level 2 [Member]
Investments Fair Value Disclosure	0	0	0	0
Auction Rate Securities [Member] | Level 3 [Member]
Investments Fair Value Disclosure	13	18	13	18
Structured Finance [Member]
Investments Fair Value Disclosure	96	89	96	89
Structured Finance [Member] | Level 1 [Member]
Investments Fair Value Disclosure	0	0	0	0
Structured Finance [Member] | Level 2 [Member]
Investments Fair Value Disclosure	96	89	96	89
Structured Finance [Member] | Level 3 [Member]
Investments Fair Value Disclosure	0	0	0	0
Other Debt Obligations [Member]
Investments Fair Value Disclosure	74	30	74	30
Other Debt Obligations [Member] | Level 1 [Member]
Investments Fair Value Disclosure	73	29	73	29
Other Debt Obligations [Member] | Level 2 [Member]
Cash And Cash Equivalents Fair Value Disclosure		0		0
Investments Fair Value Disclosure	0	0	0	0
Other Debt Obligations [Member] | Level 3 [Member]
Investments Fair Value Disclosure	1	1	1	1
Liability Derivatives [Member]
Derivatives-net	54	17	54	17
Liability Derivatives [Member] | Level 1 [Member]
Derivatives-net	0	0	0	0
Liability Derivatives [Member] | Level 2 [Member]
Derivatives-net	54	17	54	17
Liability Derivatives [Member] | Level 3 [Member]
Derivatives-net	0	0	0	0
Interest Rate Swap [Member]
Derivatives-net	20	2	20	2
Interest Rate Swap [Member] | Level 1 [Member]
Derivatives-net	0	0	0	0
Interest Rate Swap [Member] | Level 2 [Member]
Derivatives-net	20	2	20	2
Interest Rate Swap [Member] | Level 3 [Member]
Derivatives-net	0	0	0	0
Cross Currency Interest Rate Contract [Member]
Derivatives-net	43	436	43	436
Cross Currency Interest Rate Contract [Member] | Level 1 [Member]
Derivatives-net	0	0	0	0
Cross Currency Interest Rate Contract [Member] | Level 2 [Member]
Derivatives-net	43	436	43	436
Cross Currency Interest Rate Contract [Member] | Level 3 [Member]
Derivatives-net	0	0	0	0
Asset Derivatives [Member]
Derivatives-net	82	28	82	28
Derivative Fair Value Of Derivative Asset	0	0	0	0
Asset Derivatives [Member] | Level 1 [Member]
Derivatives-net	0	0	0	0
Asset Derivatives [Member] | Level 2 [Member]
Derivatives-net	82	28	82	28
Asset Derivatives [Member] | Level 3 [Member]
Derivatives-net	0	0	0	0
Equity Securities [Member]
Investments Fair Value Disclosure	66	70	66	70
Equity Securities [Member] | Level 1 [Member]
Investments Fair Value Disclosure	66	70	66	70
Equity Securities [Member] | Level 2 [Member]
Investments Fair Value Disclosure	0	0	0	0
Equity Securities [Member] | Level 3 [Member]
Investments Fair Value Disclosure	0	0	0	0
Business Acquisition Contingent Consideration [Member]
Derivatives-net	-630	-366	-630	-366
Business Acquisition Contingent Consideration [Member] | Level 1 [Member]
Derivatives-net	0	0	0	0
Business Acquisition Contingent Consideration [Member] | Level 2 [Member]
Derivatives-net	0	0	0	0
Business Acquisition Contingent Consideration [Member] | Level 3 [Member]
Derivatives-net	-630	-366	-630	-366
EscrowFundsMember [Member]
Escrow Deposit	125		125
EscrowFundsMember [Member] | Level 1 [Member]
Escrow Deposit	125		125
EscrowFundsMember [Member] | Level 2 [Member]
Escrow Deposit	0		0
EscrowFundsMember [Member] | Level 3 [Member]
Escrow Deposit	$0		$0

MARKETABLE_SECURITIES_Details

MARKETABLE SECURITIES (Details) (USD $)	0 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Marketable Securities [Abstract]
Available For Sale Securities	$259	$216
Cost	266	213
Gross unrealized holding gains	19	25
Gross unrealized holding losses	26	22
Available-for-sale securities by report caption
Cash and cash equivalents	10	9
Short-term investments	73	28
Other non-current	176	179
Available For Sale Securities	259	216
Contractual maturities of debt securities
2015	83
2016	0
2017	0
2018	0
2019	109
2020 and thereafter	1
Total maturities of available-for-sale securities, at fair value	$193

INVENTORIES_Details

INVENTORIES (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Inventories [Abstract]
Raw and packaging materials	$1,279	$1,576
Products in process	638	715
Finished products	2,268	2,567
Materials in transit and payments on account	186	195
Inventories	$4,371	$5,053

PROPERTY_PLANT_AND_EQUIPMENT_D

PROPERTY, PLANT AND EQUIPMENT (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property Plant and Equipment Net [Abstract]
Land owned or held under long-term leases	$372	$446
Buildings	2,653	2,635
Machinery and equipment	4,893	4,633
Computer equipment and other assets	1,391	1,310
Payments on account	571	716
Subtotal	9,880	9,740
Less-accumulated depreciation	3,345	3,105
Property, Plant and Equipment, Net, Total	6,535	6,635	6,315
Depreciation expense for the year	464	458	428
Impairment charge during the year on property, plant and equipment	$163	$61	$190
Capitalized Land Lease Estimated Useful Lives Minimum	30
Capitalized Land Lease Estimated Useful Lives Maximum	99

GOODWILL_DISCLOSURE_Details

GOODWILL DISCLOSURE (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Goodwill Roll Forward [Line Items]
Goodwill, balance as of January 1	$18,981
Translation Differences And Other	-756
Goodwill acquired	183
Goodwill, balance as of December 31	18,408
Generics [Member]
Goodwill Roll Forward [Line Items]
Goodwill, balance as of January 1	9,088
Translation Differences And Other	-358
Goodwill, balance as of December 31	8,730
Specialty [Member]
Goodwill Roll Forward [Line Items]
Goodwill, balance as of January 1	8,668
Translation Differences And Other	-349
Goodwill acquired	183
Goodwill, balance as of December 31	8,502
Other Good Will [Member]
Goodwill Roll Forward [Line Items]
Goodwill, balance as of January 1	1,225
Translation Differences And Other	-49
Goodwill, balance as of December 31	$1,176

IDENTIFIABLE_INTANGIBLE_ASSET_1

IDENTIFIABLE INTANGIBLE ASSET (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Intangible Assets [Abstract]
Product rights, at cost	$9,606	$10,037
Finite Lived Trade Names Gross	243	270
Research and development in process gross	1,060	825
Intangible assets, gross, excluding goodwill	10,909	11,132
Product rights, accumulated amortization	5,343	4,601
Finite Lived Trade Names Accumulated Amortization	54	55
Intangible assets accumulated amortization	5,397	4,656
Products rights net	4,263	5,436
Trade Names Net	189	215
Research and development in process net	1,060	825
Intangible assets, net (excluding goodwill) total	5,512	6,476
Intangible assets charges against earnings
Amortization Of Intangible Assets	1,036	1,180	1,272
Impairment of intangible assets	224	393	858
Estimated aggregate amortization of intangible assets
2014	796
2015	677
2016	650
2017	609
2018	489
AcquiredIndefiniteLivedIntangibleAssetsLineItems
Research and development in process net	1,060	825
Revascor Cephalon [Member]
Intangible Assets [Abstract]
Research and development in process net	258
AcquiredIndefiniteLivedIntangibleAssetsLineItems
Research and development in process net	258
Cinquil Cephalon [Member]
Intangible Assets [Abstract]
Research and development in process net	215
AcquiredIndefiniteLivedIntangibleAssetsLineItems
Research and development in process net	215
Lama Laba Microdose [Member]
Intangible Assets [Abstract]
Research and development in process net	62
AcquiredIndefiniteLivedIntangibleAssetsLineItems
Research and development in process net	62
LBR 101 Labrys [Member]
Intangible Assets [Abstract]
Research and development in process net	439
AcquiredIndefiniteLivedIntangibleAssetsLineItems
Research and development in process net	$439

SHORT_TERM_DEBT_Details

SHORT TERM DEBT (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Debt Current
Bank loans, overdrafts and financial institution loans	$46	$458
Principal amount currently outstanding on the debt instrument	530	530
Current portion of long term senior notes and loans	1,185	816
Debt, Current, Total	$1,761	$1,804
Debt Current Additional Information
Weighted average interest rate	1.10%	0.90%

SHORT_TERM_DEBT_Details1

SHORT TERM DEBT (Details1) (USD $)	0 Months Ended
	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2013
Line Of Credit Facility [Line Items]
Bank loans, overdrafts and financial institution loans		$46,000,000	$458,000,000
Syndicated Credit Facility [Member]
Line Of Credit Facility [Line Items]
Line Of Credit Termination Terms	five-year
Line Of Credit Facility Maximum Borrowing Capacity	3,000,000,000
Bank loans, overdrafts and financial institution loans
Bilateral Revolving Lines Of Credit [Member]
Line Of Credit Facility [Line Items]
Line Of Credit Facility Maximum Borrowing Capacity	$2,500,000,000

SALES_RESEARVES_AND_ALLOWANCES1

SALES RESEARVES AND ALLOWANCES (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Sales Researves And Allowancess [Abstract]
Sales Reserves And Allowances	$5,849	$4,918
Medicaid	1,099	848
Rebates	2,842	2,242
Chargebacks	1,129	1,114
Returns	593	573
Other	$186	$141

LONG_TERM_EMPLOYEE_RELATED_OBL2

LONG TERM EMPLOYEE RELATED OBLIGATIONS (Details) (USD $)	0 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Employee-related obligations long-term
Accrued severance pay	$146	$132
Defined benefit plans	188	149
Total	334	281
Employee-related obligations information
Long-term investments earmarked for severance pay liabilities in Israel	146	156
Expected contributions to the pension funds	126
Future minimum benefit payments
2015	8
2016	10
2017	10
2018	12
2019	10
2020-2024	$57

SENIOR_NOTES_AND_LOANS_Details

SENIOR NOTES AND LOANS (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Apr. 30, 2012	Mar. 31, 2014
In Millions, unless otherwise specified
Long Term Debt By Components Alternative [Abstract]
Senior notes	$8,335	$9,517
Loans, mainly from banks	1,401	1,671	800
Debentures	15	15
Total long-term debt	9,751	11,203
Current Portion Long Term Debt	-1,185	-816
Notes and Loans, Noncurrent, Total	8,566	10,387
Maturities Of Long Term Debt [Abstract]
2016	978
2017	568
2018	779
2019	1,517
2020 and thereafter	4,724
Total Long Term Debt Maturities Repayments Of Principal	8,566
Senior Notes Additional Information [Abstract]
Fair Value Of The Interest Rate Swap Transactions Terminated	27
One Point Seven Senior Notes Due 2014 [Member]
Debt Instrument [Line Items]
Debt Instrument, Annual Principal Payment				250
Floating Rate Senior Notes Issued Nov 2011 [Member]
Debt Instrument [Line Items]
Debt Instrument, Annual Principal Payment				$500

SENIOR_NOTES_AND_LOANS_Details1

SENIOR NOTES AND LOANS (Details 1)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014
In Millions, unless otherwise specified	USD ($)	USD ($)	Syndicated Loan [Member]	Syndicated Loan [Member]	Bank Loan Two [Member]	Bank Loan Two [Member]	Long Credit Agreement 2017 [Member]	Long Credit Agreement 2019 [Member]	Senior Unsecured Fix Rate Credit Agreement [Member]	Senior Unsecure Five Years Term Loan [Member]
			USD ($)	USD ($)	USD ($)	USD ($)		USD ($)	JPY (¥)	JPY (¥)
Debt Instrument [Line Items]
Debt instrument stated interest rate percentage	7.20%						99.00%	142.00%
Interest rate information					denominated in Euro				fixed rate term loan agreement for five and seven years, bearing interest of 0.99% and 1.42%, respectively	borrowed in December 2013, bearing interest of JPY LIBOR + 0.3% (approximately $0.3 billion)
Original principal amount of debt instrument			$118	$207	$148	$168		$1,000	¥ 100,500	¥ 35,000
Principal amount currently outstanding on the debt instrument	$530	$530

CONVERTIBLE_SENIOR_DEBENTURES_

CONVERTIBLE SENIOR DEBENTURES (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Debt Instrument [Line Items]
Principal amount currently outstanding on the debt instrument	$530	$530

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	0 Months Ended													12 Months Ended
	Dec. 31, 2014	Sep. 30, 2013	Jun. 30, 2013	Dec. 31, 2012	Aug. 31, 2012	Nov. 30, 2011	Oct. 31, 2011	Jul. 07, 2010	Jan. 31, 2010	Mar. 31, 2009	Aug. 31, 2008	Apr. 30, 2005	Jan. 31, 1997	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2010	Mar. 31, 2012	Jul. 31, 2008	Feb. 28, 2005
Operating Leases Future Minimum Payments Due Abstract
2015	$139,000,000													$139,000,000
2016	114,000,000													114,000,000
2017	96,000,000													96,000,000
2018	79,000,000													79,000,000
2019	69,000,000													69,000,000
2020 and thereafter	145,000,000													145,000,000
Operating Leases Related Parties Expense	500,000
Lease And Rental Expense														153,000,000	117,000,000	132,000,000
Business Acquisition, Contingent Consideration, Potential Cash Payment	2,400,000,000													2,400,000,000
Intellectual Property Matters [Abstract]
Pantoprazole Insurance Coverage														250,000,000
Pantoprazole Settlement Additional Provision			930,000,000	670,000,000
Pantoprazole Settlement Agreement Amount														1,600,000,000
Wyeths Protonix Settlement Payment To Date														1,600,000,000
Annual sales of Provigil			500,000,000												495,000,000			1,000,000,000
Annual Sales of Effexor								2,600,000,000
Annual Sales of Lamictal																			2,300,000	950,000,000
Ciprofloxacin Plaintiffs Proposed Settlement With Bayer							74,000,000						500,000,000
Annual Sales of Nexium									6,300,000,000					6,000,000,000
Annual Sales of Niaspan		1,100,000,000										416,000,000
Annual Sales of Solodyn						765,000,000				380,000,000
Annual Sales Of Aggrenox											340,000,000			470,000,000
Annual Sales Of Actos					2,800,000,000												3,700,000,000
Annual Sales Of Actoplus					430,000,000												500,000,000
CivilPenaltyForEachAllegedlyFalseClaimSubmittedRange														Under the federal False Claims Act, the government (or relators who pursue the claims without the participation of the government in the case) may seek to recover up to three times the amount of damages in addition to a civil penalty of $5,500 to $11,000 for each allegedly false claim submitted to the government for payment.
Cephalon Losses Resulting From The Promotion and Prescription of Actiq	700,000,000													700,000,000
Compensatory Damages For The State of Illonois														100,000,000
Annual Sales Of Wellbutrin														1,000,000,000
Pantoprazole Insurance Recovery														$200,000,000
Teva And Subsidiaries [Member]
Statement [Line Items]
Approximate number of product liability cases														4,000
Approximate number of pending cases	500													500
Approximate Number Of Plaintiffs Claiming Injuries	4,400													4,400
Teva And Subsidiaries [Member] | Teva Parental Medicines Inc [Member]
Statement [Line Items]
Parties To Tort Proceeding Cases Against Teva In Philadelphia Court														40

EQUITY_Details

EQUITY (Details)	12 Months Ended
Share data in Millions, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Oct. 31, 2011
	USD ($)	ILS	USD ($)	USD ($)	USD ($)
Common stock
Ordinary shares, issued	957	957	947
Purchase of treasury shares	$500,000,000		$497,000,000	$1,161,000,000
Treasury Stock Shares Acquired	8.7	8.7	12.8	28.1
Stock Repurchase Program, Authorized Amount	2,500,000,000				3,000,000,000
Treasury stock
Treasury stock, value	-500,000,000		-497,000,000	-1,161,000,000
Retained earnings
Dividends declared and paid	$1.34		$1.28	$1.03
Additional dividends declared		1.33
Other Comprehensive Income (Loss) Net Of Tax [Abstract]
Currency translation adjustment, net of tax	-1,283,000,000		151,000,000	175,000,000
Unrealized gain (loss) from available-for-sale securities, net of tax	-7,000,000		5,000,000	-7,000,000
Unrealized loss from cash flow hedge	40,000,000		-197,000,000	-93,000,000
Accumulatedothercomprehensiveincomelossotheradjustments	-93,000,000		-50,000,000	-92,000,000
Comprehensive income attributable to Teva	($1,343,000,000)		($91,000,000)	($17,000,000)

EQUITY_Details_1

EQUITY (Details 1)	0 Months Ended
	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The vesting period of the outstanding options, RSUs and PSUs is generally 1 to 4 years from the date of grant. The rights of the ordinary shares obtained from the exercise of options, RSUs or PSUs are identical to those of the other ordinary shares of the Company. The contractual term of these options is primarily for seven years in prior plans and ten years for options granted under the 2010 plan described above.

EQUITY_Details_2

EQUITY (Details 2) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward
Options granted WA fair value	$9.30	$6.60	$7.40
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology Abstract
Dividend yield	2.90%	3.30%	2.60%
Expected volatility	25.00%	23.00%	24.00%
Risk-free interest rate (in dollar terms)	1.90%	2.10%	1.30%
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1	9 years 12 months 31 days		8 years 12 months 31 days	6 years 12 months 31 days
Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures Abstract
Closing stock price	$57.51
The total number of exercisable options that are in-the-money as of December 31, 2010	3,400,000
The total intrinsic value of options exercised during the years	$74	$19	$6
Average market price of Teva's ordinary shares during the year	$51.57	$38.99	$41.63
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested [Roll Forward]
Employee Service Share Based Compensation Nonvested Award Total Compensation Cost Not Yet Recognized Period For Recognition R S Us	1
Employee Service Share Based Compensation Nonvested Award Total Compensation Cost Not Yet Recognized Period For Recognition Stock Option	1
Stock Options Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward
Balance outstanding at beginning of year	32,481,000	36,580,000	33,298,000
Granted	6,935,000	1,701,000	7,231,000
Exercise of options and RSUs by employees, shares	-11,423,000	-2,797,000	-704,000
Forfeited	-1,260,000	-3,003,000	-3,245,000
Balance outstanding at end of year	26,733,000	32,481,000	36,580,000
Weighted average exercise price	$45.91	$45.05	$44.40	44.92
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology Abstract
Options exercisable at end of year	12,632,000	17,082,000	14,230,000
Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures Abstract
Weighted average exercise price	$47.16	$47.30	$44.30
The total unrecognized compensation cost before tax on employee stock options and RSUs	87
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested [Roll Forward]
Granted	$48.60	$38.37	$40.50
Vested	$45.05	$32.17	$33.36
Forfeited	$46.11	$45.51	$44.76
The total unrecognized compensation cost before tax on employee stock options and RSUs	87
Employee Service Share Based Compensation Aggregate Disclosures Abstract
Restricted stock units RSUs	47	40	58
Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures Abstract
The total unrecognized compensation cost before tax on employee stock options and RSUs	77
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested [Roll Forward]
RSUs outstanding at beginning of year	2,512,000,000	3,744,000,000	3,093,000,000
Granted	1,342,000,000	289,000,000	1,320,000,000
Vested	-1,146,000,000	-1,222,000,000	-519,000,000
Forfeited	-242,000,000	-299,000,000	-150,000,000
RSUs outstanding at end of year	2,466,000,000	2,512,000,000	3,744,000,000
Weighted-average grant date fair value per share - RSUs at beginning of year	$40.48	$41.04	$43.23
Granted	$46.09	$35.80	$38
Vested	$41.55	$41.04	$45.65
Forfeited	$40.05	$40.98	$43.97
Weighted-average grant date fair value per share - RSUs at end of year	$43.05	$40.48	$41.04
The total unrecognized compensation cost before tax on employee stock options and RSUs	77
Employee Service Share Based Compensation Aggregate Disclosures Abstract
Restricted stock units RSUs	38	24	24
Omnibus Long Term Share Incentive Plan [Member]
Employee Service Share Based Compensation Aggregate Disclosures Abstract
Restricted stock units RSUs	85	64	82
Tax effect on stock-based compensation expense	14	14	13
Net effect	$71	$50	$69

EQUITY_Details_3

EQUITY (Details 3) (USD $)	Dec. 31, 2014
In Thousands, except Per Share data, unless otherwise specified
Number of ordinary shares issuable upon exercise of outstanding options
Number of shares	26,733
Weighted average exercise price	$45.91
Weighted average remaining life	6.54
Aggregate intrinsic value	$312,224
Number of ordinary shares issuable upon exercise of vested options
Number of shares	12,632
Weighted average exercise price	$47.16
Weighted average remaining life	4.62
Aggregate intrinsic value	132,753
Exercise Price Range Three [Member]
Number of ordinary shares issuable upon exercise of outstanding options
Number of shares	4,686
Weighted average exercise price	$38.65
Weighted average remaining life	8.07
Aggregate intrinsic value	88,370
Exercise Price Range Four [Member]
Number of ordinary shares issuable upon exercise of outstanding options
Number of shares	7,365
Weighted average exercise price	$41.96
Weighted average remaining life	6.11
Aggregate intrinsic value	114,519
Number of ordinary shares issuable upon exercise of vested options
Number of shares	1,896
Weighted average exercise price	$38.81
Weighted average remaining life	7.98
Aggregate intrinsic value	35,460
Exercise Price Range Five [Member]
Number of ordinary shares issuable upon exercise of outstanding options
Number of shares	9,909
Weighted average exercise price	$48.60
Weighted average remaining life	7.98
Aggregate intrinsic value	88,293
Number of ordinary shares issuable upon exercise of vested options
Number of shares	3,267
Weighted average exercise price	$41.87
Weighted average remaining life	4.78
Aggregate intrinsic value	51,093
Exercise Price Range Six [Member]
Number of ordinary shares issuable upon exercise of outstanding options
Number of shares	4,134
Weighted average exercise price	$52.42
Weighted average remaining life	2.73
Aggregate intrinsic value	21,042
Number of ordinary shares issuable upon exercise of vested options
Number of shares	3,170
Weighted average exercise price	$48.72
Weighted average remaining life	5.76
Aggregate intrinsic value	27,869
Exercise Price Range Seven [Member]
Number of ordinary shares issuable upon exercise of outstanding options
Number of shares	475
Weighted average exercise price	$59.48
Weighted average remaining life	2.99
Aggregate intrinsic value	0
Number of ordinary shares issuable upon exercise of vested options
Number of shares	3,711
Weighted average exercise price	$52.57
Weighted average remaining life	2.18
Aggregate intrinsic value	18,331
Exercise Price Range Eight [Member]
Number of ordinary shares issuable upon exercise of outstanding options
Number of shares	164
Weighted average exercise price	$64.31
Weighted average remaining life	2.15
Aggregate intrinsic value	0
Number of ordinary shares issuable upon exercise of vested options
Number of shares	163
Weighted average exercise price	$64.31
Weighted average remaining life	2.15
Aggregate intrinsic value	$0

EQUITY_Details_4

EQUITY (Details 4) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Currency translation adjustment [Abstract]
Other comprehensive income (loss) before reclassifications, currency translation adjustments	($1,429)	($46)
Amounts reclassified from accumulated other comprehensive loss before tax, currency translation adjustments	-5	17
Net other comprehensive income (loss) before tax, currency translation adjustments	-1,434	-29
Income tax related to items of other comprehensive income (loss), currency translation adjustments	0	5
Net other comprehensive income (loss) after tax, currency translation adjustment	-1,434	-24
Unrealized gain (loss) from available-for-sale securities
Other comprehensive income (loss) before reclassifications, available-for-sale-securities	-12	18
Gains on marketable securities, included in financial expenses - net	2	-6
Net other comprehensive income (loss) before tax, available-for-sale-securities	-10	12
Income tax related to items of other comprehensive income (loss), available-for-sale-securities	-2	0
Net other comprehensive income (loss) after tax, available-for-sale-securities	-12	12
Unrealized gain (loss) on derivative financial instruments
Other comprehensive income (loss) before reclassifications, cash flow hedges	240	-111
Loss on derivative financial instruments, included in net revenues	-3	7
Net other comprehensive income (loss) before tax, cash flow hedges	237	-104
Income tax related to items of other comprehensive income (loss), cash flow hedges	0	0
Net other comprehensive income (loss) after tax, cash flow hedges	237	-104
Defined benefit plan items
Other comprehensive income (loss) before reclassifications, defined benefit plan	-55	20
Loss on defined benefit plans, included in various statement of income items	-2	24
Net other comprehensive income (loss) before tax, defined benefit plan	57	-44
Income tax related to items of other comprehensive income (loss), defined benefit plan	-14	2
Net other comprehensive income (loss) after tax, defined benefit plan	43	-42
Total accumulated other comprehensive income (loss)
Other comprehensive income (loss) before reclassifications	-1,256	-119
Amounts reclassified from accumulated other comprehensive loss before tax:
Amounts reclassified from accumulated other comprehensive loss before tax, currency translation adjustments	-5	17
Gains on marketable securities, included in financial expenses - net	2	-6
Loss on derivative financial instruments, included in net revenues	-3	7
Loss on defined benefit plans, included in various statement of income items	-2	24
Amounts reclassified from accumulated other comprehensive loss before tax	-8	42
Net other comprehensive income (loss) before tax	-1,264	-77
Income tax related to items of other comprehensive income (loss)	12	3
Net other comprehensive income (loss) after tax	($1,252)	($74)

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	0 Months Ended			12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2010
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
The Company and its Israeli subsidiaries				$2,139,000,000	$1,303,000,000	$1,660,000,000
Non-Israeli subsidiaries				1,499,000,000	-53,000,000	159,000,000
Income before income taxes				3,638,000,000	1,250,000,000	1,819,000,000
Effect of acquired research and development in process on non-Israeli companies							1,402,000,000
Income Tax Expense Benefit Continuing Operations By Jurisdiction
In Israel				147,000,000	197,000,000	5,000,000
Outside Israel				444,000,000	-240,000,000	-142,000,000
Income Tax Expense (Benefit), Total				591,000,000	-43,000,000	-137,000,000
Federal Income Tax Expense Benefit Continuing Operations
Current				879,000,000	1,096,000,000	564,000,000
Deferred income taxes-net and uncertain tax positions				-288,000,000	-1,139,000,000	-701,000,000
Income taxes				591,000,000	-43,000,000	-137,000,000
Effective Income Tax Rate Reconciliation
Statutory tax rate in Israel				26.50%	25.00%	25.00%
Amendment Sixty Nine Payments	286,000,000			577,000,000
Short-term deferred tax assets (liabilities)-net:
Inventory related	383,000,000	405,000,000		383,000,000	405,000,000
Sales reserves and allowances	357,000,000	321,000,000		357,000,000	321,000,000
Provisions for employee-related obligations, current	59,000,000	179,000,000		59,000,000	179,000,000
Carryforward losses and deductions, current	66,000,000	81,000,000		66,000,000	81,000,000
Provision for legal settlements	229,000,000	235,000,000		229,000,000	235,000,000
Other	78,000,000	75,000,000		78,000,000	75,000,000
Short-term deferred tax assets (liabilities)-gross	1,172,000,000	1,296,000,000		1,172,000,000	1,296,000,000
Valuation allowance-in respect of carryforward losses and deductions that may not be utilized	-213,000,000	-249,000,000		-213,000,000	-249,000,000
Short-term deferred tax assets (liabilities)-net	959,000,000	1,047,000,000		959,000,000	1,047,000,000
Long-term deferred tax assets (liabilities)-net:
Deferred Tax Liabilities Property Plant And Equipment	-218,000,000	-181,000,000		-218,000,000	-181,000,000
Intangible assets	-1,098,000,000	-1,412,000,000		-1,098,000,000	-1,412,000,000
Provisions for employee related obligations, noncurrent	39,000,000	19,000,000		39,000,000	19,000,000
Carryforward losses and deductions, noncurrent	1,043,000,000	1,415,000,000		1,043,000,000	1,415,000,000
Other	-21,000,000	60,000,000		-21,000,000	60,000,000
Long-term deferred tax assets (liabilities)-gross	-255,000,000	-99,000,000		-255,000,000	-99,000,000
Deferred Tax Assets Valuation Allowance Noncurrent	-458,000,000	-542,000,000		-458,000,000	-542,000,000
Long-term deferred tax assets (liabilities)-net	-713,000,000	-641,000,000		-713,000,000	-641,000,000
Deferred tax assets (liabilities) - net	246,000,000	406,000,000		246,000,000	406,000,000
Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward
Balance at the beginning of the year				665,000,000	903,000,000	907,000,000
Increase related to prior year tax positions, net				38,000,000	29,000,000	-10,000,000
Increase related to current year tax positions				51,000,000	176,000,000	151,000,000
Tax assessments settlements				-38,000,000	-461,000,000	-146,000,000
Acquisition				0	0	0
Other				-3,000,000	18,000,000	1,000,000
Balance at the end of the year	713,000,000	665,000,000	903,000,000	713,000,000	665,000,000	903,000,000
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense	12,000,000	69,000,000	29,000,000
Balance of accrued potential penalties and interest in unrecognized tax benefits	87,000,000	75,000,000	144,000,000	87,000,000	75,000,000	144,000,000
Income Tax Contingency [Line Items]
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense	12,000,000	69,000,000	29,000,000
Amount Of Tax Exempt Profit Earned By Company From Approved Enterprises				9,700,000,000
Tax Payable Refer To Distributed Dividends				1,500,000,000
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Income before income taxes				3,638,000,000	1,250,000,000	1,819,000,000
Statutory tax rate in Israel				26.50%	25.00%	25.00%
Theoretical provision for income taxes				964,000,000	313,000,000	455,000,000
Increase (decrease) in effective tax rate due to:
IncomeTaxReconciliationChangeInEnactedTaxRate				-524,000,000	-535,000,000	-520,000,000
IncomeTaxReconciliationOtherAdjustments				0	248,000,000	0
IncomeTaxReconciliationForeignIncomeTaxRateDifferential				88,000,000	-275,000,000	-83,000,000
IncomeTaxReconciliationTaxContingencies				63,000,000	206,000,000	11,000,000
Income taxes				591,000,000	-43,000,000	-137,000,000
Year 2007 [Member]
Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense	213,000,000
Income Tax Contingency [Line Items]
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense	$213,000,000

INCOME_TAXESs_Details_1

INCOME TAXESs (Details 1) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Tax Carryforwards And Deductions Expiration Period One [Member]
Other Tax Carryforward [Line Items]
First year in period	1-Jan-16
Last year in period	31-Dec-17
Tax effect of unspecified carryforward losses and deductions	$192
Tax Carryforwards And Deductions Expiration Period Two [Member]
Other Tax Carryforward [Line Items]
First year in period	1-Jan-18
Last year in period	31-Dec-24
Tax effect of unspecified carryforward losses and deductions	302
Tax Carryforwards And Deductions No Expiration [Member]
Other Tax Carryforward [Line Items]
Tax effect of unspecified carryforward losses and deductions	194
Tax Carryforwards And Deductions Indefinite [Member]
Other Tax Carryforward [Line Items]
Tax effect of unspecified carryforward losses and deductions	$505

INCOME_TAXES_Details_2

INCOME TAXES (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Deferred Taxes By Report [Line Items]
Deferred tax assets (liabilities) - net	$246	$406
Prepaid Expenses And Other Current Assets [Member]
Deferred Taxes By Report [Line Items]
Deferred tax assets (liabilities) - net	993	1,084
Other Current Liabilities [Member]
Deferred Taxes By Report [Line Items]
Deferred tax assets (liabilities) - net	-34	-37
Other Assets Deferred Taxes And Deferred Charges [Member]
Deferred Taxes By Report [Line Items]
Deferred tax assets (liabilities) - net	388	606
Deferred income taxes [Member]
Deferred Taxes By Report [Line Items]
Deferred tax assets (liabilities) - net	($1,101)	($1,247)

FINANCIAL_INSTRUMENTS_AND_RISK2

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details) (USD $)	0 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Derivative [Line Items]
Stated interest rate on Senior Notes due 2016	7.20%		7.20%
Proceeds from Accounts Receivable Securitization	$585	$590	$4,287	$3,662

FINANCIAL_INSTRUMENTS_AND_RISK3

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Swap [Member] | Long Term Investments And Receivables [Member] | Designated As Hedging Instrument [Member]
Derivative Asset, Fair Value, Net [Abstract]
Derivative Fair Value Of Derivative Asset	$14	$0
Swap [Member] | Senior Notes And Loans [Member] | Designated As Hedging Instrument [Member]
Derivative Liability, Fair Value, Net [Abstract]
Derivative Fair Value Of Derivative Liability	-43	-233
Swap [Member] | Accounts Payable [Member] | Designated As Hedging Instrument [Member]
Derivative Asset, Fair Value, Net [Abstract]
Derivative Fair Value Of Derivative Asset	6	0
Foreign Exchange Contract [Member] | Deferred Taxes And Other Current Assets [Member] | Designated As Hedging Instrument [Member]
Derivative Asset, Fair Value, Net [Abstract]
Derivative Fair Value Of Derivative Asset	14	3
Foreign Exchange Contract [Member] | Accounts Payable [Member] | Designated As Hedging Instrument [Member]
Derivative Liability, Fair Value, Net [Abstract]
Derivative Fair Value Of Derivative Liability	-1	-8
Foreign Exchange Contract [Member] | Accounts Payable [Member] | Nondesignated [Member]
Derivative Asset, Fair Value, Net [Abstract]
Derivative Fair Value Of Derivative Asset	68	25
Derivative Liability, Fair Value, Net [Abstract]
Derivative Fair Value Of Derivative Liability	-53	-9
Interest Rate Swap [Member] | Long Term Investments And Receivables [Member] | Designated As Hedging Instrument [Member]
Derivative Asset, Fair Value, Net [Abstract]
Derivative Fair Value Of Derivative Asset	0	2
Interest Rate Swap [Member] | Senior Notes And Loans [Member] | Designated As Hedging Instrument [Member]
Derivative Liability, Fair Value, Net [Abstract]
Derivative Fair Value Of Derivative Liability	$0	($203)

FINANCIAL_INSTRUMENTS_AND_RISK4

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details 2) (Financial Expenses Net [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Foreign Exchange Contract [Member]
Derivative Instruments Gain Loss [Line Items]
Gain (loss) recognized in earnings for the period on derivative contracts	($85)	($76)	$45
Swap [Member]
Derivative Instruments Gain Loss [Line Items]
Gain (loss) recognized in earnings for the period on derivative contracts	$41	$35

FINANCIAL_INSTRUMENTS_AND_RISK5

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details 3) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Interest Rate Swap [Member]
Derivative [Line Items]
InterestRateFairValueHedgeDerivativeAtFairValueNet	$1,750	$2,500
Cross Currency Interest Rate Contract [Member]
Derivative [Line Items]
InterestRateCashFlowHedgeDerivativeAtFairValueNet	1,875	1,875
Cross Currency Interest Rate Contract Forecasted Work Plan Exposure [Member]
Derivative [Line Items]
InterestRateCashFlowHedgeDerivativeAtFairValueNet	$280	$300

FINANCIAL_INSTRUMENTS_AND_RISK6

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details 4) (USD $)	0 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Derivative Instruments and Hedging Activities [Absract]
Sold receivables at the beginning of the year			$590	$535
Proceeds from sale of receivables	585	590	4,287	3,662
Cash collections (remitted to the owner of the receivables)			4,202	3,635
Effect of currency exchange rate changes			-90	28
Sold receivables at the end of the year	$585	$590	$585	$590

FINANCIAL_EXPENSES_NET_Details

FINANCIAL EXPENSES NET (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Financial Expenses Net [Abstract]
Income from investments	$24	$32	$26
Interest expense and other bank charges	-300	-314	-355
Losses from hedging transactions in connection with the ratiopharm acquisition	0	0	0
Foreign Currency Transaction (Gain) Losses - net	-30	-8	-25
Other Than Temporary Impairment of Securities	0	0	0
Gain From Interest Rate Swap Transaction	0		-32
Other Finance Expenses	-7	-109	0
Financial expenses-net	($313)	($399)	($386)

RESTRUCTURING_AND_IMPAIRMENT_D

RESTRUCTURING AND IMPAIRMENT (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Impairment [Line Items]
Impairment of intangible assets	$224	$393	$858
Impairment of Intangible Assets, Finite-lived		227	233
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	108	166	625
Impairment charge during the year on property, plant and equipment	163	61	190
Impairment Restructuring And Others [Abstract]
Impairment of long-lived assets	387	524	1,071
Restructuring	246	201	221
Other expenses	17	63	-33
Total	650	788	1,259
Restructuring Reserve [Roll Forward]
Charges made	246	201	221
Charges made	246	201	221
MDT-637 [Member]
Impairment [Line Items]
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	$102

LEGAL_SETTLEMENTS_Details

LEGAL SETTLEMENTS (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Impairment Of Long Lived Assets And Contingent Consideration [Abstract]
Loss Contingency		$495
Legal Settlements Acquisition And Restructuring And Impairment	-111	1,524
LitigationSettlementExpenseForPantoprazoleLitigation		$930

SEGMENTS_Details

SEGMENTS (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Revenues	$20,272	$20,314	$20,317
Gross profit	11,056	10,707	10,652
Research and development expenses	1,488	1,427	1,356
Selling and marketing expenses	3,861	4,080	3,879
Segments Profitability	3,951	1,649	2,205
Segments [Member]
Segment Reporting Information [Line Items]
Segments Profitability	6,723	6,195	6,756
Generics [Member]
Segment Reporting Information [Line Items]
Revenues	9,814	9,902	10,385
Gross profit	4,247	4,079	4,518
Research and development expenses	517	492	485
Selling and marketing expenses	1,582	1,919	1,971
Segments Profitability	2,148	1,668	2,062
Specialty [Member]
Segment Reporting Information [Line Items]
Revenues	8,560	8,388	8,150
Gross profit	7,457	7,274	7,173
Research and development expenses	881	883	793
Selling and marketing expenses	2,001	1,864	1,686
Segments Profitability	$4,575	$4,527	$4,694

SEGMENTS_Details_1

SEGMENTS (Details 1) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Segments Profitability	$3,951	$1,649	$2,205
Amounts not allocated to segments [Abstract]
Depreciation And Amortization	1,508	1,642	1,708
General and administrative expenses	1,217	1,239	1,238
Legal Settlements And Loss Contingencies	-111	1,524	715
Impairments Restructuring And Others	650	788	1,259
Financial expenses - net	-313	-399	-386
Income before income taxes	3,638	1,250	1,819
Segments and Other activities [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Segments Profitability	6,949	6,437	6,953
Segments [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Segments Profitability	6,723	6,195	6,756
Generics [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Segments Profitability	2,148	1,668	2,062
Specialty [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Segments Profitability	4,575	4,527	4,694
All Other Segments [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Segments Profitability	226	242	197
Segment Reconciling Items [Member]
Amounts not allocated to segments [Abstract]
Depreciation And Amortization	1,036	1,180	1,272
General and administrative expenses	1,217		1,238
Legal Settlements And Loss Contingencies	650	788	1,259
Impairments Restructuring And Others	-111	1,524	715
Otehr Unallocated Amounts	$206	$57	$264

SEGMENTS_Details_2

SEGMENTS (Details 2) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues From External Customers And Long Lived Assets [Line Items]
Net sales by geographic area	$20,272	$20,314	$20,317
Information About Major Customers And Products [Abstract]
The net sales to the Companys largest customer as a percentage of total net sales	18.00%	17.00%	16.00%
Percentage Of Total Receivables For Largest Customer	31.00%
Percentage of Total Revenue for Another Customer	17.00%	13.00%
Generics [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net sales by geographic area	9,814	9,902	10,385
Branded [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net sales by geographic area	8,560	8,388	8,150
Other Products [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net sales by geographic area	1,898	2,024	1,782
Us Group One [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net sales by geographic area		264
Us Group One [Member] | Generics [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net sales by geographic area	4,418	4,172	4,381
Us Group One [Member] | Branded [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net sales by geographic area	6,110	6,025	5,857
Us Group One [Member] | Other Products [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net sales by geographic area	106		200
Europe Group Two [Member] | Generics [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net sales by geographic area	3,148	3,362	3,482
Europe Group Two [Member] | Branded [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net sales by geographic area	1,898	1,854	1,575
Europe Group Two [Member] | Other Products [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net sales by geographic area	777	772	741
Segment Geographical Groups Of Countries Group Three [Member] | Generics [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net sales by geographic area	2,248	2,368	2,522
Segment Geographical Groups Of Countries Group Three [Member] | Branded [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net sales by geographic area	552	509	718
Segment Geographical Groups Of Countries Group Three [Member] | Other Products [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net sales by geographic area	$1,015	$988	$841

SEGMENTS_Details_3

SEGMENTS (Details 3) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Product Information [Line Items]
Net revenues	$20,272	$20,314	$20,317
Branded CNS [Member]
Product Information [Line Items]
Net revenues	5,575	5,545	5,464
Branded Respiratory Products [Member]
Product Information [Line Items]
Net revenues	957	964	856
Branded Womens Health Products [Member]
Product Information [Line Items]
Net revenues	504	510	448
Branded Oncology Products [Member]
Product Information [Line Items]
Net revenues	1,180	1,005	860
Other Branded Products [Member]
Product Information [Line Items]
Net revenues	344	364	522
Branded C N S Copaxone [Member]
Product Information [Line Items]
Net revenues	4,237	4,328	3,996
Branded C N S Azilect [Member]
Product Information [Line Items]
Net revenues	428	371	330
Branded C N S Nuvigil [Member]
Product Information [Line Items]
Net revenues	388	320	347
Branded Respiratory Proair [Member]
Product Information [Line Items]
Net revenues	478	429	406
Branded Respiratory Qvar [Member]
Product Information [Line Items]
Net revenues	286	328	297
Branded Oncology Treanda [Member]
Product Information [Line Items]
Net revenues	767	709	608
Branded [Member]
Product Information [Line Items]
Net revenues	$8,560	$8,388	$8,150

SEGMENTS_Details_4

SEGMENTS (Details 4) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment, net	$6,535	$6,635	$6,315
Israel [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment, net	1,949	1,834	1,649
United States [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment, net	691	852	896
Croatia [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment, net	446	492	644
Hungary [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment, net	515	479	415
Germany [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment, net	367	403	367
Japan [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment, net	520	526	498
Other Countries [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment, net	$2,047	$2,049	$1,846

SEGMENTS_Details_5

SEGMENTS (Details 5) (USD $)	12 Months Ended
In Billions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting [Abstract]
CopaxoneUS revenues	$3.10
Percentage Of CopaxoneRevenues Of Total US	29.00%
Copaxone Outside US Revenues	$1.10
Percentage Of Copaxone Revenues Of Total Non US	12.00%
Profitability Of MS As A Percentage Of Copaxone Revenues	75.10%	75.60%	74.50%

EARNINGS_PER_SHARE_Details

EARNINGS PER SHARE (Details) (USD $)	0 Months Ended			12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net Income And Weighted Average Number Of Shares Used In Computation Of Basic And Diluted Earnings Per Share [Abstract]
Net income attributable to Teva				$3,055	$1,269	$1,963
Interest expense on convertible senior debentures, and issuance costs, net of tax benefits				0	0	0
Net income used for the computation of diluted earnings per share				$3,055	$1,269	$1,963
Weighted average number of shares used in the computation of basic earnings per share				853	849	872
Additional shares from the assumed exercise of employee stock options and unvested RSU's				3	1	1
Weighted average number of additional shares issued upon the assumed conversion of convertible senior debentures				2	0	0
Weighted average number of shares used in the computation of diluted earnings per share	1	7	6	858	850	873
Ordinary And Special Shares Outstanding [Abstract]
Ordinary shares - issued	957	947		957	947
Treasury, shares	105	99		105	99

SCHEDULE_II_VALUATION_AND_QUAL2

SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Allowance For Doubtful Accounts Current Member
Valuation And Qualifying Accounts Disclosure [Line Items]
Charged to costs and expenses	$22	$44	$32
Charged to other accounts	-18	3	5
Deductions	-42	-5	-8
Ending balance	149	187	145	116
Valuation Allowance Tax Carryforward Losses And Deductions [Member]
Valuation And Qualifying Accounts Disclosure [Line Items]
Charged to costs and expenses	128	182	384
Charged to other accounts	0	0	2
Deductions	-248	-117	-112
Ending balance	$671	$791	$726	$452

Uncategorized_Items

Uncategorized Items
[teva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod]	ten	seven
[us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh]			125,000,000	130,000,000
[us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized]					70,000,000